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Abbreviations 
AADC, Aromatic amino acid decarboxylase 
AAAOH, Aromatic amino acid hydroxylase 
AGMO, Alkylglycerol monooxygenase  
BH4, ( 6R)-L-erythro-5,6,7,8-tetrahydrobiopterin  
CNS, Central nervous system 
CSF, Cerebrospinal fluid 
DCoH, Dimerization cofactor of hepatocyte nuclear factor-1α  
DHPR, Dihydropteridine reductase 
ES cells, Embryonic stem cells 
GFRP, GTP cyclohydrolase feedback regulatory protein 
GMC, German Mouse Clinic 
GTPCH, Guanosine triphosphate cyclohydrolase  
5-HIAA, 5-hydroxyindoleacetic acid 
HVA, Homovanillic acid 
HPA, Hyperphenylalaninemia 
5-HT, Serotonin, 5-hydroxytryptamin 
5-OH-Trp, 5-Hydroxytryptophan 
5-HTTLPR, 5-HTT gene-linked polymorphic promoter region 
Het, Heterozygous 
Homo, Homozygous 
Ki, Knock-in 
Ko, Knock-out 
L-DOPA, L-3,4-dihydroxyphenylalanine 
MAO-A, Monoamine oxidase A 
NO, Nitric oxide 
NOS, Nitric oxide synthase 
PAH, Phenylalanine hydroxylase 
PCD/DCoH, Pterin-4α-carbinolamine dehydratase 
PMAT, Plasma membrane monoamine transporter 
Pts-ki/ki, Homozygous Pts-R15C-knock-in 
Pts-ki/wt, Heterozygous Pts -R15C-knock-in 
Pts-ko, Homozygous Pts-knock-out 
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Summary 
The present dissertation is based on different aspects within tetrahydrobiopterin (BH4) and 
monoamine neurotransmitter deficiency in mouse models and human disease. Thus, it is 
subdivided into two parts covering (A) new animal models to study the pathophysiology and 
potential treatment options in mice deficient for BH4 (chapters 2 and 3), as well as (B) human 
genetic studies in subjects with low brain serotonin, autism spectrum disorders (ASDs) and 
serotonin re-uptake transporter mutations (chapters 4 and 5).  
 
(A) New mouse model to study BH4 deficiency by targeting a biosynthetic (Pts) and cofactor 
regulatory (Gchfr) gene 
Previous studies have shown that homozygous Pts-knock-out (Pts-ko/ko) mice exhibit 
newborn lethality (whereas Pts-ko/wt mice had no phenotype). Thus, the generation of a new 
and suitable mouse model to study human BH4 deficiency was essential. One goal of this 
study was to generate two new Pts mouse models to study PTPS deficiency: a homozygous 
Pts-R15C-knock-in (Pts-ki/ki) and a compound heterozygous Pts-R15C-ki/Pts-ko (Pts-ki/ko). 
After successful generation, the biochemical characterization of the Pts-ki/ki mice revealed no 
hyperphenylalaninemia (HPA) or brain monoamine neurotransmitter deficiency, but reduced 
PTPS enzyme activity and elevated neopterin in liver and brain. Despite that Pts-ki/ki mice 
were found not to be a suitable mouse model to study BH4 deficiency, they displayed 
compared to wild type mice an abnormal fat distribution, and unexpected and progressive 
weight gain when exposed for several weeks to either standard chow or high fat diet.  
Breeding of Pts-ki/ko mice led to two different phenotypes depending on the maternal 
genotype: one lethal 3-4 days after birth (“affected”) and one which survived (“unaffected”) 
until sacrificed at 3 weeks of age. The biochemical characterization of the “affected” Pts-
ki/ko mice, which were born from Pts-ki/ki mothers crossed with Pts-ko/wt fathers, 
demonstrated reduced PTPS enzyme activity and biopterin in liver and brain, elevated 
neopterin in liver and brain, mild HPA as well as brain monoamine neurotransmitter 
deficiency. In contrast, “unaffected” Pts-ki/ko mice, which were born from Pts-ko/wt mothers 
crossed with Pts-ki/ki fathers, revealed reduced PTPS enzyme activity in liver and brain but 
normal levels of blood phenylalanine, biopterin (liver and brain), neopterin (liver and brain) 
and brain monoamine neurotransmitters. Therefore, “affected” Pts-ki/ko mice had all 
biochemical hallmarks of BH4 deficiency, and were thus found to be a suitable mouse model 
to study BH4 deficiency.  
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Furthermore, it is our hypothesis that the severe BH4 deficiency observed in the “affected” 
Pts-ki/ko F1-offspring mice is due to limited BH4 supply during early life phase by the Pts-
ki/ki mothers.   
 
To study the in vivo role of the BH4-regulatory protein GFRP in liver and brain, as well as its 
potential contribution to human diseases, we aimed at generating the first animal model for 
GFRP, a conditional knock-out by targeted mutagenesis of the murine Gchfr gene. Successful 
targeting event in ES cells followed by morula aggregation led to the generation of four 
chimeras with up to 80 % chimerism. Unfortunately, Gchfr-floxed heterozygous mice could 
not be generated due to unsuccessful germline transmission. In the following, we decided to 
test a new and improved targeting vector. This alternative targeting vector was recently 
linearized and electroporated into ES cells derived from the C57BL/6 strain.  
 
(B) Low brain serotonin, ASDs and serotonin re-uptake transporter mutations 
In a previous study from our laboratory, five boys were described with motor delay, 
hypotonic-ataxic, learning deficits and short attention span. The catecholamine and serotonin 
neurotransmitter were investigated in the cerebrospinal fluid (CSF) due to the neuro-
developmental abnormalities. The metabolic analysis of the CSF revealed isolated low 
serotonin end-metabolite 5-hydroxyindoleacetic acid (5-HIAA), which suggested a down-
regulation of the serotonin turnover. For that reason, the five patients received daily treatment 
with serotonin precursor 5-hydroxytryptophan and AADC inhibitor carbidopa, which led to 
clinical improvements and normalization of the 5-HIAA levels in CSF and urine.  
 
To investigate the underlying genetic aspects responsible for the low brain serotonin and the 
neuro-developmental abnormalities, I performed a genetic candidate gene approach within all 
five affected boys. Since it was hypothesized that dysfunction of the brain serotonin 
development system contributes to the observed phenotype, the coding sequences of the 
serotonin re-uptake transporter gene SLC6A4, encoding SERT, and of the BH4 regulatory 
gene GCHFR, encoding GFRP, were investigated first. GFRP is the only gene in the BH4 
metabolism for which no human deficiency has been descried. No mutations were found 
within the GCHFR gene, but in one patient I found the heterozygous p.G56A mutation in the 
SLC6A4 gene, which previously has been shown to be associated with autism and rigid-
compulsive behaviour. In retrospect, this patient was diagnosed with atypical autism and 
speech delay when subjected to the diagnostic criteria for autistic disorder according to DSM-
IV. Altogether, this study showed for the first time an association between low CNS 
serotonin, atypical autism and heterozygous SERT-G56A allele, suggesting that patients with 
Summary 
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atypical autism, carrying the heterozygous SERT-G56A mutation, may respond to treatment 
with 5-hydroxytryptophan and carbidopa by clinical improvement and normalization of 
serotonin turnover in the brain. Moreover, these findings suggested for the first time the 
metabolic and underlying genetic abnormalities for atypical autism.  
The novel findings encouraged me to investigate a cohort of 125 ASDs patients with either 
unknown, normal or isolated low 5-HIAA in the CSF using a genetic candidate gene approach 
involving besides SLC6A4 and GCHFR, the serotonin re-uptake transporter gene SLC29A4 
encoding PMAT. In this cohort, I found five patients carrying the known heterozygous 
p.G56A mutation in the SLC6A4 gene. Again, no patients were found with mutations in the 
GCHFR gene. Moreover, I identified for the first time patients with mutations in the SLC29A4 
gene: in 9 ASD patients I found one of the following heterozygous mutations: p.M24L, 
p.D29G, p.A138T and p.D326E. Moreover, they were found to be negative in an independent 
group of at least 300 control subjects. One patient was found to carry heterozygous mutations 
in both genes, SLC6A4 (p.G56A) and the SLC29A4 (p.D326E).  
 
By investigating the function and location of the two PMAT-mutant alleles p.A138T and 
p.D326E, which were found in patients diagnosed with isolated low 5-HIAA and ASDs, we 
found that both PAMT mutant transporters, 138T and 326E, exhibited reduced transport 
activities for serotonin and dopamine, and that they were located in the plasma membrane of 
the transiently transfected (MDCK) cells, similar to wild-type PMAT.  
 
In a next step, whole exome sequencing was performed on the two patients carrying the 
heterozygous PMAT alteration p.A138T or p.D326E (and SERT-Gly56Ala) plus their healthy 
parents and sister to potentially understand the genetic link between isolated low 5-HIAA in 
CSF, ASDs and serotonin re-uptake transporter mutations.  
Based on a hypothetic “genetic accumulation-model” for ASD, we specifically selected for 
non-synonymous amino acid substitutions within all reported serotonin-related and/or autism-
associated candidate genes, and with a mutant-allele frequency of <1. The cumulative genetic 
burden using such a filtering strategy, revealed a tendency towards more “serotonin gene hits” 
in the two ASD affected patients, as compared to the other family members, indicating that 
alterations in mainly serotonin homeostasis genes might be responsible for the autistic 
phenotype. Furthermore, our exome sequencing data support the hypothesis that ASDs may 
be caused by a certain (threshold) number of individual heterozygously mutated genes 
associated with serotonin homeostasis. 
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Zusammenfassung 
Die vorliegende Dissertation befasst sich mit verschiedenen Aspekten des 
Tetrahydrobiopterin (BH4)- und Monoamin-Neurotransmitter-Mangels in Maus-Modellen und 
beim Menschen. Die Resultate sind in zwei Teile gegliedert, (A) neue Tiermodelle zur 
Untersuchung der Pathophysiologie und potentiellen Behandlungsmöglichkeiten des BH4-
Mangels in Mäusen (Kapitel 2 und 3) und (B) genetische Untersuchungen von Patienten mit 
deutlich erniedrigtem Serotonin im ZNS, Autismusspektrum-Störung (ASD) und Mutationen 
in Serotonin-Reuptake Transporter-Genen.  
 
(A) Neue Mausmodelle zur Untersuchung des BH4-Mangels durch gezielte Mutagenese eines  
biosynthetischen (Pts) und eines  Kofaktor-regulatorischen (Gchfr) Gens 
Vorangegangene Experimente mit transgenen Mäusen haben gezeigt, dass sich ein 
homozygoter Pts-knock-out (Pts-ko/ko) postnatal letal auswirkt (hingegen sind Pts-ko/wt 
Mäuse phänotypisch unauffällig). Somit bestand die Notwendigkeit für die Generierung neuer 
Tiermodelle zur Untersuchung des BH4-Mangels beim Menschen. Ein Ziel dieser Arbeit 
bestand darin, zwei Pts-Mausmodelle zur Untersuchungen des BH4-Mangels herzustellen, 
eine homozygote Pts-R15C-knock-in (Pts-ki/ki) und eine „compound“ heterozygote Pts-
R15C-ki/Pts-ko (Pts-ki/ko) Mausmutante. Nach erfolgreicher Generierung dieser 
Mausmutanten ergaben biochemische Untersuchungen bei der homozygoten Pts-ki/ki Maus 
keine Anzeichen von Hyperphenylalaninämie (HPA) oder Monoamin-
Neurotransmittermangel, hingegen zeigten die Tiere reduzierte Enzymaktivitäten für die 6-
Pyruvolytetrahdropterin Synthase (PTPS) und erhöhte Neopterin-Werte in Leber und Gehirn. 
Obwohl die Pts-ki/ki Mutante kein geeignetes Modell für den BH4-Mangel darstellte, hatten 
diese Mäuse im Vergleich zur Wildtypkontrolle eine abnorme Fettverteilung sowie eine 
ungewöhnliche Gewichtszunahme nach Fütterung über mehrere Wochen mit normalem oder 
fettangereichertem Futter.  
Die Generierung von heterozygoten Pts-ki/ko Mäusen führte zu zwei unterschiedlichen 
Phänotypen, abhängig vom Genotyp der Mutter: während Mäuse in einer Gruppe 3-4 Tage 
nach der Geburt verstarben (so genannte „betroffene“), überlebten die Tiere einer zweiten 
Gruppe problemlos (so genannte „nicht betroffene“) bis sie im Alter von 3 Wochen für 
Untersuchungszwecke euthanasiert wurden. Die biochemische Charakterisierung der 
„betroffenen“ Pts-ki/ko Mäuse, Nachkommen von Pts-ki/ki Müttern gepaart mit Pts-ko/wt 
Vätern, zeigte verminderte PTPS-Enzymaktivitäten und Biopterinwerte in Leber und Gehirn, 
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erhöhte Neopterinwerte in Leber und Gehirn, eine milde HPA sowie einen Monoamin-
Neurotransmittermangel im Gehirn. Im Gegensatz dazu zeigten „nicht betroffene“ Pts-ki/ko 
Mäuse, Nachkommen von Pts-ko/wt Müttern gepaart mit Pts-ki/ki Vätern, eine reduzierte 
PTPS-Aktivität in Leber und Gehirn, jedoch normale Phenylalaninwerte im Blut sowie 
normale Werte für Biopterin (Leber und Hirn), Neopterin (Leber und Hirn) und Monoamin-
Neurotransmitterwerte im Gehirn. Demzufolge sind die „betroffenen“ Pts-ki/ko Mäuse ein 
geeignetes biochemisches Modell zur Untersuchung des BH4-Mangels. Weiter spekulieren 
wir, dass der schwere BH4-Mangel bei den „betroffenen“ Pts-ki/ko Mäusen durch eine 
begrenzte Verfügbarkeit von BH4 in der Muttermilch der Pts-ki/ko Mütter während der frühen 
Lebensphase der Nachkommen verursacht wird.  
 
Um die in vivo Rolle des regulatorischen „feed-back regulatory protein“ GFRP in Leber und 
Gehirn sowie die potentielle Rolle des GFRP-Mangels beim Menschen zu untersuchen, sollte 
eine konditionelle knock-out Maus durch gezielte Mutagenese des murinen Gchfr Gens 
erzeugt werden. Nach erfolgreichem Gen-Targeting in ES-Zellen und Morula-Aggregation 
wurden vier Mäuse mit bis zu 80%-igem Chimärismus geboren. Es wurde darum beschlossen, 
einen verbesserten Targeting-Vektor zu konstruieren und in ES-Zellen zu testen. Mit Hilfe 
dieses alternativen Targeting-Vektors wurde kürzlich eine erfolgreiche Elektroporation in 
C57BL/6-ES-Zellen durchgeführt.  
 
(B) Abnormtiefes Serotonin im ZNS, Autismusspektrum-Störung (ASD) und Mutationen in 
Serotonin-Reuptake Transporter-Genen 
In einer vorangegangenen Studie wurden fünf Knaben mit motorischer Retardierung, 
hypotoner Ataxie, Lerndefizit und kurzer Aufmerksamkeitsspanne beschrieben. Die 
Metabolite der Katecholamin- und Serotonin-Neurotransmitterbiosynthese wurden im Liquor 
untersucht (auch Zerebrospinal-Flüssigkeit). Diese Analyse zeigte deutlich erniedrige Werte 
für den Serotonin-Metaboliten 5-Hydroxyindolessigsäure (5-HIAA), was auf eine erniedrigte 
Regulation des Serotoninumsatzes schliessen liess. Aus diesem Grund erhielten die fünf 
Patienten eine tägliche Behandlung mit der Serotoninvorstufe 5-Hydroxytryptophan (plus 
dem Decarboxylase-Hemmer „Carbidopa“), was zu einer klinischen Verbesserungen und 
Normalisierung der 5-HIAA im Liquor und im Urin führte.  
 
Zur weiteren ursächlichen Abklärung der abnormtiefen Serotoninwerte im Gehirn und der 
neuronalen Entwicklungsstörungen dieser Knaben wurde eine Kandidaten-Gen-Analyse 
durchgeführt, basierend auf der Hypothese, dass Funktionsstörungen des Serotonin- 
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Gleichgewichtszustandes („Serotonin-Homöostase“) vorliegen. Im Folgenden wurden die 
kodierenden Sequenzen des Serotonin-Reuptake-Gens SLC6A4, das für das SERT Protein 
kodiert, und für das GCHFR Gen, welches für das BH4-regulatorische Protein GFRP kodiert, 
untersucht. Das GCHFR Gen ist das einzige Gen im BH4-Metabolismus, für das bislang kein 
Defekt beim Menschen  beschrieben wurde.  
 
Es wurden keine Mutationen im GCHFR gefunden, hingegen wurde in einem der 
untersuchten Patienten die heterozygote p.G56A Mutation im Gen SLC6A4 nachgewiesen. 
Dieses gut untersuchte Mutanten-Allel wurde in verschiedenen Studien mit Autismus und 
zwanghaftem Verhalten assoziiert. Weiter wurde retrospektiv bei dem von der Mutation 
betroffenen Patienten ein atypischer Autismus und eine Sprachverzögerung diagnostiziert 
(gemäss den diagnostischen Kriterien zur Autismus-Diagnose nach DSM-IV). Die hier 
vorgelegte Studie zeigt somit zum ersten Mal einen Zusammenhang zwischen abnormtiefem 
Serotonin im ZNS, Autismusspektrum-Störung (ASD) und der heterozygoten p.G56A 
Mutation in einem Serotonin-Reuptake Transporter-Gen. Weiter reagiert dieser Patient mit 
atypischem Autismus auf die Behandlung mit 5-Hydroxytryptophan (und Carbidopa) mit 
einer klinischen Besserung und Normalisierung der Serotoninmetabolite im ZNS. 
Zusammenfassend weisen diese Ergebnisse zum ersten Mal auf einen möglichen (Serotonin-) 
Stoffwechseldefekt als genetische Ursache für einen atypischen Autismus hin.  
 
Die neuen Erkenntnisse ermutigten mich, eine Kohorte von 125 Patienten mit ASD und 
normalem oder abnormtiefen 5-HIAA in der Zerebrospinalflüssigkeit auf Mutationen im  
SLC6A4 und GCHFR Gen, sowie dem SLC29A4 Gen, das für den Serotonin-Reuptake 
Transporter PMAT kodiert, zu untersuchen. In dieser Gruppe fand ich fünf Patienten mit der 
bekannten heterozygoten p.G56A Mutation im SLC6A4 Gen. Wie zuvor hatte keiner dieser 
Patienten eine Mutation im GCHFR Gen. Hingegen fand ich zum ersten Mal Patienten mit 
Mutationen im SLC29A4 Gen: in 9 ASD Patienten wurden folgende heterozygote Varianten 
nachgewiesen: p.M24L, p.D29G, p.A138T und p.D326E. Gleichzeitig kommen diese 
Mutationen in einer unabhängigen Kontrollgruppe von mindestens 300 Individuen nicht vor. 
Einer der Patienten wies gleichzeitig eine Mutation im SLC6A4 Gen (SERT-G56A) und im 
Gen SLC29A4 auf (PMAT-D326E).  
 
In der Folge wurde die Funktion der zwei PMAT-Mutanten-Allele A138T und D326E, die 
beide bei je einem Patienten mit tiefem 5-HIAA im Liquor und ASD diagnostiziert wurden, 
charakterisiert. Beide Transportermutationen, 138T und 326E, hatten reduzierte 
Transportaktivitäten für Serotonin und Dopamin. Weiter wurde nachgewiesen, dass die 
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beiden PMAT-Mutationen, ähnlich wie das Wildtyp PMAT Protein, in der Plasmamembran 
von transient transfektierten (MDCK) Zellen lokalisiert sind.   
 
In einem nächsten Schritt wurde eine komplette Exom-Analyse bei den beiden Patienten, 
welche die heterozygoten PMAT Mutationen p.A138T und p.D326E (sowie die SERT-G56A 
Mutation) trugen, durchgeführt. Als Kontrollen wurden je deren gesunde Eltern und je ein 
Geschwister analysiert. Das Ziel war, eine mögliche genetische Verbindung zwischen 
Serotonin-Reuptake Transporter Mutationen, tiefen 5-HIAA-Werten im Liquor in der 
Zerebrospinalflüssigkeit und ASD zu finden.  
Basierend auf einem hypothetischen "genetic accumulation-model" für ASD wurden nur 
„non-synonymous“ Aminosäurenaustausche von allen bekannten Genen, die ein bekannte 
Assoziation mit Serotonin Homöostase und/oder ASD-assoziierte Kandidatengene zeigten 
und eine Mutanten-Allel-Frequenz von <1 aufwiesen, selektiert. Die aus dieser Such-
Strategie  resultierende kumulative genetische Belastung ergab eine Tendenz zu vermehrten 
"Serotonin-Gen-Hits" in den beiden ASD Patienten im Vergleich zu den anderen 
Familienmitgliedern. Dies weist darauf hin, dass in erster Linie  Veränderungen  in Genen der 
Serotonin-Homöostase für den autistischen Phänotyp  verantwortlich sein könnten. Weiter 
unterstützen unsere Resultate zur Exom-Sequenzierung die Hypothese, dass ASD durch eine 
bestimmte (Schwellen-) Zahl von einzelnen heterozygot mutierten Genen, die mit der 
Serotonin Homöostase assoziiert sind, verursacht werden könnte.  
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1 Introduction 
( 6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for several enzymes 
in the human metabolism. Among these are the aromatic amino acid hydroxylases (AAAOH): 
phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase 
(TPH), all three isoforms (neuronal, inducible, and endothelial) of nitric oxide synthases 
(NOS) and alkylglycerol monooxygenase (AGMO) (Figure 1). Hence, BH4 plays a central 
role in the metabolism involving phenylalanine degradation, monoamine neurotransmitter 
biosynthesis and nitric oxide production. Consequently, BH4 deficiency leads to dopamine 
and serotonin monoamine neurotransmitter deficiency, reduced NO production, and often but 
not always to hyperphenylalaninemia (HPA). The requirement of BH4 is reflected by the 
severe disturbance or even lethality in the case of cofactor limitation due to mutations in 
human BH4-metabolic genes.  
 
1.1 De novo biosynthesis of Tetrahydrobiopterin (BH4)  
 
BH4 can be synthesized by two distinct pathways: 1) the de novo pathway uses guanosine 
triphosphate (GTP) as a precursor, and 2) the salvage pathway depends on pre-existing 7,8-
dihydropterin (Blau et al., 2001, Thöny et al., 2000).    
 
In the de novo biosynthetic pathway BH4 is generated from GTP by three enzymatic reactions 
(Figure 1). The first and rate-limited enzyme is GTP cyclohydrolase I (GTPCH) which 
catalyzes the conversion of GTP to 7,8-dihydroneopterin triphosphate (NH2TP). The GTPCH 
reaction requires Zn2+ and involves two hydrolyses and an Amadori rearrangement of the 
ribose moiety, yielding formic acid as a by-product (Blau et al., 2001, Thöny et al., 2000) 
(Figure 1). The second enzyme in the de novo pathway is 6-pyruvoyl-tetrahydropterin 
synthase (PTPS), which converts NH2TP to 6-pyruvoyl-tetrahydropterin (PPH4) by a two-step 
reaction involving an internal redox transfer and triphosphate elimination in a Mg2+-and Zn2+-
dependent reaction (Blau et al., 2001, Thöny et al., 2000) (Figure 1). The third and last 
enzyme is sepiapterin reductase (SR), which requires NADPH for the convention of 6-
pyruvoyltetrahydropterin to BH4. A two-step reduction is necessary to convert both side-chain 
keto groups into hydroxyl functions with proper stereochemistry (Blau et al., 2001, Thöny et 
al., 2000) (Figure 1).  
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Figure 1: BH4 de novo biosynthesis and BH4-dependent metabolism 
The (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) cofactor is synthesized from guanosine triphosphate 
(GTP) by a set of reactions involving three enzymes: GTP cyclohydrolase I (GTPCH), 6-pyruvoyl-
tetrahydropterin synthase (PTPS) and sepiapterin reductase (SR). The complete hydroxylating system of 
aromatic amino acids consists of the two additional BH4-regenerating enzymes namely pterin-4α-carbinolamine 
dehydratase (PCD/DCoH) and dihydropteridine reductase (DHPR). The presence of the amino acid 
phenylalanine (Phe) or cofactor BH4 itself is thought to regulate cofactor biosynthesis in liver via the GTP 
cyclohydrolase I feedback regulatory protein (GFRP) mainly through its protein-super complex with GTPCH. 
One of the best investigated function of BH4 is its action as a natural cofactor for the aromatic amino acids 
hydroxylase (AAAOH), i.e. phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan 
hydroxylase type 1 and 2 (TPH1, peripheral and TPH2, neuronal). Moreover, BH4 is an essential cofactor for all 
three isoforms of nitric oxide synthase (inducible, endothelial, neuronal NOS) as well as alkylglycerol 
monooxygenase (AGMO). The various colours represent enzymes for BH4 biosynthesis (blue), BH4 regeneration 
(red), BH4 cofactor function (purple) and BH4 feedback regulation (green). The dash line indicates that BH4 as a 
cofactor for all three isoforms of NOS is not oxidized to pterin-4a-carbinolamine (OH-BH4) but instead is 
converted into a pterin cation radical (not shown). Note the differences for detecting monoamine 
neurotransmitter metabolites in the CNS between mouse (whole brain extracts) and humans (CSF) are indicated 
by the light-blue boxes. Phe: Phenylalanine, Tyr: Tyrosine, L-DOPA: L-3,4-dehydroxyphenylalanine, Trp: 
Tryptophan, 5-OH-Trp: 5-hydroxytryptophan, AADC: aromatic amino acid decarboxylase, MAO-A: 
monoamine oxidase A, Arg: Arginine, NO: nitric oxide. 
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1.2 Regeneration of BH4  
The three AAAOHs require two electrons, molecular oxygen and iron for the enzymatic 
hydroxylate of their amino acid substrates Phe, Tyr and Trp. One electron is transferred to 
Fe3+ in the active site of the AAAOH causing a reduction to Fe2+ which has been linked to the 
formation of an active AAAOH and the other electron is transferred to molecular oxygen, 
which during the catalytic event of the AAAOH, is transferred to the corresponding amino 
acid. Both electrons are provided by the cofactor BH4 and as a consequence, BH4 is oxidized 
to its hydroxyl compound pterin-4α-carbinolamine (also known as 4α-Hydroxy-BH4, BH4-4a-
carbinolamine and BH4-OH) (Figure 1) (Thöny et al., 2000). Two enzymes are responsible for 
the dehydration and reduction of pterin-4α-carbinolamine back to BH4 namely pterin 4α-
carbinolamine dehydratase (PCD) as well as dihydropteridine reductase (DHPR), respectively 
(Thöny et al., 2000).  
 
In the BH4 regeneration, PCD catalyzes the dehydration of pterin-4α-carbinolamine to 
quinonoid dihydrobiopterin (q-BH2) by elimination of one molecule of water from the 
oxidized pterin. Besides the role of PCD in the BH4 regeneration, PCD is also a cofactor that 
regulates dimerization of the mammalian homeodomain protein HNF-1α thus PCD is also 
known as dimerization cofactor of hepatocyte nuclear factor-1α (DCoH) (Mendel et al., 
1991). The final conversion of q-BH2 into BH4 is carried out by NADH and the second 
enzyme dihydropteridine reductase (DHPR) (Thöny et al., 2000) (Figure 1).  
 
In the absence of PCD/DCoH and DHPR (e.g. in patients with PCD/DCoH deficiency or 
DFPR deficiency), pterin-4α-carbinolamine and q-BH2 are non-enzymically converted to 7-
dihydrobiopterin (primapterin) and 7,8-dihydrobiopterin (biopterin), respectively which are 
both excreted in the urine (Thöny et al., 2000).  
 
The enzymatic recycling or regeneration of BH4 is necessary for two reasons: first to ensure a 
continuous supply of reduced cofactor and second to prevent accumulation of harmful 
metabolites produced by rearrangement of pterin-4α-carbinolamine (Thöny et al., 2000).  
 
As a cofactor for NOS, BH4 is not oxidized to pterin-4α-carbinolamine but instead, during the 
transfer of electrons to the ferrous-dioxygen complex in the oxygenase domain, converted 
into a pterin cation radical (BH3•H+ or BH4+•) (Werner et al., 2003, Wei et al., 2003, Schmidt 
and Alp, 2007). Subsequently, the pterin cation radical returns to the BH4 state after each 
electron transfer step thus BH4 regeneration by PCD/DCoH and DHPR is not a requirement 
for NOS activity (Schmidt and Alp, 2007, Thöny et al., 2000).  
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1.3 Regulation of BH4 biosynthesis  
1.3.1 BH4 regulates its biosynthesis primarily via GTPCH  
GTPCH, the first and rate-limiting enzyme of the biosynthesis of BH4 which catalyses the 
conversion of GTP to H2NTP, is the major controlling point of the BH4 production (Thöny et 
al., 2000, Werner-Felmayer et al., 2002). Changes in GTPCH activity are directly correlated 
with changes in the BH4 levels and its activity is predominantly regulated at the 
transcriptional level by a variety different stimuli such as proinflammatory cytokines like 
interferon-γ (Gesierich et al., 2003), interleukin-1β, TNF-α, INF-α and β (Milstien et al., 
1996). Moreover, administration of bacterial lipopolysaccharide (LPS) to rats have shown to 
increase GTPCH activity and subsequently the BH4 levels within the cerebellum, liver, spleen 
and adrenal gland (Milstien et al., 1996, Werner-Felmayer et al., 2002). Additionally, certain 
hormones (e.g. follicle stimulating hormone), growth factor (e.g. epithelial growth factor 
(EGF)) or neuronal growth factors (NGF)), cAMP, the vasodilatory peptide adrenomedullin 
and insulin have been found to induce GTPCH expression (Werner-Felmayer et al., 2002, 
Ishii et al., 2001). Likewise, several stimuli have been shown to down-regulate GTPCH 
expression among these are the anti-flammatory cytokines IL-4, IL-10, TGF-β and the 
neurohormone melatonin (Werner-Felmayer et al., 2002). GTPCH activity has also been 
reported to be modulated at the post-transcriptional level by phosphorylation (Imazumi et al., 
1994, Lapize et al., 1998, Ishii et al., 2001).  
 
1.3.2 GTP cyclohydrolase feedback regulatory protein (GFRP) 
In vitro studies on rat liver extracts have shown that BH4 regulates its own biosynthesis 
through feedback inhibition of GTPCH and that this end-product feedback inhibition is 
mediated through protein complex formation with GTP cyclohydrolase feedback regulatory 
protein (GFRP) (Harada et al., 1993) (Figure 1).  
 
Furthermore, structural based studies have demonstrated that feedback inhibition of the 
GTPCH-GFRP complex also can be induced by dihydrobiopterin (BH2) (Maita et al., 2004).  
 
L-phenylalanine has been shown to reverse the BH4-mediated feedback inhibition as it 
changes the inactive GTPCH-GFRP complex to its active form (Yoneyama et al., 1997) 
(Figure 1).  Hence, the activity of GTPCH is positively/stimulatory regulated in presence of 
the amino acid phenylalanine and negatively (inhibitory) by the cofactor BH4 itself. Both the 
positive and negative feedback regulation takes place GFRP through a reversible protein-
protein interaction with GTPCH (Maita et al., 2002).  
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Cross-linking experiments have shown that both the stimulatory and inhibitory GTPCH-
GFRP complexes consist of two pentamers of GFRP interacting with one decamer of GTPCH 
in a face-to-face manner (Yoneyama and Hatakeyama, 1998, Maita et al., 2002). The 
phenylalanine-mediated feed-forward stimulation via GFRP not only regulates the BH4 
biosynthesis but also provides a mechanism to regulate phenylalanine catabolism and to avoid 
toxic accumulation of phenylalanine (Bader et al., 2001). This may explain the high plasma 
BH4 concentration observed in patients with hyperphenylalaninemia (HPA) caused by PAH 
deficiency (Ponzone et al., 1993).  
 
GFRP has been purified, sequenced and cloned from rat liver (Milstien et al., 1996, Bader et 
al., 2001, Yoneyama et al., 1997). The known GFRP sequences are highly homologous, 
suggesting that the interaction between GTPCH and its regulatory protein are similar in many 
species (Bader et al., 2001). The rat GFRP protein consists of 83 amino acid residues and is a 
pentamer of 50 kDa with identical subunits (Yoneyama and Hatakeyama, 1998, Yoneyama et 
al., 1997, Bader et al., 2001). Crystral structure of rat GFRP has revealed that each of the five 
subunits in GFRP is folded into a α/β-structure with a dominant six-stranded anti-parallel β-
sheet and that the five subunits form a propeller-like pentamer with helix H2 located in the 
interface between the subunits (Bader et al., 2001).   
 
Like GTPCH, GFRP is subjected to transcriptional regulation which contributes to changes in 
both the GTPCH activity and subsequently the BH4 levels. Several studies have demonstrated 
that GFRP mRNA expression is altered in response to different stimuli like bacterial LPS and 
hydrogen peroxide (Gesierich et al., 2003, Kalivendi et al., 2005, Werner et al., 2002) thus 
suggesting that BH4 biosynthesis can be independent of metabolic control by phenylalanine 
(Werner et al., 2002).  
GFRP mRNA studies by Northern blot analysis and in situ hybridization have revealed that 
the expression pattern in rat tissues correlates with that of GTPCH, i.e. GFRP has been found 
to be expressed in the brain but also in peripheral organs such as liver, kidney, heart, lung, 
skeletal muscle, spleen, testis (Milstien et al., 1996, Kapatos et al., 1999).  
 
In contrast to the liver, the regulation of BH4 biosynthesis in brain is not yet known, but 
GFRP appears to be specifically expressed in some brain areas or cell types as indirect 
evidence from studies with primary neuronal cultures which have indicated that GFRP 
regulates BH4 biosynthesis within serotonergic neurons but not within dopaminergic neurons 
(Kapatos et al., 1999).  
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Beside the regulation of the BH4 biosynthesis via GTPCH either at the transcriptional level, 
the posttranscriptional level or by the action of BH4 (feedback inhibition) and phenylalanine 
(feedforward stimulation), the BH4 biosynthesis has also been shown to be regulated via 
PTPS as cell-type-specific exon 3 skipping in the PTPS pre-mRNA have been shown to cause 
a premature stop codon and thereby influencing the PTS gene expression (Leitner et al., 2003, 
Werner et al., 2011). Moreover, phosphorylation of PTPS has been shown to be essential for 
normal protein activity (Scherer-Oppliger et al., 1999). 
 
1.4 BH4 cofactor function 
BH4 is an essential cofactor for several enzymes, among them the three AAAOHs: 1) PAH, 
which is responsible for the degradation of the tyrosine to phenylalanine in the liver, 2) TH, 
which is the rate-limiting enzyme in the biosynthesis of catecholamines (e.g. dopamine) and 
3) TPH1, peripheral and TPH2, neuronal (Walther and Bader, 2003), which are the rate-
limiting enzyme in the 5-hydroxytryptamine (serotonin) biosynthesis (Thöny et al., 2000). 
Moreover, BH4 is cofactor for all three isoforms (neuronal, inducible, and endothelial) of 
NOS as well as AGMO (previous identified as GEMO or ether lipid oxidase) (Wei et al., 
2003, Watschinger et al., 2010, Werner et al., 2003) (the function of NOS and AGMO are 
breifly described below).  
For that reason, BH4 plays an important role in the human metabolism involving 
phenylalanine degradation, monoamine neurotransmitter biosynthesis and nitric oxide (NO) 
production.  
The BH4-dependent NOSs catalyze two sequential monooxygenase reactions: L-arginine 
(Arg) is first hydroxylated to generate N-hydroxy-L-arginine as an enzyme-bound 
intermediate, which is further oxidized in a second reaction to generate nitric oxide (NO) and 
citrulline (Wei et al., 2003). NO plays an important role in the regulation of vascular tone by 
mediating endothelium-dependent vasodilatation.  
 
Furthermore, NO is a potent inhibitor of platelet and leukocyte adhesion to the vascular wall 
and inhibits smooth muscle cell proliferation (Gesierich et al., 2003). There is a positive 
correlation between the availability of BH4 and the biosynthesis of NO in endothelial cells 
and smooth muscle cells (Gesierich et al., 2003). When BH4 is limited in the endothelial cells, 
the electron transferred from eNOS flavins (flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN)) becomes uncoupled to Arg oxidation, the ferrous-dioxygen 
dissociates and superoxide (O2-) is produced from the oxygenase domain.  
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Superoxide generation by eNOS due to limited BH4 has been observed in several vascular 
diseases including diabetes, cigarette smoking, hypertension, chronic nitrate tolerance and 
overt atherosclerosis (Schmidt and Alp, 2007).  
 
AGMO is the only enzyme known to cleave the O-alkyl ether bond in alkylglycerols, yielding 
an aldehyde and a glycerol derivate (Watschinger et al., 2010). The aldehyde is detoxified by 
conversion to the corresponding acid by long-chain fatty aldehyde dehydrogenase. BH4 leaves 
the reaction as q-BH2 which is subsequently recycled back to BH4 by DHPR (Watschinger et 
al., 2010).  
 
Beside, the essential cofactor function for the three AAAOHs, the three NOSs and AGMO, 
BH4 has been found to be involved in other less defined cellular functions such as cell 
proliferation, differentiation, neuroprotection, neurotransmitter release, neuropathic and 
inflammatory pain, dopaminergic neurodegeneration in Parkinson’s disease (Choi et al., 2006, 
Koshimura et al., 2000, Tegeder et al., 2006). Several experiments with PC12 cells have 
demonstrated how the decision whether a cell proliferates or dies, either due to apoptosis or 
necrosis, is influenced by BH4 (Werner-Felmayer et al., 2002). Moreover, it has been reported 
that 6R-BH4 content in CSF decreases in aged people suggesting a role of 6R-BH4 for aging 
(Koshimura et al., 2000).  
 
Additionally, BH4 biosynthesis has also been found to be important in cells that do not 
contain the AAAOHs for instance lymphocytes where the production of biopterins are 
significantly increased during immune activation (1988).  
 
1.5 Human BH4 deficiencies 
Human BH4 deficiencies, previously termed “atypical PKU”, are a highly heterogeneous 
group of rare progressive neurological disorders ranking from mild forms without any 
treatment to more severe forms which require life-long treatment (Shintaku et al., 1988). BH4 
deficiencies are caused by autosomal recessively inherited (expect for the autosomal dominant 
inherited form of GTPCH deficiency (Segawa’s disease or dopa-responsive dystonia (DRD) 
(Segawa et al., 1976, Ichinose et al., 1994)) mutations either in one of the three genes 
encoding for the biosynthetic enzymes (GTPCH, gene GCH1, PTPS, gene PTS and SR, gene 
SPR) or in one of the two genes encoding for the regenerating enzymes (PCD/DCoH, gene 
PCBD and DHPR, gene QDPR) (Thöny and Blau, 2006) (Figure 2).  
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In most cases, BH4 deficiencies are affecting the biosynthesis of catecholamines (e.g. 
dopamine, norepinephrine and epinephrine) and indoleamines (serotonin and melatonin) 
(Nagatsu and Ichinose, 1999), the phenylalanine homeostasis (except for the dominant form 
of GTPCH deficiency and SR deficiency (Blau et al., 2001) as well as the NO production 
(Schmidt and Alp, 2007) (Campeau et al., 2007).  
 
Symptoms associated with BH4 deficiencies are characterized by developmental delay, 
progressive neurological deterioration, hypokinesia (abnormally diminished motor activity), 
hypersalivation and drooling, swallowing difficulties, truncal hypotonia (floppiness), 
increased limb tone, myoclonus (sudden twitching of muscles) and temperature instability 
(Bonafe et al., 2001, Thöny and Blau, 2006).  
 
The diagnosis of BH4 deficiencies is an integral part of the newborn screening program for 
phenylkenonuria (PKU) by Guthrie test (Guthrie and Susi, 1963) (in healthy normal people, 
phenylalanine levels are usually under 120 µmol/L) (Blau et al., 1996).  
 
The definitive diagnosis of BH4 deficiencies in newborns with blood phenylalanine levels 
greater then 120 µmol/L and in order children with consistent neurological symptoms, is 
achieved by urinary pterin analysis, DHPR activity measurements (e.g. in erythrocytes), BH4 
loading tests and examination of the cerebrospinal fluid (CSF) as well as DNA analysis (Blau 
et al., 1996, Longo, 2009). Moreover, the analysis of neopterin and biopterin as well as the 
neurotransmitter metabolites, HVA and 5-HIAA in the CSF, enables differentiation between 
severe and mild forms of BH4 deficiencies (Blau et al., 1996).  
 
Two BH4 deficiencies occur without HPA namely the dominant form of GTPCH deficiency 
as well as SR deficiency and thus can not be detected by the newborn screening program for 
PKU (Blau et al., 2001, Thöny and Blau, 2006). Instead, these deficiencies are recognized 
either by typical clinical signs and symptoms or by analysis of the neurotransmitter 
metabolites and pterins in CSF and investigation of cultured skin fibroblasts (Blau et al., 
2001).  
 
1.5.1 PTPS deficiency 
According to the international database of BH4 deficiencies BIODEF (Blau et al., 1996) 
(available at www.biopku.org), the most common cause of BH4 deficiencies is due to 
autosomal recessively inherited mutations in the PTS gene (approximately 54 % of all cases 
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of BH4 deficiencies) (Figure 2). Among the 356 patients with PTPS deficiency (BIODEF), 
more than 52 mutant alleles have been found (International database of mutations causing 
tetrahydrobiopterin deficiencies, BIOMDB (available at www.bh4.org)). 
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Figure 2:  The most common cause of BH4 deficiency is due to mutations in the PTS gene  
Human BH4 deficiency is caused by mutation in one of the three enzymes involved in the biosynthesis of BH4 
(GTPCH, PTPS and SR) or in one of the two enzymes involved in the recycling of BH4 (PCD and DHPR). The 
most common cause of BH4 deficiency is according to the international database of BH4 deficiencies BIODEF 
(available at www.bh4.org) due to insufficient PTPS activity. Note that the GCHFR gene, encoding GFRP, is 
the only gene in the BH4 metabolism for which no human deficiency has been described. The numbers of BH4 
deficient patients (total of 628) were obtained from the international database of BH4 deficiencies BIODEF at 
www.bh4.org. 
 
Patients with insufficient PTPS enzyme activity have difficulties with the conversion of 
NH2TP to PPH4, consequently this leads to an accumulation of NH2TP. In the tissue, NH2TP 
is dephosphoylated by various endogenous phosphatases to the intracellular active 7,8-
dihydroneopterin which is predominant in several body fluids and can among others be 
detected in the urine and CSF as neopterin which is the oxidized form of 7,8-dihydroneopterin 
(1988). Moreover, PTPS-deficient patients develop HPA and neurological symptoms mainly 
due to lack of catecholamines and serotonin (Demos et al., 2005).  
 
Mutations in the PTPS gene, which are distributed throughout all six exons (Thony and Blau, 
1997), are associated with a broad spectrum of phenotypes ranging from HPA only to 
abnormal monoamine neurotransmitter biosynthesis.  
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In 80 % of the PTPS-deficient patients a severe central phenotype is observed with 
monoamine neurotransmitter deficiency assessed by CSF measurement of catecholeamines 
and serotonin metabolites (HVA and 5-HIAA) (Thöny and Blau, 2006, Longo, 2009). 
Conversely, 13 % of the PTPS patients have a mild peripheral phenotype characterized with 
moderate or transient HPA only (no neurological involvement and normal neurotransmitter 
homeostasis in the CSF) (Thöny and Blau, 2006, Longo, 2009). The molecular mechanisms 
for these phenotypic distinctions are unknown.  
 
The patients with the severe/central form of PTPS deficiency require a combined therapy with 
oral neurotransmitter precursors (L-dopa, 5-hydroxytryptophan and carbidopa (AADC 
inhibitor)) as well as BH4 supplementation whereas the patients with the mild/peripheral 
require “only” mono-therapy with BH4 supplementation to maintain normal blood 
phenylalanine concentrations (Dudesek et al., 2001). Unfortunately, some infants do not 
respond to conventional therapy despite early diagnose and some of them died (Dudesek et 
al., 2001).  
 
The severe form of PTPS deficiency resemble Parkinson’s Disease (indicating a lack of 
dopamine in the basal ganglia) and is associated with truncal hypotonia, increased limb tone, 
postural instability, hypokinesia, choreatic or dystonic limb movements, gait difficulties, 
seizures (myoclonic and tonic clonic), hypersalivation and drooling due to swallowing 
difficulties as well as oculogyric crises (a paroxysm in which the eyes are held in a fixed 
position) (Dudesek et al., 2001, Blau et al., 1996). Moreover, ataxia (failure of muscular 
coordination), hyperreflexia (exaggeration of reflexes), hypothermia (body temperature below 
35oC) as well as episodes of hyperthermia (in the absence of infections), drowsiness 
(sleepiness), irritability, lethargy (state of sluggishness, inactivity, and apathy), disturbed 
sleep pattern, ptosis (dropping upper eyelid), pinpoint pupils and convulsions (involuntary 
contractions) are often observed (Dudesek et al., 2001, Blau et al., 1996).  
 
The symptoms may become evident in the first weeks of life (abnormal signs in the neonatal 
period includes poor sucking, impaired tone and microcephaly (abnormal smallness of the 
head)) but are mostly seen at an average age of 4 months (Dudesek et al., 2001).  
 
In order to investigate the phenotypic distinctions associated with mutations in the PTS gene 
and to analyze the consequences of BH4 deficiency and its potential treatment in more details, 
corresponding animal models are required.   
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1.6 Mouse models in the BH4 metabolism 
Since the development of transgenic mouse model technology, mouse models have become 
the leading mammalian model organism for studying human genetic diseases. Today, 
numerous mutated mouse lines exist, in fact estimations have suggested that approximately 
half of all the mouse genes have been targeted and corresponding mouse lines established 
(Beckers et al., 2009).  
 
Several mouse gene knock-out programs such as the NIH knock-out mouse project (KOMP), 
the European Conditional Mouse Mutagenesis Program (EUCOMM), the North American 
Conditional Mouse Mutagenesis Project (NorCOMM) and the Texas A&M Institute for 
Genomic Medicine (TIGM) have all been established exclusively with the aim of generating a 
null mutation in every gene in the mouse genome (Thöny and Finnell, 2009).  
 
Several mouse models for human defects in the BH4 metabolism have been generated 
including the autosomal dominant from of GTPCH (DRD, Segawa’s disease) (hph-1 mouse 
as a model for dominantly inherited GTPCH deficiency), PTPS, SR, PCD/DCoH and DHPR 
((Thöny and Gibson, 2006), (Thöny and Finnell, 2009) and (Werner et al., 2011)) (Table 1). 
So far no animal models for either the autosomal recessive form of GTPCH or GFRP have 
been generated (Table 1).  
 
Table 1: Available mouse models within the BH4 metabolism 
___________________________________________________________________________ 
Human BH4 deficiency                          Available mouse model                                                  References 
____________________________________________________________________________________________________ 
GTPCH, recessive  Not available      - 
GTPCH, dominant (DRD)      Available (hph-1)      (Hyland et al., 2003, Sato et al., 2008, McDonald et al., 1988) 
PTPS   Available (Pts-knock-out)   (Elzaouk et al., 2003, Sumi-Ichinose et al., 2001) 
SR  Available (Spr-knock-out)             (Takazawa et al., 2008, Yang et al., 2006)  
PCD/DCoH Available (DCoH-knock-out)               (Bayle et al., 2002) 
DHPR Available (Dpr-knock-out)                     Unpublisheda  
GFRP Not available                                 - 
___________________________________________________________________________ 
 
Table 1 is adapted from (Thöny and Gibson, 2006), (Thöny and Finnell, 2009) and (Werner et al., 2011). 
a
 Oral Presentation (BH4 Metabolism in the Brains of KO mice) at the 14th International Symposium on 
Pteridines and Folates by Prof. Hiroshi Ichinose. 
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The first BH4-deficient mouse to be generated was a Pts-knock-out mouse (Pts-ko) with a 
complete disruption of the Pts gene (Ichinose et al., 2008).  
Studies have shown that the homozygous Pts-ko mice died within hours after birth (Elzaouk 
et al., 2003, Sumi-Ichinose et al., 2001). The biochemical analysis revealed HPA, no PTPS 
enzyme activity in liver and brain, high levels of neopterin in liver and brain, low levels of 
biopterin in liver and brain as well as neurotransmitter deficiency in the CNS due to 
undetectable or very low levels of dopamine and serotonin (Elzaouk et al., 2003). 
Nevertheless, daily oral administration of BH4 and neurotransmitter precursors (5-
hydroxytryptophan and L-dopa) rescued the mice from lethality. Yet, the overall condition of 
the homozygous Pts-ko mice was very serious partly because of severe dwarfism due to 
growth deficiency (Elzaouk et al., 2003).  
 
Patients with PTPS deficiency do not reveal newborn lethality although symptoms may be 
notable during the neonatal period (Elzaouk et al., 2003). Furthermore, low birth weight and 
microcephaly, which are typical for human PTPS deficiency, were not observed in the 
homozygous Pts-ko mice (Elzaouk et al., 2003). On the other hand, some symptoms like 
hypersalivation and temperature instability were found both in the Pts-ko mice and in the 
human patients (Elzaouk et al., 2003).  
 
Mouse models for SR and PCD/DCoH deficiencies have all been successful generated 
although these models were only partially reflecting the corresponding human counterparts 
(Takazawa et al., 2008, Yang et al., 2006, Bayle et al., 2002). As an example, the Spr knock-
out (Spr-ko) mice exhibit HPA and severe growth retardation (Yang et al., 2006, Takazawa et 
al., 2008, Ichinose et al., 2008).  
 
1.6.1 German Mouse Clinic (GMC) 
To take full advantage of transgenic mice as model organism for human diseases systematic 
(assessing all mouse lines) and systemic (assessing all organs) phenotypings are crucial 
(Beckers et al., 2009).  
 
Comprehensive systemic phenotyping at the German Mouse Clinic (GMC) in Munich has 
thus far identified new and unexpected phenotypes in 96 % of the more then 100 mutant 
mouse lines investigated (Gailus-Durner et al., 2005, Fuchs et al., 2009, Beckers et al., 2009, 
Fuchs et al., 2011).  
 
A complete primary screen at the GMC requires 80 mice (20 mutant males, 20 mutant 
females, 20 male controls and 20 female controls). The 80 mice which are born with 7 days 
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difference to reduce the heterogeneity within the cohort are imported to the clinic at the age of 
8 weeks. After adaptation, the primary screening is started in the second week and completed 
after 10 weeks when the mice are at the age of 18 weeks (Figure 3).  
 
Within the primary screen, the mice are distributed into two different pipelines; each pipeline 
consists of a cohort of 10 animals per sex and genotype.  
 
 
 
Figure 3: Schematic representation of the primary screening at the German Mouse Clinic (GMC) 
The primary screening at the GMC consists of 550 parameters and detailed pathological examination. Within 
the primary screening), the 80 mice (20 mutant males, 20 mutant females, 20 male controls and 20 female 
controls) are distributed into two different pipelines; each pipeline consists of a cohort of 10 animals per sex 
and genotype. The primary screening takes 10 weeks and ends when the mice are at the age of 18 weeks. Based 
on the out-come of the primary screening, decisions for secondary and tertiary screening are made. DEXA: 
Dual-energy X-ray absorption, IPTGTT: Intraperitoneal glucose tolerance test, LIB: Laser interference 
biometry, PPI: Pre-pulse inhibition, SHIRPA: a protocol for comprehensive behaviour assessment, FACS: 
fluorescence activated cell sorting, PBC: peripheral blood cell, Ig: Immunoglobulin, DHEA: 
Dehydroepiandrosteron, ECG: electrocardiogram.   
                                                                                Figure from http://www.mouseclinic.de/index.php?id=11119.  
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In the first pipeline, the mice are subjected to non-invasive tests which among others 
investigate the dysmorphology, blood pressure, calorimetry, intraperitoneal glucose tolerance, 
bone densitometry, axial eye length and lung function (Fuchs et al., 2009) (Figure 3).  
 
In the second pipeline, the mice are subjected to a series of behavioural and neurological tests 
including open field, modified SHIPRA, grip strength, rotarod, acoustic startle, pre-pulse 
inhibition, hot plate test as well as examination of the eyes and vision (Fuchs et al., 2009). 
Furthermore, blood-samples are taken to examine different parameters within immunology, 
allergy, clinical chemistry, cardiovascular and steroid parameters (Fuchs et al., 2009) (Figure 
3).  
 
Depending on the primary screening, secondary and tertiary screenings are performed 
conversely these additional screenings requires a new cohort of mice (Beckers et al., 2009, 
Fuchs et al., 2009).  
 
1.7 Metabolism and function of serotonin 
Serotonin which is also known as 5-hydroxytryptamine or 5-HT is synthesized from the 
essential amino acid tryptophan (Trp) via 5-hydroxytryptophan (5-OH-Trp) by the action of 
two enzymes: BH4-cofactor-dependent TPH and AADC, respectively (Haavik et al., 2008). 
TPH exist in two isoforms with distinct function and  localization,  a  peripheral  isoform  
called  TPH1  and  a  neuronal  isoform called TPH2 (Walther and Bader, 2003, Haavik et al., 
2008). Degradation of serotonin to its end-metabolites 5-hydroxyindolacetic acid (5-HIAA) 
involves monoamine oxidase A (MAO-A) in combination with aldehyde dehydrogenase 
(ALDH) (Figure 1) (Haavik et al., 2008).  
 
 
In the periphery, the primary source for serotonin is in the gut, where it is synthesized by 
enterochromaffin cells of the mucosa. The serotonin production in the intestinal wall makes 
up more than 90% of the total generated serotonin. From the enterochromaffin cells, the 
serotonin is releases into the bloodstream, where it is taken up by platelets and transported to 
all vascularised tissues (Haavik et al., 2008, Alenina et al., 2006).  
 
Serotonin is involved in a broad spectrum of biological, behavioural and psychological 
conditions including mood, sleep, depression, autism, memory, learning, appetite, eating 
disorders, obesity, anxiety, seizures, aggression, migraine, alcoholism, cognition, attention-
deficit/hyperactivity disorder (ADHD), body temperature, obsessive-compulsive disorders 
(OCD), sexual and motor activity, schizophrenia, pain perception, cardiovascular function, 
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muscle contraction homeostasis, endocrine functions, adult respiratory distress syndrome 
(ARDS), substance abuse disorders, neurodegenerative disorders, as well as social interaction 
and affiliation (Hahn and Blakely, 2007, Murphy et al., 2008, Haavik et al., 2008).  
 
1.7.1 Serotonin and brain development  
In addition to its neurotransmitter function in the mature nervous system, serotonin also plays 
an important role during the development of the brain. In the human brain, serotonergic 
neurons are first evident by 5 weeks of gestation which makes serotonin the first of the 
monoamine neurotransmitter systems to be present in the terminal regions (Whitaker-Azmitia, 
2001). This fact emphasizes the importance of serotonin during brain development. The 
amount of serotonergic neurons increases rapidly through the first 10th week of gestation and 
by the 15th week of gestation, the typical organization of serotonin cell bodies into the raphe 
nuclei can be seen. The serotonin levels then increase slowly throughout the first two years of 
life and then decline to the adult levels by the age of 5 years (Whitaker-Azmitia, 2001).  
 
Serotonin indirectly stimulates and inhibits its own growth thereby insuring that the serotonin 
terminals reach their correct target areas (Whitaker-Azmitia, 2001).  
At the target areas serotonin influences several processes such as neurogenesis and/or 
neuronal removal, dendritic refinement, synaptic remodelling and maintenance and cell 
migration (Whitaker-Azmitia, 2001). Studies on rats have shown that removal of serotonin 
during very early fetal development causes a permanent reduction in the number of neurons in 
adult brain (Whitaker-Azmitia, 2001). The concentration of serotonin can be changed during 
development by viral infection, malnutrition, social enrichment and/or isolation, hypoxia and 
stress (Whitaker-Azmitia, 2001).  
 
1.7.2 Neurohormone 
Beside, numerous roles as a monoamine neurotransmitter both in the central and peripheral 
nervous system, serotonin is also a neurohormone that via the hypothalamic-pituitary-
adrenal (HPA) axis and the hypothalamic-spinal-adrenal (HAS) axis modulates the 
glucocorticoid secretion upon response to stressful stimuli (Mueller et al., 2010, Lowry, 
2002). Subsequently, the released glucocorticoids influence metabolic, immune and 
developmental processes (Mueller et al., 2010). Studies on newborns have linked promoter 
region polymorphisms within the serotonin transporter gene to an increased stress reactivity 
of the HPA-axis (Mueller et al., 2010).  
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1.8 Serotonin transporters (SERT and PMAT) 
1.8.1 Serotonin re-uptake transporter (SERT) 
The human serotonin re-uptake transporter (SERT or 5-HTT) which is encoded by the 
SLC6A4 gene belongs together with the genes encoding for dopamine transporters (DAT, 
SLC6A3) and norepinephrine transporters (NET, SLC6A2) to the solute carrier 6A (SLC6A) 
family, (member 4) (Hahn and Blakely, 2007, Torres et al., 2003). Solute carrier 6A (SLC6A) 
is a gene family of ion-coupled plasma membrane co-transporters that mediate the movement 
of their substrate (e.g. serotonin) into cells to regulate synaptic transmission, neurotransmitter 
recycling, metabolic function and fluid homeostasis (Hahn and Blakely, 2007).  
 
The SLC6A4 gene is located on chromosome 17q11.1-17q12 and consists of 15 exons 
spanning approximately 40 kb (Murphy et al., 2008, Ramamoorthy et al., 1993). Transcription 
of the SLC6A4 gene leads to a plasma membrane protein composed of 630 amino acids, 12 
transmembrane domains as well as cytoplasmic amino and carboxy termini (Torres et al., 
2003). The transcriptional activity of the SLC6A4 gene is modulated by several factors among 
these are two common variable number of tandem repeat (VNTR) polymorphisms in the 5-
HTT gene-linked polymorphic promoter (5-HTTLPR) region and in intron 2 (serotonin 
transporter intron 2 VNTR or STin2 VNTR), respectively.  
 
The 5-HTTLPR promoter sequence which is located about 1 kb upstream of the transcription 
start site contains two VNTR polymorphisms known as the long (L) or short variant (S), 
which differ with respect to an insertion/deletion of 44 base-pairs (Esterling et al., 1998, Heils 
et al., 1996, Lesch et al., 1996). The long 5-HTTLPR variant with 16-repeats and short 5-
HTTLPR variant with 14-repeats are known to lead to different expressions of the serotonin 
re-uptake transporter protein in pre-synaptic nerve membranes (Heils et al., 1996, Lesch et al., 
1996, D'Souza and Craig, 2006).  
Studies have shown that the long 5-HTTLPR variant expresses significantly more SERT 
mRNA and subsequently more SERT protein on the pre-synaptic nerve membrane compared 
to the L/S and S/S variants (Heils et al., 1996, D'Souza and Craig, 2006) (Figure 4).  
As a consequence, the L/L 5-HTTLPR variant leads to a lowered concentration of serotonin 
in the synaptic cleft as the serotonin re-uptake is more than 2-fold higher in L/L expressing 
cells than cells carrying one (L/S) or two (S/S) copies of the short 5-HTTLPR variant of the 
promoter (Lesch and Gutknecht, 2005) (Figure 4). 
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Opposite, the short variant of 5-HTTLPR leads to a reduced rate of SERT mRNA 
transcription thus less SERT protein is expressed on the pre-synaptic nerve membrane and the 
serotonin re-uptake activity is lowered (Lesch et al., 1996, D'Souza and Craig, 2006) 
(Figure 4).  
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Figure 4: Expression of  the long 5-HTTLPR and short 5-HTTLPR in the pre-synaptic nerve terminal 
In the pre-synaptic nerve terminal, serotonin is synthesized from tryptophan (Trp) via 5-hydroxytryptophan (5-
OH-Trp) by the BH4-dependent tryptophan hydroxylase (TPH) and the aromatic amino acid decarboxylase 
(AADC). Serotonin is released from the pre-synaptic axon terminal into the synaptic cleft by serotonin-carrying 
vesicles. The action of serotonin in the synaptic cleft is tightly regulated by serotonin re-uptake transporter 
(SERT) located in the pre-synaptic plasma membrane. The long 5-HTTLPR variant of the SLC6A4 gene 
produces significantly more SERT mRNA and protein than the short 5-HTTLPR variant. Consequently, the 
long 5-HTTLPR variant leads to lower concentration of the serotonin in the synaptic cleft compared to the short 
5-HTTLPR variant. After re-uptake of serotonin into the pre-synaptic nerve terminal by SERT, serotonin can 
either be recycled (back into the serotonin-carrying vesicles by vesicular monoamine transporter (VMAT)) or 
degraded to its end-metabolite 5-hydroxyindoleacetic acid (5-HIAA) by monoamine oxidase A (MAO-A). 
Figure adapted from (Canli and Lesch, 2007) and (Gerretsen and Pollock, 2008). 
 
 
 
Another common variant of the SLC6A4 locus, which potentially modulates the serotonin 
re-uptake transport protein in terms of function and expression, is a variable number of 
tandem repeat (VNTR) polymorphism of 17-bp repeats in intron 2, STin2.9, STin2.10, and 
STin2.12, containing 9, 10 and 12 copies of the VNTR element, respectively (MacKenzie and 
Quinn, 1999).  
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Expression in transgenic embryos and embryonic stem cells suggests that the STin2 VNTR 
polymorphism acts as a regulator of transcription (Hahn and Blakely, 2007). The STin2.12 
allele, which is the most common of the three VNTRs, has been reported to cause a 
significantly higher expression of the SLC6A4 gene in embryonic mouse rostral hindbrain 
compared to the STin2.9 and STin2.10 alleles demonstrating that STin2.12 is a transcriptional 
enhancer (MacKenzie and Quinn, 1999). In contrast, a smaller number of VNTRs such as 
STin2.9 and STin2.10 have been hypothesized to influence the stability of the transcription 
complexes and steady-state concentrations of mRNA, thereby causing less SLC6A4 gene 
expression than STin2.10 (Ogilvie et al., 1996).  
 
Besides, the non-coding functional VNTR polymorphisms of the SLC6A4 gene in the 
promoter region and intron 2, a number of functional gene variants in the coding alleles have 
also been shown to modulate the SERT activity in terms of gene expression, protein 
trafficking or protein regulation (Lesch et al., 1996, Murphy et al., 2008, Prasad et al., 2009).  
 
Among them is the non-synonymous variant Gly56Ala in exon 3, which has been reported to 
be associated with autism and rigid compulsive behaviours (Sutcliffe et al., 2005). 
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Figure 5: Gly56Ala in SERT causes an up-regulation regarding serotonin transport (gain of function) 
Both the heterozygous (Gly56Ala) and homozygous (Ala56Ala) amino acid substitution at position 56 in the 
SERT protein have been shown to cause a significant increase in serotonin uptake (5-HT Uptake 
pmol/5min/106 cells) when transfected into lymphoblastoid cells compared to cells expressing the wild-type 
(Gly56Gly) SERT protein. This figure is adapted from (Sutcliffe et al., 2005). 
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This alanine to glycine exchange at position 56, which showed constitutively elevated SERT 
activity, is located in the N-terminal intracellular tail of the SERT protein (Sutcliffe et al., 
2005) (Figure 6). Pharmacological studies of serotonin re-uptake by lymphoblastoid cells 
expressing the heterozygous Gly56Ala or homozygous 56Ala protein mutants indicated a 
progressive gain of function by 1.4 or 1.8 fold, respectively, despite normal surface 
expression compared to lymphoblastoid cells expressing the wild-type SERT (Gly56) 
(Sutcliffe et al., 2005, Veenstra-Vanderweele et al., 2009) (Figure 5).  
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Figure 6: Ion coupling stoichiometry for SERT and location of SERT-coding variant Gly56Ala 
A: External serotonin is transported together with Na+ and Cl- ions into the intracellular space by SERT (grey 
circle). This co-transport of serotonin, Na+ and Cl- ions causes a conformational change within the SERT 
protein which allows an intracellular K+ ion to be transported outwards, which makes the transport cycle 
electronneutral and the SERT protein capable of binding another molecule of external serotonin. This figure is 
adapted from (Rudnick, 1998). B: Schematic model representation of the 12 transmembrane SERT with 
intracellular NH2 and COOH termini. The functional SERT-coding variant Gly56Ala (black circle), which has 
demonstrated elevated SERT activity, is located in the NH2-terminal intracellular tail of the SERT protein. This 
figure is adapted from (Prasad et al., 2009), (Veenstra-Vanderweele et al., 2009) and (Sutcliffe et al., 2005). 
 
The driving force for the re-uptake of serotonin by SERT is the ion concentration gradient of 
Na+ and Cl- ions generated by the plasma membrane ion-pumping Na+/K+ ATPase (Torres et 
al., 2003).  The binding of serotonin together with Na+ and Cl- ions (one of each) to the 
extracellular part of SERT causes a conformational change allowing the concomitant 
translocation of serotonin, Na+ and Cl- ions into the cytoplasm as well as exposure of an 
intracellular K+ ion binding site (Figure 6).  
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In exchange, one intracellular K+ ion is transported outwards, which makes the transport cycle 
electronneutral and the SERT protein capable of binding another molecule of external 
serotonin (Torres et al., 2003, Barker et al., 1999, Rudnick, 1998) (Figure 6).  
 
In the brain, monoamine transporters are expressed almost exclusively in the neurons that 
contain their cognate transmitter which means that SERT is expressed in the median and 
dorsal raphe nuclei (Torres et al., 2003). Additionally, SERT protein has also been found in 
peripheral locations, including the platelets, intestinal tract, placenta, mast cells, basophils and 
adrenal gland (Torres et al., 2003). Altogether, demonstrating that SERT serves many 
different physiological functions both in the CNS and the periphery (Rudnick, 1998). 
 
The SERT protein is a target for several pharmacological agents that affect brain function, 
including psychostimulants (cocaine and amphetamines), antidepressants and neurotoxins 
(Torres et al., 2003). The pharmaclolgical agents, which bind to SERT and inhibit the 
serotonin re-uptake transport can either act as substrates, selective serotonin re-uptake 
inhibitors (SSRIs) or non-selective serotonin re-uptake inhibitors (SRIs) (Torres et al., 2003). 
Both the selective and non-selective serotonin inhibitors are thought to occupy sites 
overlapping the substrate binding site and are widely used in treatment of neuropsychiatric 
disorders including affective disorders, depression, anxiety disorders, obsessive-compulsive 
disorder (OCD), autism, eating disorders and substance abuse such as alcoholism (Lesch and 
Gutknecht, 2005, Murphy et al., 2004).  
 
1.8.2 Plasma membrane monoamine transporter (PMAT) 
The human plasma membrane monoamine transporter (PMAT or ENT4) which is encoded by 
the SLC29A4 gene, belongs to the equilibrative nucleoside transporters (ENTs) family, 
SLC29 (member 4) (Baldwin et al., 2004). This family is known to be nucleoside transporters 
that specifically transport nucleoside and their structural analogs (Kong et al., 2004). 
However, characterization studies have shown that PMAT functions as a polyspecific organic 
cation transporter for substrates such as 1-methyl-4-phenylpyridinium (MPP+), 
tetrahylammonium and biogenic amines including serotonin, dopamine, norepinephrine, 
epinephrine as well as histamine.  
Unlike the rest of the SLC29 family, PMAT only minimally interacts with nucleosides, 
nucleoside analogs, nucleobases or nucleotides (Engel et al., 2004, Zhou et al., 2007). Hence, 
the substrate selectivity of PMAT is more similar to the organic cation transporters (OCTs) in 
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the SLC22 family then the substrate selectivity of the SLC29 family (Zhou et al., 2007). The 
deviation of SLC29A4 from the rest of the SLC29 family is also reflected in the low 
homology (~ 20 %) (Engel et al., 2004). Despite similar substrate selectivity with OCTs its 
sequence identity to the OCTs is only 11-14 % (Zhou et al., 2007).  
The SLC29A4 gene is located at chromosome 7p22.1 and is translated into a plasma 
membrane transporter protein composed of 530 amino acids with a calculated molecular mass 
of 58 kDa (Engel et al., 2004) (Figure 24). Hydropathy analysis have predicted the presence 
of 11 membrane-spanning domains, a cytoplasmic N-terminus and an extracellular C-
terminus (Engel et al., 2004) (Figure 24).  
 
Whereas SERT-mediated transport is Na+ and Cl--dependent, the re-uptake activity of PMAT 
does not rely on the presence of Na+ and Cl- ions thus the PMAT-mediated re-uptake transport 
is ion-independent (Engel et al., 2004). Instead, the PMAT-mediated transport appears to be 
sensitive to changes in the membrane potential (Engel et al., 2004). Beside the ion-
independent transport, PMAT also differentiate from SERT in terms of substrate affinity and 
inhibitor insensitivity.  
The substrate affinity of PMAT for serotonin and dopamine are 2-3 orders of magnitude 
lower than those of SERT and DAT. However, the Vmax values of PMAT-mediated 
serotonin and dopamine transport are 2-3 of magnitude higher. Together, suggesting that 
PMAT in contrast to SERT is a low affinity but with high capacity transport for serotonin 
(Daws, 2009, Engel et al., 2004). Moreover, PMAT has shown to be insensitive towards the 
high affinity inhibitors of SERT such as fluoxetine (Prozac) and tricyclic antidepressant 
desipramine (Engel et al., 2004, Vialou et al., 2007).  
Northern blot analysis of human PMAT mRNA transcript has shown that PMAT is widely 
expressed in the CNS including the cerebellum, cerebral cortex, medulla, spinal cord, 
occipital pole, frontal lobe, temporal lobe and putamen (Engel et al., 2004). Beside expression 
of PMAT in different brain tissue, PMAT has also been detected in various peripheral tissue 
including the skeletal muscles, kidney, heart and liver (Engel et al., 2004).  
 
1.8.3 SLC6A4 gene variants and neurological behaviour, traits and disorders 
Several neuropsychiatric conditions have been associated with SERT gene variations, among 
these are bipolar affective disorder, depression, anxiety, OCD, suicide, eating disorders, 
schizophrenia, substance-abuse disorders such as alcohol abuse, autism, ADHD and 
neurogenerative disorders (Hahn and Blakely, 2007, Lesch and Gutknecht, 2005).  
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In addition, SERT gene variations are also implicated in diseases of peripheral systems 
particular myocardial infarction, primary pulmonary hypertension, irritable bowel syndrome 
and sudden infant death syndrome (SIDS) have also been linked to SLC6A4 gene (Hahn and 
Blakely, 2007, Murphy et al., 2008, Murphy et al., 2004).  
 
Numerous association studies have linked variants within the SLC6A4 gene with autism both 
in terms of the short and long 5-HTTLPR allele, STin2 VNTRs and coding variants in SERT 
such as Gly56Ala in exon 3 (Cook et al., 1997, Klauck et al., 1997, Sutcliffe et al., 2005, 
Prasad et al., 2009). Subsequently, studies have yielded inconsistent findings (Veenstra-
Vanderweele et al., 2009, Huang and Santangelo, 2008, Sakurai et al., 2008).  
 
The SLC6A4 gene is of special interest for autism for at least three reasons (Huang and 
Santangelo, 2008):  
 
1) Serotonin has been shown to regulate the development of the CNS (Whitaker-
Azmitia, 2001) and to be involved in a broad spectrum of behavioural and 
psychological processes (e.g. social behaviour, aggression and anxiety) and various 
psychiatric disorders (Murphy et al., 2004).  
2) Several studies have reported that approximately one-third of all autistic patients 
have elevated levels of whole blood (or platelet) serotonin (hyperserotoninemia) 
(Cross et al., 2008, Leboyer et al., 1999). This hyperserotoninemia which is believed 
to be caused by abnormal maturation of the serotonin system (Leboyer et al., 1999, 
Whitaker-Azmitia, 2001), is also suggested to be either directly or indirectly 
responsible for the immune abnormalities observed among autistic subjects (Burgess 
et al., 2006). In addition, alterations of serotonin synthesis in the 
dentatothalamocortical pathway were found in autistic boys (Chugani et al., 1997, 
Chugani, 2002). Altogether, suggesting that abnormal serotonergic transmission may 
be important in the pathogenesis of autism (Chugani et al., 1997, Chugani, 2002) .  
3) Increased repetitive behaviours and irritability were observed in autistic patients 
when subjected to a dietary depletion of the serotonin precursor tryptophan due to an 
expected reduction in extracellular serotonin availability (Veenstra-Vanderweele et al., 
2009). Opposite, increased extracellular serotonin availability due to administration of 
SSRIs to individuals with autism led to reduced symptoms of irritability and rigid-
compulsive behavior (Veenstra-Vanderweele et al., 2009, Buitelaar and Willemsen-
Swinkels, 2000).  
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1.9 Autism Spectrum Disorder (ASD) 
Autism was first recognized in 1943 by Leo Kanner in 11 boys with autistic disturbances of 
affective contact (Kanner, 1943). Throughout, the 1960s and 1970s autism was considered to 
be a form of psychosis or childhood schizophrenia. Additionally, the conventional perception 
was that autism was related to parenting styles (Geschwind, 2009). In the later decades, it was 
demonstrated that autism is not caused by bad parenting but rather due to heritable factors 
determined by multiple genes whose identity or variation may be distinct in different families 
(Spence, 2004, Prasad et al., 2009). Moreover, autism was found not to be a mental illness but 
instead a complex lifelong neuro-developmental disorder affecting the functioning of the 
brain and which typically appears during the first three years of life (Lamb et al., 2009).  
 
Classical autism, which is also known as Kanner autism or typical autism belongs together 
with Asperger’s syndrome and pervasive developmental disorder – not otherwise specified 
(PDD-NOS) (or atypical autism) to autism spectrum disorders (ADSs) (Levy et al., 2009).  
 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
(DSM-IV), the diagnostic criteria for ASDs are based on severe and pervasive impairments 
within three behavioural domains 1) social interaction, 2) language, verbal and non-verbal 
communication as well as imaginative play and 3) repetitive, restrictive, stereotyped or 
unusual patterns of behaviours, interests and activities (Muhle et al., 2004, Geschwind, 2009). 
The diagnostic assessment of ASDs depends on the number and distribution of endorsed 
behavioural descriptions in each of the three domains as well as on the age of onset (Muhle et 
al., 2004). In addition, to the three domains, several other areas of clinical dysfunction are 
observed in autistic patients including sensory abnormalities, motor abnormalities, sleep 
disturbance, gastrointestinal symptoms and epilepsy (Geschwind, 2009).  
 
Strong evidence has reported that ASDs are highly heritable disorders. The heritability, which 
has been estimated from family and twin studies, suggests that about 90 % of variance is 
attributable to genetic factors (Levy et al., 2009). ASDs are due to multi-factors which act 
together to produce the phenotype (i.e. gene-gene and/or gene-environmental interactions) 
(Levy et al., 2009). Despite, the evidence from twin and family studies, the identity and 
number of genes involved are not yet known (Muhle et al., 2004). Current models estimate 
that at least 20 genes interact with each other and probably with environmental factors to 
create these complex disorders (Spence, 2004).  
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1.10 Aim of the thesis 
Transgenic mouse models are essential for studying gene function and provide an important 
tool in experimental medicine and in modelling human genetic disorders. This also applies to 
human BH4 deficiencies, which are a highly heterogeneous group of rare autosomal recessive 
inherited disorders, mostly characterized by HPA, reduced BH4 levels and monoamine 
neurotransmitter deficiency in the CNS. For a better understanding of BH4 deficiencies, the 
need for efficient animal models to study various aspects of human BH4 deficiency is crucial.  
 
In the design phase of this thesis in 2007, several mouse models for human defects in the BH4 
metabolism had already been generated including dominant form of GTPCH, PTPS, SR and 
PCD/DCoH. The first mouse model for PTPS, a complete knock-out of the Pts gene (Pts-ko) 
exhibited newborn lethality and revealed severe conditions consequently the Pts-ko mouse 
was not a suitable mouse model to study BH4 deficiency. 
 
This motivated us to generate a new Pts mouse models: a homozygous Pts-R15C-ki (Pts-
ki/ki) and a compound heterozygous Pts-R15C-ki/Pts-ko (Pts-ki/ko) to study human BH4 
deficiency. We aimed to explore whether the Pts-ki/ki mice would result in a mild or peripheral 
phenotype and whether the Pts-ki/ko mice would generate a severe or central phenotype without 
newborn lethality, respectively as this potential could reveal the phenotypic diversities observed 
in human BH4 deficiencies (Chapter 2).  
 
The GCHFR gene is the only gene within the BH4 metabolism for which no human deficiency 
or mouse model has been described. In consideration of this, we aimed to generate the first 
animal model for GFRP, a conditional knock-out for the murine Gchfr gene to study the in 
vivo regulatory role of GFRP in liver and brain (Chapter 3).  
 
Furthermore, using a genetic candidate gene approach, we aimed to analyse a cohort of 
patients with ASDs and normal, unknown or isolated low 5-HIAA in the CSF. Due to the 
findings in the SLC6A4 and  SLC29A4 genes coding for SERT and PMAT, respectively, we 
addressed by whole exome sequencing, the genetic characterization linking isolated low 5-
HIAA in CSF, ASDs and serotonin re-uptake-transporter mutations (Chapters 4 and 5).  
 
Taken together, the four studies presented in this dissertation aim to cover different aspects 
within 6-pyruvovyl-tetrahydropterin synthase (PTPS), GTP cyclohydrolase feedback 
regulatory protein (GFRP), serotonin re-uptake transporter (SERT) and plasma monoamine 
membrane transporter (PMAT) in order to get a better understanding of tetrahydrobiopterin 
and monoamine neurotransmitter deficiency in mouse models and human disease. 
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2.1 Abstract 
Human BH4 deficiencies are a highly heterogeneous group of rare inherited neurological 
disorders, primarily due to recessive mutations in the biosynthetic 6-pyruvoyl-
tetrahydropterin-synthase (PTS) gene. The majority of PTPS deficient patients exhibit a 
severe or central phenotype with brain monoamine neurotransmitter deficiency, whereas the 
minority has a mild or peripheral phenotype characterized with hyperphenylalaninemia (HPA) 
only. Previous studies have shown that the homozygous Pts knock-out mouse (Pts-ko) 
displayed newborn lethality. Therefore we established an alternative Pts mouse model by 
‘knocking-in’ a single codon exchange in the Pts gene (Pts-ki). Homozygous Pts-R15C-ki 
mice (Pts-ki/ki) showed no signs of HPA or brain monoamine neurotransmitter deficiency, 
but significant reduced PTPS enzyme activity and elevated neopterin in liver and brain.  
In addition, we bred compound heterozygous Pts-R15C-ki/Pts-ko (Pts-ki/ko) mice which 
gave rise to two phenotypes: one dying 3-4 days after birth “affected” Pts-ki/ko and one 
which survived “unaffected” Pts-ki/ko.  
The “affected” Pts-ki/ko mice showed significant reduced PTPS enzyme activity and 
biopterin in liver and brain, elevated neopterin in liver and brain, mild HPA as well as 
monoamine neurotransmitter deficiency in the CNS. In comparison, “unaffected” Pts-ki/ko 
mice showed reduced PTPS activity in liver and brain but normal levels of blood 
phenylalanine. Furthermore, the biopterin and neopterin levels (both in liver and brain) as 
well as the brain monoamine neurotransmitters were found to be within the normal range.  
In summary, the “affected” Pts-ki/ko mice have potential to be a suitable mouse model to 
study BH4 deficiency as they mimic the biochemical hallmarks of human BH4 deficiency 
. 
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2.2 Introduction 
BH4, which is generated from guanosine triphosphate (GTP) by three enzymes: GTP 
cyclohydrolase I (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS) and sepiapterin 
reductase (SR) (Thöny et al., 2000) (Figure 1), is an essential cofactor for the three aromatic 
amino acid hydroxylases: phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and 
tryptophan hydroxylases 1/2 (TPH1, peripheral and TPH2, neuronal (Walther and Bader, 
2003)). Furthermore, BH4 is cofactor for all three isoforms of nitric oxide synthase (neuronal, 
inducible and endothelial NOS) as well as alkylglycerol monooxygenase (AGMO) (Wei et al., 
2003, Watschinger et al., 2010, Werner et al., 2003) (Figure 1). As a consequence of the 
hydroxylation of the three aromatic amino acid hydroxylases, BH4 is regenerated by the 
action of the two regenerating enzymes: pterin 4a-carbinolamine dehydratase (PCD/DCoH) 
and dihydropteridine reductase (DHPR) (Thöny et al., 2000) (Figure 1).  
 
Human BH4 deficiencies are caused by genetic defects in either one of the three genes 
encoding for the biosynthetic enzymes (GTPCH, PTPS and SR) or in one of the two genes 
encoding for the regenerating enzymes (PCD/DCoH and DHPR) (Thöny and Blau, 2006) 
(Figure 2). PTPS deficiency, which is the most common cause of BH4 deficiency, is 
associated with a broad spectrum of phenotypes range from severe and central to mild and 
peripheral. The molecular mechanisms for these phenotypic diversities are unknown.  
 
The first BH4-deficient mouse generated was a Pts-knock-out mouse (Pts-ko) with a complete 
disruption of the Pts gene (Elzaouk et al., 2003, Sumi-Ichinose et al., 2001). These studies have 
shown that the homozygous Pts-ko mice died within hours after birth, which indicated newborn 
lethality. The biochemical analysis revealed HPA (1290-1414 µmol/L), no PTPS enzyme 
activity, high levels of neopterin (liver and brain), low levels of biopterin (liver and brain) as 
well as neurotransmitter deficiency in the CNS due to undetectable or very low levels of 
dopamine and serotonin, but with normal NO values (Elzaouk et al., 2003). Despite, daily 
administration of BH4 and neurotransmitter precursors which rescued the homozygous Pts-ko 
mice from newborn lethality, the homozygous Pts-ko mice were among others found to be 
sexually immature and to suffer from dwarfism due to severe growth deficiency (Elzaouk et al., 
2003).  
 
The overall very bad condition of the homozygous Pts-ko mice and the phenotypic diversities 
between the mouse ko-mutant and human patients motivated us to generate new Pts mouse 
models by ‘knocking-in’ a single codon exchange in the Pts gene (Pts-R15C-ki).  
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Besides generating a Pts-ki/ki mouse which was expected to reflect the mild or peripheral 
phenotype, we also generated a compound heterozygous Pts-R15C-ki/Pts-ko (Pts-ki/ko) 
mouse which was expected to reflect the severe or central phenotype of PTPS deficiency but 
without newborn lethality. The compound heterozygous mouse was generated by breeding the 
Pts-R15C-ki allele into the Pts-ko allele.  
 
In this study, we successfully generated Pts-ki/ki and Pts-ki/ko mice. Moreover, we found 
that Pts-ki/ki mice are associated with a very mild phenotype that biochemically is 
characterized by reduced PTPS enzyme activity (liver and brain) as well as increased 
neopterin (liver and brain) and that they exhibit an abnormal fat distribution when subjected 
to standard mouse chow or high fat diet for 10 weeks. Furthermore, we found that “affected” 
Pts-ki/ko mice, in contrast to Pts-ki/ki and “unaffected” Pts-ki/ko mice, exhibited a more 
severe phenotype which mimics the biochemical hallmarks of human BH4 deficiency thus 
demonstrating that “affected” Pts-ki/ko mice are a suitable mouse model to study BH4 
deficiency.   
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2.3 Materials and methods 
Pts Gene Targeting 
A genomic clone containing the Pts gene was as described previously in (Turri et al., 1998), 
isolated from a 129/Sv-λ phage library. For targeting vector (pMSY211) construction, a 1.3 
kb fragment of the Pts gene spanning exon 1 was used as short arm of homology (see Figure 
1). A phosphoglycerate kinase promoter (Pgk)-Diphtheria Toxin (DT) gene cassette, essential 
for the negative selection of the embryonic stem (ES) cells, was added 5’ to the short arm of 
homology. The long arm of homology was a 5.1 kb fragment containing exons 2, 3 and 4 of 
the Pts gene, and as positive selective marker, a “floxed” Pgk-neomycin resistance gene (neo) 
cassette was introduced between the short and the long arm of homology. After successful 
construction, the pMSY211 targeting vector was linearized and electoporated into ES cells 
derived from 129S6/SvEvTac strain. ES cell clones, in which homologous recombination has 
occurred, were confirmed by a nested PCR with 40 cycles (MSY220: 5’-GCACCCCAAGGT 
AGCCAAGAATTTG-3’ and MSY221: 5’-TTCTTCGCCCACCCCGAAATTGATG-3’) and 
25 cycles (MSY226: 5’-ACCGGGCTGGAGAACATCTGATAAG-3’ and MSY228: 5’-TCA 
GCAGCCTCTGTTCCACATACAC-3’), respectively and standard amplification conditions 
(not shown). For further confirmation of correctly targeted ES cell clones, Southern blot 
analysis was performed (not shown). One correctly targeted ES cell clone was chosen for 
blastocyst injection. Blastocyst injection (FVB/N host embryos) led to generation of one 50 % 
chimaric male that, when sexually mature, was mated with FVB females. The chimaera 
revealed to be germline transmitter thus resulted in the generation of heterozygous Pts-R15C-
ki targeted mice (correct genotype was confirmed on genomic DNA from tail biopsies by Pts-
ki/ki PCR, for details see below).  
 
Targeting vector pMSY211 construction, blastocyst injection and generation of one chimaric 
male was carried out by Dr. Rossana Scavelli at the Division of Clinical Chemistry and 
Biochemistry (University Children’s Hospital, Zürich) as well as at Institute of Laboratory 
Animal Science (University of Zürich). The work is described in details in PhD-dissertation 
“Tetrahydrobiopterin Metabolism in the Mouse: Feeding Studies and Generation of a New 
Mutant Model”, University of Zürich, 2006.   
 
DNA purification   
Genomic mouse DNA was purified from tail biopsies by using DNeasy Blood and Tissue kit 
from Qiagen (Cat. no: 69506).  
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Genotyping of Pts-ki/ki mice from tail biopsies  
Pts-R15C-ki mice were genotyped by using the following primers: HRM_F: 5’-GAGTTTGC 
ACTGCGCAGCCG-3’ (forward) and HRM_R: 5’-AGTGCCGGTAGTGCAGCTCC-3’ 
(reverse). The PCR-reaction, which amplified a 313 bp fragment, was performed in a final 
volume of 25 µl consisting of 2µl genomic DNA from tail biopsies (see DNA purification, 0.5 
µl of each primer (10 µM), 0.5 µl 20 mM dNTPs, 0.25 µl Hot FirePol Hotstart DNA 
polymerase (Solis Biodyne), 2.5 µl 25 mM MgCl2, 2.5 µl 10x A1 buffer (Solis Biodyne) 
and 2.5 µl S-solution (Solis Biodyne). The PCR-reaction was performed in a GeneAmp PCR 
System 9700 from Applied Biosystems using standard thermal cycling: 95oC for 15 min, 35 
cycles of (95°C for 1 min, 58°C for 45 sec and 72°C for 1 min), 72°C for 10 minutes and 
termination at 4oC. The R15C codon exchange destroys a BssSI restriction site for that reason 
digestion with BssSI leads to different fragments depending on the presence of the wild-type 
(R15) or mutant codon (C15): the wild-type allele contains the BssSI restriction site therefore 
two fragments, whereas the mutant allele R15C has no BssSI restriction site therefore one 
fragment. The heterozygous condition contains all three fragments.  
 
Genotyping of Pts-ki/ki, Pts-ki/wt and wt/wt mice shown in Figure 7 is from another PCR-
set-up (using MSY120: 5’-CGCTAGCTTGTGAGTCTTCG-3’ and MSY121: 5’-
CCTTCACCATTTCCTCTTCG-3’ primers resulting in a 233 bp PCR-product before BssSI 
digestion and other reagents that are no longer commercial available) however the genotyping 
principle is the same with the “new” primers (HRM_F and HRM_R). 
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Figure 7:  Genotyping of Pts-ki/ki, Pts-ki/wt and wt/wt  
The wild-type allele contains a BssSI restriction site therefore PCR and BssSI digestion result in two fragments 
(158 bp bp and 75 bp), whereas the mutant R15C allele has no BssSI restriction site therefore result in one 
fragement (233 bp). The heterozygous condition contains all three fragments (233 bp, 158 bp and 75 bp).   
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The BssSI digested PCR fragments (PCR-product, 100xBSA, 10XNEBuffer 3 and 1000 units 
BssSI from New England Biolabs (R0587L) were incubated in 6 hours at 37oC) were run on a 
2 % agarose gel and visualized under ultraviolet (UV) light in the presence of GelRed 
10,000X in water (Biotium).  
 
Genotyping of Pts-ki/ko mice from tail biopsies 
Compound heterozygous (Pts-ki/ko) mice were genotyped by using the Pts-R15C-knock-in 
PCR described above and the Pts-knock-out PCR described in (Elzaouk et al., 2003). The Pts-
knock-out PCR consists of 3 primers: MSY107: 5’-TGACTATGGGCAGAGTTGTT-3’ 
(forward), MSY108: 5’-GATTGTTGCATTTCCCAAAC-3’ (reverse) and PLACZ8: 5’-GGC 
-TCAGTTCGAGGTGCT-3’ (reverse). The Pts-knock-out PCR-reaction was performed in a 
final volume of 25 µl containing 2 µl of genomic DNA from tail biopsies (see DNA 
purification), 0.5 µl of each primer (10 µM), 0.25 µl 20 mM dNTPs, 0.2 µl Hot FirePol 
Hotstart DNA polymerase (Solis Biodyne), 2.5 µl 25mM MgCl2, 2.5 µl 10x Buffer A1 (Mg2+, 
detergent free, Solis Biodyne) and 3 µl 10x Solution S (Solis Biodyne). The PCR reactions 
were performed in a GeneAmp PCR System 9700 from Applied Biosystems using standard 
thermal cycling: hot start activation at 95oC for 15 minutes, followed by 35 cycles of 
denaturation 95°C for 1 minute, annealing 53°C for 45 seconds and extension at 72°C for 1 
minute, a final extension was performed at 72°C for 10 minutes and termination at 4oC. The 
PCR fragments were run on a 2 % agarose gel and visualized under ultraviolet (UV) light in 
the presence of GelRed 10,000X in water (Biotium).  
 
Preparation of Mouse Tissues  
Brains and livers were removed immediately from the scarified mice and snap-frozen in 
liquid nitrogen. Frozen harvested tissue was ground to powder and blended at 4oC with an 
electric homogenizer (Kinematic GmbH, Luzern, Switzerland) in cold homogenization buffer 
consisting of 50 mM Tris-HCl, pH 7.5/100 mM KCl/1 mM EDTA, 1 mM DTT in H2O, 0.2 
mM PMSF in isopropanol (10mg/ml), 1 µM leupeptin in H2O (5mg/ml) and 1 µM pepstatin in 
methanol (1mg/ml). Tissue extracts were clarified by centrifugation at 15000 g for 20 min at 
4oC and the supernatants were stored at minus 80oC prior to use. 4x homogenization buffer 
for PTPS enzyme activity assays (4 µl/mg tissue) and 10x homogenization buffer for 
neopterin, biopterin as well as neurotransmitter measurements (10 µl/mg tissue). 
 
 
New mouse models to study BH4 deficiency  
55  
RNA extraction   
RNA was extracted from mouse tissue (liver) by QIAGEN OneStep RT-PCR kit (100) from 
Qiagen (Cat. no: 210212).  
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
The OneStep RT-PCR reaction was performed in a final volume of 50 µl (RNase-free water) 
containing 2 µl of RNA template, 3 µl of forward (cDNA fn: 5’-GGCGGGTGACCTTCGT-
3’) and reverse primer (mPTPS cDNA r n1: 5’-CGATGTTGTTGTCGGTTTCA-3’) (5 µM), 
2 µl Qiagen OneStep RT-PCR enzyme mix, 2 µl 10 mM deoxyribonucleoside triphosphates 
(dNTPs), 10 µl 5x Qiagen OneStep RT-PCR buffer and 10 µl 5x Q-solution. The RT-PCR 
reactions were performed in a GeneAmp PCR System 9700 from Applied Biosystems using 
the following conditions: 50oC for 30 minutes, 95oC for 15 minutes, 35 cycles of 94°C for 30 
seconds, 55°C for 30 seconds and 72°C for 1 minute, a final extension was performed at 72°C 
for 10 minutes and termination at 4oC.  
The following primers (forward: R15C_F: 5’-AGCT GGGGTTTCTTTTTGGT-3’ and 
reverse: R15C_R: 5’-GTAGCCCATGCTCCTGTCAT-3’) as well as BigDye Terminator v1.1 
Cycle Sequencing Kit from Applied Biosystems were used to sequence the cDNA. The 
sequencing PCR was performed in a 10 µl reaction mixture consisting of 0.5 µl RT-PCR 
product, 0.8 µl primer (5 µM), 1.5 µl BigDye and 1.25 µl 5x sequencing buffer and using 
standard thermal cycling: 95oC for 1 min, followed by 25 cycles (96oC for 10 sec, 50oC for 5 
sec, 60oC for 3 min) and termination at 4oC. After end run 15 µl H2O was added to the 
sequencing reactions before purified by gel filtration (using MultiScreen HV 96-well filter 
plates (Millipore) with Sephadex G-50 (GE Healthcare)) and analyzed on a 3130xl Genetic 
Analyzer (Applied Biosystems). Sequencing results were compared with the wildtype 
sequence of the murine Pts gene (Ensembl Transcript ID: ENSMUST00000034570). 
 
Protein Measurement 
Protein concentration (g/L) was measured by using the M-TP Mikroprotein kit from Beckman 
Coulter Synchron LX-System (Beckman Coulter Inc, Brea, CA) (kit-no. 445860).  
 
PTPS enzyme activity assay 
The PTPS enzyme activity assay was measured in extracts from liver and brain according to 
(Thöny, 2008). To start, a reaction mixture consisting of 25 µl 100 mM Tris-HCl pH 7.4 
(stored at room temperature), 5.5 µl 200 mM MgCl2 (stored at room temperature), 5.5 µl 20 
mM NADPH (freshly made), 5.5 µl 20 mM NADH (freshly made), 13.2 µl 0.5 mM NH2P3 
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(stored at -80oC), 3 µl 1 U/ml SR (stored at -80oC) and 2.3 µl 96 U/ml DHPR (stored at -
20oC) was prepared. 50 µl brain lysate (liver lysate 25 µl and 25 µl 10mM Tris-HCl pH 7.4 
1% Triton X-100 (stored at room temperature)) was added to the 60 µl reaction mixture and 
incubated for 2 hours at 37oC in darkness. The reaction was terminated by the addition of 33 
µl 30 % trichloroacetic acid (TCA) (30 g TCA in 100 ml H2O, stored at room temperature) 
and placed on ice for 10 minutes for protein precipitation, before centrifugation (5 min. 13000 
rpm). A 20 µl 1 % iodine solution (0.1 g I2 and 0.2 g KI in 10 ml 1M HCl) was added to 100 
µl of the supernatant to oxidize all the pterines to the same oxidation state. This new mixture 
was incubated in the dark at room temperature and after 1 hour oxidation the reaction was 
stopped by adding 30 µl 1 % ascorbic acid (10 mg in 1 ml H2O, freshly made) to destroy 
excess iodine. After mixing, the samples were centrifuged for 10 minutes at 13000 rpm 
through an Amicon® Ultra-0.5 Centrifugal Filter (Millipore, Cat. no: UFC501096). The total 
amount of biopterin generated from the dihydroneopterin triphosphate substrate was detected 
by reversed-phase high-performance liquid chromatography (HPLC). Additionally, two 
different blanks were prepared. The first composed of 60 µl reaction mixture and 50 µl 100 
mM Tris-HCl pH 7.4, the second of 60 µl 100 mM Tris-HCl pH 7.4 and 50 µl tissue lysate. 
Both blanks were incubated at ice for 2 hours in the dark and then treated as the rest of the 
samples from the 30% TCA step on. One unit of PTPS produced 1 µmol of biopterin per 
minute at 37°C. The activity was expressed in µU per mg protein.  
 
Neopterin and Biopterin Measurements 
Neopterin and biopterin were measured as described in (Thöny, 2008). Tissue lysates from 
homoganized mouse liver or mouse brain were prepared as described under “Preparation of 
Mouse Tissue”. The neopterin and biopterin measurements were started by adding 10 µl 0.5 % 
iodine solution in 1 M HCl to 100 µl lysate (liver only 20 µl plus 80 µl homogenizations 
buffer followed by incubated for 1 hour at room temperature in darkness. Three reagents were 
added to the lysates and incubated for 1 hour at 37oC in darkness:  1) 10 µl 2 % ascorbic acid 
(2 mg ascorbic acid/100 µl H2O, prepare fresh), 2) 14 µl 1 M sodium hydroxide, 3) 20 µl 
alkaline phosphatase solution (alkaline phosphatase was diluted 1:10 in 3.2 M ammonium 
sulphate solution, 1 mM MgCl2, 0.1 M ZnCl2, pH=7). Finally, 5 µl 2 M HCl was added to the 
lysates. The lysates were centrifuged for 15 minutes at 6500 rpm through Amicon® Ultra-0.5 
Centrifugal Filter (Millipore, Cat. no: UFC501096) before transferred to the HPLC-system. 
The neopterin and biopterin concentrations were calculated as followed: (nmol/L neopterin or 
biopterin x 159) / (µl lysate/assay x mg/ml protein) = pmol/mg protein. 
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Neurotransmitter Measurements 
The monoamine neurotransmitter (dopamine, HVA, serotonin and 5-HIAA) were measured as 
previous described in (Blau et al., 1999, Elzaouk et al., 2003). Tissue lysates from 
homoganized mouse brain was prepared as described under “Preparation of Mouse Tissue”. 
15 µl 1 M HCl was added to 150 µl brain lysate and centrifuged at 4oC for 15 minutes at 7500 
rpm through Amicon® Ultra-0.5 Centrifugal Filter (Millipore, Cat. no: UFC501096) before 
transferred to the HPLC-system. Each monoamine neurotransmitter concentration (dopamine, 
HVA, serotonin and 5-HIAA) was calculated as followed: ((monoamine neurotransmitter 
nmol/L)/150) x (165/(mg/ml protein)) = pmol/mg protein. 
 
Phenylalanine Concentration in the Blood 
The blood from the mice was collected on Guthrie cards (filter paper card) (Guthrie and Susi, 
1963). Phenylalanine (and tyrosine) concentrations (µmol/L) were measured using 
electrospray tandem mass spectrometry (ESI-MS/MS) (Rashed et al., 1995).  
 
Statistical analysis 
All tests were performed using GraphPad PRISM 5.0 software. Descriptive statistics 
including mean ± standard deviation (S.D) and Student’s t-tests were used. p values <0.05 
were considered significant.   
 
Systemic phenotype analysis by the German Mouse Clinic  
To obtain the required number of animals of the primary screening (80 in total consisting of 
20 Pts-ki/ki males, 20 Pts-ki/ki females, 20 wt/wt males and 20 wt/wt females), we bred 45 
breeding-pairs of Pts-ko/wt males with Pts-ki/wt females. All the breeding-pairs were 
separated after six days of mating to reduce heterogeneity of the cohort (not more than 7 days 
difference in age between the littermates to be phenotypical analyzed). Within the one week 
237 mice were born (120 males and 117 females).  In addition, 51 mice were born (25 males 
and 26 females) outside the mating-window consequently this cohort was kept as second 
choice. From the two cohorts of mice (mostly the first except for three Pts-ki/ki females): 20 
Pts-ki/ki males, 20 Pts-ki/ki females, 20 wt/wt males and 18 wt/wt females were sent to the 
GMC at the age of 8 weeks for comprehensive phenotypical and behavioural characterization 
of the homozygous Pts-R15C-ki allele.  
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2.4 Results  
2.4.1 Generation of Pts-ki/ki mice 
In order to generate a Pts mouse model by ‘knocking-in’ a single codon exchange (Pts-R15C) 
in the Pts gene (Pts-ki) (Turri et al., 1998) a targeting vector (pMSY211) was generated 
(Scavelli, University of Zürich, 2006).  
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Figure 8: PTPS sequence alignment and PTPS activity of recombinant PTPS in COS-1 cells 
A: Sequence alignment of human and mouse, which share 82 % sequence, identity. Mouse Pts-R15C is 
equivalent to the human PTS-R16C mutation. Human PTS-R16C and mouse Pts-R15C are marked in arrows. 
Human PTPS: NP_000308, Mouse PTPS: NP_035350. B: PTPS enzyme activity of recombinant PTPS protein 
in mammalian COS-1 cells revealed that mouse Pts-R15C has a significant reduced PTPS enzyme activity (15 
%) compared to wild-type (100 %). Moreover, the mouse Pts-R15C (15 %) and human PTS-R16C (12 %) 
mutations demonstrated comparable PTPS enzyme activity levels. Figure B is adapted from (Oppliger et al., 
1995) and (Scherer-Oppliger et al., 1999). 
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Arginine 15 to cysteine (Pts-R15C) was chosen because it is equivalent to the human PTS-
R16C mutation which is associated with a peripheral or mild phenotype that do not 
synthesizes BH4 in peripheral organs but lead to normal BH4 and neurotransmitter levels in 
the CNS (Thony et al., 1994) (Figure 8). Beside, the Pts-R15C allele the patient was also 
having on the second allele a 14 bp deletion leading to a frameshift at lysine 120 and a 
premature stop codon (Thöny et al., 1994).  
 
In addition, previous in vivo PTPS activity studies on recombinant PTPS protein transfected 
into mammalian COS-1 cells have shown that the mouse R15C mutation has significant 
reduced PTPS enzyme activity compared to wild-type but on the other hand showed 
comparable PTPS enzyme activity levels with the human R16C mutation (Oppliger et al., 
1995, Scherer-Oppliger et al., 1999) (Figure 8).  
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Figure 9:  Targeting of Pts gene locus by homologous recombination in ES cells  
Schematic representation of the Pts gene locus (top), the targeting vector including the R15C codon exchange 
(marked by *), a Pgk-DT-gene-cassette (yellow) for negative selection and a “floxed” Pgk-neo-gene-cassette 
(green) for positive selection (middle) and the targeted Pts locus after homologous recombination (bottom). 
Additionally, the “floxed” Pgk-neo-gene-cassette was deleted by Cre recombinase.  
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The targeting vector pMSY211 was constructed with a 1.3 kb fragement of the Pts gene, 
spanning exon 1 as the short arm of homology and a 5.1 kb fragment including exon 2, 3 and 
4 of the Pts gene as the long arm of homology.  
For positive and negative selection, a Pgk-DT-gene-cassette was added 5’ to the short arm of 
homology and a “floxed” Pgk-neo-cassette was introduced between the short and long arm of 
homology, respectively. The targeting strategy for introducing the pMSY211 targeting vector 
into ES cells by homologous recombination is depicted in Figure 9.  
Correct homologous recombination event in neomycin-resistant ES cells was identified by 
nested PCR (not shown) as well as Southern blot analysis using a 5’ probe (upstream to the 
targeting vector) and a 3’ probe (inside the targeting vector) (not shown) (Scavelli, University 
of Zürich, 2006). One correctly targeted ES cell clone was injected by blastocyst injection 
into FVB/N host embryos, which led to the generation of one chimera male (50 % chimeric) 
and subsequently to heterozygous Pts-R15C-ki targeted mice (Pts-ki/wt) due to germline 
transmission. Pts-ki/wt mice revealed to be viable, fertile and phenotypical normal thus the 
heterozygous Pts-R15C-ki allele was breed to homozygosity (Pts-ki/ki) (Scavelli, University 
of Zürich, 2006).  
 
Before the newly generated Pts-ki/ki and Pts-ki/wt mice were subjected to a broad range of 
biochemical analysis for characterization, the expression of the R15C codon in the transgenic 
mouse tissue (liver and brain) was confirmed by RT-PCR and cDNA sequencing (not shown).  
 
Due to the pronounced observations within homozygous Pts-ko mice among this newborn 
lethality (Elzaouk et al., 2003, Sumi-Ichinose et al., 2001) (see also Introduction: Mouse 
models in the BH4 metabolism), the overall condition of the Pts-ki/ki mice in terms of weight, 
movement, behaviour, sexual maturation and fur was carefully observed. Our breeding 
experiments revealed that Pts-ki/ki mice in contrast to homozygous Pts-ko mice are viable, 
fertile and showed no noticeable abnormalities concerning weight, movements, behaviour or 
fur compared to Pts-ki/wt and wt/wt mice from the same litter.   
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2.4.2 Biochemical characterization of Pts-ki/ki 
The biochemical hallmarks of human BH4 deficiency due to mutations in the PTS gene, are 
characterized by very low or absent of PTPS enzyme activity, high neopterin levels, very low 
or not detectable biopterin levels, HPA (elevated blood phenylalanine) as well as monoamine 
neurotransmitter deficiency in the CNS (exclusive for the severe/central phenotype of PTPS 
deficiency) (Campeau et al., 2007).  
 
Therefore, we investigated PTPS enzyme activity (liver and brain), neopterin and biopterin 
levels (liver and brain), blood phenylalanine concentration as well as brain monoamine 
neurotransmitters levels within Pts-ki/ki, Pts-ki/wt and wt/wt mice to see whether the Pts-
ki/ki phenotype would mimic the biochemical hallmarks for human BH4 deficiency.  
 
As indicated in Figure 10A, the Pts-ki/ki mice had a significant reduced PTPS enzyme 
activity both in liver and brain compared to Pts-ki/wt and wt/wt mice.  
Neopterin measurements by HPLC analysis revealed highly elevated neopterin levels in the 
Pts-ki/ki mice compared to the Pts-ki/wt mice (Figure 10B). Whereas, the neopterin levels 
were detectable within liver and brain tissue from Pts-ki/ki and Pts-ki/wt mice, the neopterin 
levels within liver and brain tissue from wt/wt mice were not detectable (Figure 10B). In 
contrast to the neopterin, the brain and liver biopterin levels showed, no variations among the 
three measured genotypes (Pts-ki/ki, Pts-ki/wt and wt/wt) (Figure 10C).  
Reduced biopterin is a common feature for almost all human BH4 deficiencies except SR and 
DHPR deficiency (Longo, 2009) thus the Pts-ki/ki biochemical phenotype clearly diverges 
from the phenotypes associated with human BH4 deficiency.  
Blood phenylalanine concentration were measured from Guthrie cards using electrospray 
tandem mass spectrometry (ESI-MS/MS) (Rashed et al., 1995). The ESI-MS/MS results 
revealed no significant differences in the blood phenylalanine concentrations between the Pts-
ki/ki, Pts-ki/wt and wt/wt mice (Figure 10D). Moreover, none of the three groups showed 
HPA (Elzaouk et al., 2003).  
This encouraged us to challenge the mice with two different concentrations (30 mg/L and 30 
g/L) of phenylalanine in the drinking water for 5 days in order to investigate whether a 
phenylalanine challenge would lead to HPA or whether the mice would be able to cope with 
the increased intake of phenylalanine in the drinking water (on standard mouse chow (KLIBA 
NAFAG diet no. 3430) the daily intake of pheylalanine is approximately 25-50 mg/day). The 
exact amount of phenylalanine received via the drinking water (average 4-10 ml water/day) 
was not controlled.  
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As it appears in Figure 10D, the Pts-ki/ki mice showed no indications of HPA when 
challenged with two different concentration of phenylalanine in the drinking water.  
 
In addition, we analyzed the monoamine neurotransmitters serotonin and dopamine plus their 
end-metabolites 5-HIAA and HVA, respectively in brain tissue to investigate whether the Pts-
ki/ki mice were subjected to monoamine neurotransmitter deficiency in the CNS.  
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Figure 10: Biochemical characterization of liver and brain tissue from Pts-ki/ki, Pts-ki/wt and wt/wt mice  
A: PTPS enzyme activity (PTPS/protein uU/mg) in liver and brain. B: Neopterin levels (pmol/mg protein) in liver 
and brain. C: Biopterin levels (pmol/mg protein) in liver and brain. D: Blood phenylalanine concentrations 
(µmol/L) before and after phenylalanine challenge with 300 mg/L Phe and 30 g/L Phe, respectively in the drinking 
water for 5 days. E. Brain monoamine neurotransmitters (dopamine and serotonin) and their end-metabolites (HVA 
and 5-HIAA) (pmol/mg protein). The genotypes are indicated by the bar colour: wt/wt (white), Pts-ki/wt (grau) and 
Pts-ki/ki (black). n.d. indicates not detectable. Values are the mean ± S.D from n independent measurements. 
Significant difference from the corresponding value for wild-type is indicated by asterisks: *, p < 0.05, **, p < 
0.01, ***, p < 0.001, ****, p < 0.0001 (Student’s t test).  
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As seen in Figure 10E, no significant differences were shown neither in the monoamine 
neurotransmitter levels nor their end-metabolites between Pts-ki/ki, Pts-ki/wt and wt/wt mice 
(Pts-ki/wt showed significant reduced dopamine compared to Pts-ki/ki and wt/wt). These 
findings indicated that Pts-ki/ki mice, unlike homozygous Pts-ko mice did not suffering from 
brain monoamine neurotransmitter deficiency (Figure 10E).  
 
2.4.3 Systemic phenotype analysis by the German Mouse Clinic  
For further comprehensive phenotypical and behavioural characterization of Pts-ki/ki mice, 
we decided to collaborate with the German Mouse Clinic (GMC) in Munich, Germany (Fuchs 
et al., 2009, Beckers et al., 2009, Fuchs et al., 2011, Gailus-Durner et al., 2005). Over a period 
of 10 weeks 78 mice (20 Pts-ki/ki males, 20 Pts-ki/ki females, 20 wt/wt males and 18 wt/wt 
females) were subdivided into two pipelines and subjected to numerous non-invasive tests 
including measurements of approximately 550 parameters within 14 different areas (Figure 
3). The results of the primary screening are outlined in the next paragraphs and in 
Supplementary Information.  
 
 
A B
 
Figure 11: Body composition analysis by non-invasive NMR  
Non-invasive NMR scans were used to determine the fat mass (g), lean mass (g) and body mass (g) in the Pts-
ki/ki mutant mice (both males and females) compared to wt/wt control mice. The Pts-ki/ki mice used for NMR 
scans had a significant reduced body mass (both males and females) and sex-specific shift in body composition 
as the Pts-ki/ki mutant males had a higher body fat mass and lower lean mass. Wt/wt control female (red), Pts-
ki/ki mutant females (orange), wt/wt control males (dark-blue) and Pts-ki/ki mutant males (light-blue). Data, 
table and figures provided by Dr. Jan Rozman from the GMC. 
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The body composition analysis by non-invasive NMR revealed that Pts-ki/ki mice have a 
significantly reduced body mass compared to the wt/wt control mice. However, in Pts-ki/ki 
males the body fat content was found to be significantly increased and the lean mass to be 
significantly decreased (Figure 11). No shift in body composition was detected in Pts-ki/ki 
females (Figure 11). 
 
A
B
 
Figure 12:  IgG1, IgG2b and IgE immunoglobulins in Pts-ki/ki mice compared to wt/wt  
A: The immunology and allergy screen showed slightly reduced levels of immunoglobulins IgG1, IgG2b and IgE 
in Pts-ki/ki mutant females (orange) compared to wt/wt control females (red). This observation was not found in 
either wt/wt control males (blue) or Pts-ki/ki mutant males (green). B: The plasma IgE levels of the female mice 
(wt/wt control females (red/wt) and Pts-ki/ki mutant females (orange/hom)) were repeated revealing the same 
tendency as first time. Due to the slightly reduced levels of IgG1, IgG2b and IgE in Pts-ki/ki females a secondary 
test with a new cohort of mice (n=10 to 12 per sex per group) to confirm this observation has been suggested. Data, 
table and figures provided by Dr. Antonio Aguilar Pimentel at the GMC.  
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The immunology and allergy screen showed no changes in the frequencies of most leukocyte 
subsets in peripheral blood but only subtle differences in the frequency of CD11b+ expressing 
NK cells (a maturation marker for NK cells) and slightly lower levels of immunoglobulins 
IgG1, IgG2b and IgE in Pts-ki/ki female mice (Figure 12A). The immunoglobulin IgE 
concentration were re-measured in plasma samples from female mice (wt/wt and Pts-ki/ki) 
and also the second time the same tendency was observed (Figure 12B). Due to the lower 
levels of IgG1, IgG2b and IgE in Pts-ki/ki females a secondary test with a new cohort of mice 
(n=10 to 12 per sex per group) to confirm the observed phenotype was suggested. 
 
Taken together, the primary screening of the Pts-ki/ki mice at the GMC led to many 
interesting observations (see also Supplementary Information). Two of these were more 
pronounced namely the indication that Pts-ki/ki males have an increased body fat mass and 
decreased lean mass compared to wt/wt males (Figure 11) and that Pts-ki/ki females have a 
slightly reduced IgG1, IgG2 and IgE levels than wt/wt females (Figure 12). For confirmation 
of these findings, secondary screenings with a new cohort of mice within energy metabolism 
and immunology have been suggested.  
 
2.4.4 Abdominal obesity in Pts-ki/ki mice on standard mouse chow and high fat diet 
A previous observation in our laboratory have shown that Pts-ko/wt males (n=4) upon feeding 
with high fat diet (58 kcal% fat with sucrose compared to normal diet with 11 kcal% fat with 
corn starch) over a period of several weeks increases their intra-abdominal adipose tissue 
(sum of epididymal and perigonadal fat) compartments two-fold compared to 1.6-fold 
increase in wt/wt males (Table 1). Yet, in a standard oral glucose tolerance loading test there 
was no difference in glucose clearance between Pts-ko/wt and wt/wt mice.  
 
Table 1: Intra-abdominal fat tissue in Pts-ko/wt and wt/wt mice fed with high fat diet 
_________________________________________________________________________ 
Males Diet Body weight in g (increase) Intra-abdominal fat in mg (increase) 
__________________________________________________________________________________________ 
Pts-ko/wt (n = 4) normal    3.63 ± 1.24  (100 %)  421.25 ± 121.21  (100 %) 
Pts-ko/wt (n = 4) high fat    9.98 ± 1.20  (275 %)  845.50 ± 169.73  (201 %) 
 
wt/wt (n = 4) normal    4.70 ± 0.91  (100 %)  342.50 ± 142.71  (100 %) 
wt/wt (n = 4) high fat  11.20 ± 2.16  (238 %)  542.25 ± 170.12  (158 %) 
___________________________________________________________________________ 
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To confirm, this observation on a larger amount of Pts-ko/wt mice and to include Pts-ki/ki 
mice, we breed 20 wt/wt males, 20 Pts-ko/wt males as well as 20 Pts-ki/ki males and 
subjected them in collaboration with Professor Christian Wolfrum at Institute of Food 
Nutrition and Health at ETH Zürich to standard mouse chow or high fat diet (Research Diets, 
Inc. D12331: 58 kcal% fat w/sucrose Surwit Diet) for 10 weeks (ad libitum). 
 
The average increase/gain in body weight (gram) was measured at two time points: after 4 
weeks and after 10 weeks. In addition, blood glucose levels (mM) were measured after 4 
weeks and 10 weeks, respectively in the mice subjected to high fat diet.  
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Figure 13:  Average gain in body weight after 10 weeks of standard chow or high fat diet 
To confirm whether Pts-ko/wt and Pts-ki/ki mice have an abnormal body fat distribution, 60 mice (20 wt/wt, 20 
Pts-ko/wt and 20 Pts-ki/ki) were subjected to either standard mouse chow (10 of each genotype) or high fat diet 
(10 of each genotype), respectively for 10 weeks. The average △/gain in body weight (gram) was measured at 
two different time points: after 4 weeks and after 10 weeks. In addition, blood glucose levels (mM) were 
measured after 4 weeks and after 10 weeks, respectively in the mice subjected to high fat diet. The genotypes 
are indicated by the bar colour wt/wt (white column), Pts-ko/wt (dark-gray column) and Pts-ki/ki (black 
column). Values are the mean ± S.D. Significant difference from the corresponding value for wild-type is 
indicated by asterisks: **, p < 0.01, ***, p < 0.001 (Student’s t test). 
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As shown in Figure 13, we found that Pts-ki/ki male mice had a significantly increase in body 
weight at both type of diets (standard mouse chow and high fat diet) and at both time points 
(after 4 weeks and 10 weeks). Similar to the Pts-ki/ki mice, the Pts-ko/wt had a significant 
increase in body weight when subjected to high fat diet after both 4 weeks and 10 weeks.  
 
In contrast to the Pts-ki/ki mice, the Pts-ko/wt male mice only gained significant body weight 
on standard mouse chow after 10 weeks but not after 4 weeks.  
 
The blood glucose levels measured in the mice subjected to the high fat diet remained 
unchanged both after 4 weeks and after 10 weeks indicating that the blood glucose is not 
responsible for the abnormal fat distribution observed in the Pts-ko/wt and Pts-ki/ki mice. 
 
2.4.5 Generation and characterization of compound heterozygous Pts-ki/ko mice 
Compound heterozygous Pts-ki/ko mice were generated by breeding the Pts-R15C-ki-allele 
into the Pts-ko-allele to investigate whether Pts-ki/ko mice would mimic the severe/central 
phenotype of human BH4 deficiency but without newborn lethality.  
 
Due to the severe conditions observed within the homozygous Pts-ko mice (newborn 
lethality) (Elzaouk et al., 2003), the newborn Pts-ki/ko mice were carefully observed the first 
hours and days after birth for two reasons: firstly, to see whether the Pts-ki/ko allele would 
also give rise to newborn lethality and secondly, to observe the overall condition of the Pts-
ki/ko mice in terms of body size, milk-supply (white spot in the belly), movement and 
behaviour.  
 
The first hours after birth no difference between the newborn mice was observed as they 
showed similar body size, milk-supply, movement and behaviour (Figure 14). Yet, at day 1-2 
enormous diversities were observed among the mice.  
The majority of the mice showed no apparent phenotypical characteristics however a few 
mice stood out from their littermates as they were smaller in body size and showed isolated 
behaviour (alone and away from the nest) as well as inactive/passive movements (Figure 
14A). The following days, several of the “affected” mice were found either dead or eaten up 
and for that reason we sacrificed the “affected” mice which were not already dead due to their 
severe condition. Genotyping of the “affected” mice (dead, eaten up and sacrificed at day 3-4) 
revealed that they were all Pts-ki/ko mice.  
At 3-4 weeks of age the “unaffected” mice (no apparent phenotype) were sacrificed and 
shown by genotyping to be wt/wt, Pts-ko/wt, Pts-ki/wt as well as Pts-ki/ko mice.  
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Our results suggested that the Pts-ki/ko mice give rise to two phenotypes meaning that some 
of them die 3-4 days after birth (called “affected” Pts-ki/ko) whereas others survived to at 
least 3-4 weeks of age (called “unaffected” Pts-ki/ko).  
 
A B C
 
Figure 14: “Affected” Pts-ki/ko, “unaffected” Pts-ki/ko and newborn mice 
A: 3-4 days after birth”affected” Pts-ki/ko (right) mice stood out from their “unaffected” Pts-ki/ko (left) 
littermates. B: “unaffected” Pts-ki/ko mice showed no apparent phenotype and survived until sacrificed at 3-4 
weeks of age. C: Newborn mice were collected at day 0 as no apparent phenotypical differences appeared 
between the Pts-ki/ko mice (sum of “affected” and “unaffected” Pts-ki/ko) at this time point.  
 
 
Subsequently, tissue (brain and liver) as well as blood collected from the sacrificed mice were 
subjected to biochemical analysis in order to characterize the “affected” and “unaffected” Pts-
ki/ko mice, respectively and to investigate whether the “affected” and/or the “unaffected” Pts-
ki/ko mice mimic human BH4 deficiency.  
 
As shown in Figure 15A, the liver and brain PTPS enzyme activity were significant reduced 
in both the “affected” and “unaffected” Pts-ki/ko mice compared to their Pts-ko/wt, Pts-ki/wt 
and wt/wt littermates. Moreover, the neopterin and biopterin concentrations were found to be 
considerable different in the “affected” Pts-ki/ko mice compared to the rest of the measured 
genotypes (“unaffected” Pts-ki/ko, wt/wt, Pts-ki/wt and Pts-ko/wt) as the “affected” Pts-ki/ko 
mice showed elevated neopterin and significant reduced biopterin in both liver and brain 
(Figure 15C). The phenylalanine measurements demonstrated a mild HPA (~900 µmol/L) in 
the “affected” Pts-ki/ko mice (Figure 15D). In contrast, the “unaffected” Pts-ki/ko mice 
showed normal blood phe levels (Figure 15D).  
Furthermore, the monoamine neurotransmitter measurements in brain tissue from “affected” 
Pts-ki/ko mice demonstrated that they in contrast to “unaffected” Pts-ki/ko mice exhibit 
monoamine neurotransmitter deficiency (Figure 15E). 
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Figure 15: Biochemical characterization of compound heterozygous Pts-ki/ko mice 
A: PTPS enzyme activity (PTPS/protein uU/mg) in liver and brain. B: Neopterin levels (pmol/mg protein) in liver 
and brain. C: Biopterin levels (pmol/mg protein) in liver and brain. D: Blood phenylalanine (µmol/L). E: Brain 
monoamine neurotransmitters (dopamine and serotonin) and their end-metabolites (HVA and 5-HIAA) (pmol/mg 
protein). F: Compound heterozygous Pts-ki/ko mice from Pts-ki/ki or Pts-ki/wt females crossed with Pts-ko/wt 
males. The genotypes are indicated by the bar colour: 3-4 days old “Affected” Pts-ki/ko (striped column), 3-4 
weeks old “unaffected” Pts-ki/ko (white column), wt/wt (black column), Pts-ki/wt (light-gray column) and Pts-
ko/wt (black column). Values are the mean ± S.D. n.d. indicates not detectable. Significant difference from the 
corresponding value for wild-type is indicated by asterisks: *** p < 0.001, **** p < 0.0001 (Student’s t test). 
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2.4.6 Characterization of newborn Pts-ki/ko mice 
Newborn Pts-ki/ko, Pts-ki/wt, Pts-ko/wt and wt/wt mice were scarified at day 1 to 
biochemical characterize them before the subdivision into the two distinguished phenotypes 
(sum of “affected” and “unaffected” Pts-ki/ko). At this time point no apparent phenotypical 
differences appeared between the mice in terms of size, white-belly, movement or behaviour 
(Figure 14C).  
 
 
Figure 16: Biochemical characterization of newborn Pts-ki/ko mice  
A: PTPS enzyme activity (PTPS/protein uU/mg) in liver and brain. B: Neopterin (pmol/mg protein) in liver and 
brain. C: Biopterin (pmol/mg protein) in liver and brain. D: Blood phenylalanine (µmol/L). E: Brain monoamine 
neurotransmitters (dopamine and serotonin) (pmol/mg protein). F: Newborns Pts-ki/ko mice from Pts-ki/ki or Pts-
ki/wt females crossed with Pts-ko/wt males.  The genotypes are indicated by the bar colour Pts-ki/ko (white column), 
wt/wt (black column), Pts-ki/wt (light-gray column) and Pts-ko/wt (dark-gray column). Values are the mean ± S.D. 
Significant difference from the corresponding value for wild-type is indicated by asterisks: * p < 0.05, *** p < 0.001 
(Student’s t test). 
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As shown in Figure 16A, the PTPS enzyme activity was significantly reduced in liver and 
brain within the newborn Pts-ki/ko mice in contrast to its wt/wt, Pts-ki/wt and Pts-ko/wt 
littermates. Whereas, the liver neopterin levels were found to be significantly increased in the 
newborn Pts-ki/ko mice (Figure 16B), biopterin levels revealed no significant differences 
compared to the three other genotypes (newborn wt/wt, Pts-ki/wt or Pts-ko/wt) (Figure 16C). 
Unlike the brain neopteirn levels (Figure 16B), the brain biopterin levels within the newborn 
Pts-ki/ko mice were significant reduced compared to newborn wt/wt, Pts-ki/wt or Pts-ko/wt 
mice (Figure 16C). 
The blood phenylalanine concentrations measured from Guthrie cards by ESI-MS/MS 
revealed no sign of HPA in the newborn Pts-ki/ko mice (Figure 16D). Likewise, no 
pronounced differences were observed in the blood phenylalanine concentrations among the 
Pts-ki/wt, Pts-ko/wt and wt/wt mice (Figure 16D). 
To test whether newborn Pts-ki/ko mice were suffering from monoamine neurotransmitter 
deficiency in the CNS, we analyzed the brain tissue for dopamine and serotonin. No 
variations were shown in the brain monoamine neurotransmitters between the four genotypes 
(Figure 16E), indicating that newborn Pts-ki/ko mice are not suffering from monoamine 
neurotransmitter deficiency in the CNS. 
 
2.4.7 Breeding of Pts-ki/ki or Pts-ki/wt males with Pts-ko/wt females 
To reproduce, elaborate and investigate the “affected” compound heterozygous phenotype in 
more details, we breed Pts-ki/ki or Pts-ki/wt males with Pts-ko/wt females.  
During the first days after birth, we noticed that the “affected” Pts-ki/ko phenotype, which 
was generated when Pts-ki/ki or Pts-ki/wt females were crossed with Pts-ko/wt males, did not 
arise when Pts-ki/ki or Pts-ki/wt males were mated with Pts-ko/wt females.  
 
All the mice born (10 Pts-ki/ko, 7 Pts-ki/wt, 12 Pts-ko/wt as well as 8 wt/wt) survived and 
showed no indication of phenotypical abnormalities (normal body size, milk-supply (white-
belly), behaviour and movements) until sacrificed at the age of three weeks.  
 
The biochemical analyses of the four obtained genotypes, including measurements of blood 
phenylalanine, neopterin (liver and brain), biopterin (liver and brain) as well as brain 
monoamine neurotransmitters demonstrated no differences in the blood phenylalanine levels 
among the mice likewise no indications on HPA (Figure 17). With reference to the neopterin 
levels measured in the liver and brain, the Pts-ki/ko mice revealed a significant elevated 
neopterin in the liver compared to the Pts-ki/wt, Pts-ko/wt and wt/wt mice (Figure 17B).  
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In comparison, no diversities were observed between the mice within the brain neopterin just 
as the biopterin levels both in liver and brain were the same in the four genotypes (Pts-ki/ko, 
Pts-ki/wt, Pts-ko/wt and wt/wt) (Figure 17C). Moreover, we found no significant variety in the 
brain monoamine neurotransmitter levels within the Pts-ki/ko mice compared to the Pts-ki/wt, 
Pts-ko/wt and wt/wt mice thereby demonstrating that Pts-ki/ko mice born from Pts-ki/ki or 
Pts-ki/wt males and Pts-ko/wt females do not exhibit monoamine neurotransmitter deficiency 
in the CNS (Figure 17D). 
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Figure 17: Biochemical characterization of 3 weeks old Pts-ki/ko mice after crossing Pts-ki/ki or Pts-ki/wt 
males with Pts-ko/wt females 
A: Neopterin levels (pmol/mg protein) in liver and brain. B: Biopterin levels (pmol/mg protein) in liver and brain. C: 
Blood phenylalanine (µmol/L). D: Brain monoamine neurotransmitters (dopamine and serotonin) and their end-
metabolites (HVA and 5-HIAA) (pmol/mg protein). E: Pts-ki/ko mice from Pts-ko/wt females and Pts-ki/ki or Pts-
ki/wt males. The genotypes are indicated by the bar colour: Pts-ki/ko (white column), wt/wt (black column), Pts-
ki/wt (light-gray column) and Pts-ko/wt (dark-gray column). Values are the mean ± S.D. ND indicates Not 
detectable. Significant difference from the corresponding value for wild-type is indicated by asterisks: * p < 0.05 
(Student’s t test). 
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2.4.8 Allelic effect, mother effect or father effect 
To follow up, the indication that “affected” Pts-ki/ko mice only appeared when born from Pts-
ki/ki or Pts-ki/wt females and not from Pts-ki/ki or Pts-ki/wt males suggested that the 
genotype (Pts-ki/ki or Pts-ki/wt) of the mother plays an important role.  
Hence, we speculated whether the observed phenotypical diversity within the Pts-ki/ko mice 
was due to an allelic effect (homozygous versus heterozygous), a mother effect or a father 
effect (Figure 18).  
 
male x female F1
___________________________________________________________
Pts-ki/ki Pts-ki/ko affected (?) (pending)
Pts-ko/wt X
Pts-ki/wt Pts-ki/ko unaffected (?) (pending)
---------------------------------------------------------------------------------------------------
Pts-ki/ki Pts-ki/ko unaffected (confirmed)
X Pts-ko/wt 
Pts-ki/wt Pts-ki/ko unaffected (confirmed)
____________________________________________________________
“Affected” versus “unaffected” Pts-ki/ko mice
 
Figure 18: Hypothesis:  Allelic effect (homozygous versus heterozygous), mother effect or father effect 
The “affected” Pts-ki/ko mice were generated when Pts-ki/ki females or Pts-ki/wt females were bred with Pts-
ko/wt males but not when Pts-ko/wt females were bred with Pts-ki/ki males or Pts-ki/wt males suggesting a 
tendency towards a Pts-R15C-ki mother effect. To test this hypothesis, we sat up the following breeding-pairs: 
3x (Pts-ki/ki female and Pts-ko/wt male), 3x (Pts-ki/wt female and Pts-ko/wt male), 3x (Pts-ki/ki male and Pts-
ko/wt female) and 3x (Pts-ki/wt male and Pts-ko/wt female).  
 
To further investigate this hypothesis, we sat up the following breeding-pairs: a) Pts-ki/ki 
female and Pts-ko/wt male, b) Pts-ki/wt female and Pts-ko/wt male, c) Pts-ki/ki male and Pts-
ko/wt female and d) Pts-ki/wt male and Pts-ko/wt female (Figure 18).  
As in our previous breeding-studies, all the newborn mice were carefully monitored the first 
hours after birth. Diversity among the newborns were only observed within the mice born 
from Pts-ki/ki females (Figure 19) and the following day the mice that clearly stood out 
(undersized, passive, isolated/alone, cold and lack of milk (white-belly)) were either dead or 
eaten up. 
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Subsequently, mice from Pts-ki/ki females were sacrificed at day 1. Mice from the three other 
breedings-pairs (Figure 19) showed no apparent phenotype and survived until the age of three 
weeks where they were sacrificed. Additionally, newborn mice from Pts-ki/wt females, Pts-
ki/ki males and Pts-ki/wt males were also sacrificed.  
 
Currently, the tissue (brain and liver) and blood collected from the sacrificed mice (four 
breeding-pairs, five genotypes and two ages (newborn and 3 weeks of age (minus from Pts-
ki/ki female and Pts-ko/wt)) are being analyzed in terms of PTPS enzyme activity (liver and 
brain), neopterin (liver and brain), biopterin (liver and brain), blood phenylalanine 
concentration and brain monoamine neurotransmitters. Moreover, in collaboration with 
Professor Hiroshi Ichinose and PhD. Daigo Homma, Tokyo Institute of Technology, 
Yokohama, Japan, whole brains from newborn have been collected to investigate the tyrosine 
hydroxylase (TH) and tryptophan hydroxylase (TPH) status by immunohistrochemistry.  
 
A B
C D
 
Figure 19: Newborns from allelic effect, mother effect or father effect-breeding experiment 
Significant diversity among the newborns were only observed within the mice born from Pts-ki/ki females (A) 
as they were undersized, passive, isolated/alone, cold and showed lack of milk-white-belly. If not sacrificed at 
day 1, these mice were either dead or eaten up the following day. A: Newborns from Pts-ki/ki female and Pts-
ko/wt male. B: Newborns from Pts-ki/wt female and Pts-ko/wt male. C: Newborns from Pts-ki/ki male and 
Pts-ko/wt female and D: Newborns from Pts-ki/wt male and Pts-ko/wt female.  
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2.5 Discussion 
In the present study, we generated two new Pts mouse models – a Pts-ki/ki mouse and a Pts-
ki/ko mouse by targeting the biosynthetic Pts gene to study BH4 deficiency, in particular the 
phenotypical diversities associated with human PTPS deficiency.  
Our biochemical analysis revealed that the Pts-ki/ki mice neither have HPA nor considerable 
differences within the brain monoamine neurotransmitter metabolites compared to the Pts-
ki/wt and wt/wt mice, but instead showed a significant reduced PTPS enzyme activity and 
elevated neopterin both in liver and brain. Despite, the phenotypic reduced PTPS enzyme 
activity and elevated neopterin, the Pts-ki/ki mice did not mimic human PTPS deficiency 
which is characterized by reduced PTPS enzyme activity, elevated neopterin, reduced 
biopterin, HPA and monoamine neurotransmitter deficiency in the CNS thus the Pts-ki/ki 
mouse is not a suitable mouse model to study BH4 deficiency.  
 
Although, the Pts-ki/ki mice manifested at phenotype too mild compared to the human BH4 
deficient situation, we sent them to the GMC for further comprehensive phenotypical and 
biochemical characterization to see whether the Pts-ki/ki allele would give rise to an unknown 
and unexpected phenotype. Intriguingly, the Pts-ki/ki mice did not revealed an unambiguous 
Pts-R15C-ki allele specific phenotype in terms of dysmorphology, behaviour, neurology, 
nociception, eye/vision, clinical chemistry, haematology, steroid metabolism, lung function or 
pathology. Yet, the comprehensive phenotypical and biochemical analysis demonstrated new 
and interesting aspects within energy metabolism and immunology/allergy which have to be 
investigated further on another cohort to confirm whether these observations are specific 
related to this specific cohort of mice or whether these observations are a general phenotype 
feature for the Pts-ki/ki mice.  
 
In parallel with the comprehensive phenotypical and biochemical characterization at the 
GMC, we performed feeding-studies on Pts-ko/wt males and Pts-ki/ki males to confirm a 
previous unpublished observation suggesting that Pts-ko/wt males exhibit an abnormal fat 
distribution as they were shown to have a two-fold increase in intra-abdominal adipose tissue 
compared to a 1.6-fold increase in wt/wt males after subjected to high fat diet over a period of 
several weeks. Interestingly, we found that the Pts-ki/ki males, like the Pts-ko/wt males, 
displayed an abnormal fat distribution on both standard mouse chow and high fat diet.  
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This result not only supports the energy metabolism observations at the GMC but also 
demonstrates for the first time that insufficient PTPS enzyme activity plays an important role 
in the fat distribution. The underlying metabolic and/or molecular mechanisms linking PTPS 
deficiency with abdominal obesity remains unclear and has to be investigated further.  
 
The most likely explanation for this linkage between insufficient PTPS enzyme activity and 
abdominal obesity is via endothelial nitric oxide synthase (eNOS). eNOS is under adequate 
BH4 levels responsible for the NO production which plays an important role in the regulation 
of vascular tone by mediating endothelium-dependent vasodilatation (Schmidt and Alp, 
2007). Moreover, NO is a potent inhibitor of platelet and leukocyte adhesion to the vascular 
wall and inhibits smooth muscle cell proliferation (Gesierich et al., 2003).  
 
When BH4 is limited the NO production is reduced and the superoxide (O2-) production by 
uncoupled eNOS is increased which causes vascular oxidative stress within endothelial cells 
(Schmidt and Alp, 2007). These endothelial imbalances have been associated with numerous 
vascular diseases including diabetes, hypertension, experimental vascular injury and 
hypercholesterolaemia (Schmidt and Alp, 2007, Werner et al., 2011). 
 
Several studies have shown that endothelial dysfunction within e.g. streptozotocin-induced 
diabetic rats, hypercholesterolaemic ApoE-KO mice and Type 2 diabetic patients can be 
reversed by BH4 (sepiapterin) supplementation (Ishii et al., 2001, Schmidt and Alp, 2007). 
Thus, BH4 represents a potential therapeutic target for preserving eNOS function in vascular 
disease (Schmidt and Alp, 2007).  
 
Seen in this prospective, it would be interesting to explore whether oral BH4 administration 
would influence the abnormal fat distribution observed in the Pts-ko/wt and Pts-ki/ki males.  
 
In addition, oxidative stress within endothelial cells has been shown to cause a reduction of 
BH4 to BH2 (Schmidt and Alp, 2007). For that reason, it could be interesting to measure the 
amount of BH2 and/or the BH4/BH2 ratio in the Pts-ko/wt and Pts-ki/ki males after 10 weeks 
on standard mouse chow or high fat diet.  
 
Beside the Pts-ki/ki mice, we also generated Pts-ki/ko mice by breeding the Pts-R15C-ki 
allele into the Pts null allele. Surprisingly, the genotyping results revealed two different 
phenotypes – “affected” Pts-ki/ko mice (dying 3-4 days after birth) and “unaffected” Pts-
ki/ko mice (surviving until sacrificed at 3-4 weeks of age).  
 
The underlying molecular mechanisms for the two phenotypes are unknown and will be 
investigated further.  
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Both the “affected” and “unaffected” Pts-ki/ko mice showed reduced PTPS enzyme activity 
in liver and brain as expected from Pts-ki/ki and homozygous Pts-ko mice. Unlike, the 
“unaffected” Pts-ki/ko mice, the “affected” Pts-ki/ko mice showed elevated neopterin levels 
(liver and brain), reduced biopterin levels (liver and brain), mild HPA and brain monoamine 
neurotransmitter deficiency due to undetectable levels of dopamine, HVA, serotonin and 5-
HIAA. Interestingly, this phenotype imitates the human BH4 deficient situation thus making 
the “affected” Pts-ki/ko mouse a suitable model to study human BH4 deficiency.  
 
In an attempt to elucidate, the phenotypical diversities observed among the Pts-ki/ko mice, 
newborn mice were sacrificed and biochemically characterized. The subsequent analysis 
revealed significant reduced PTPS enzyme activity (liver and brain), elevated liver neopterin 
and reduced brain biopterin levels but normal blood phenylalanine and monoamine 
neurotransmitter levels in the CNS compared to Pts-ki/wt, Pts-ko/wt and wt/wt mice. 
Thereby, demonstrating that “affected” and “unaffected” Pts-ki/ko mice set apart in terms of 
the liver biopterin, blood phenylalanine and brain monoamine neurotransmitters. This 
indication suggests that the phenotypical deviation observed between the “affected” and 
“unaffected” Pts-ki/ko occurs after birth.  
 
In order to reproduce the “affected” Pts-ki/ko phenotype we breed Pts-ki/ki or Pts-ki/wt 
males with Pts-ko/wt females. This breeding experiment demonstrated that “affected” Pts-
ki/ko mice only appeared when born from Pts-ki/ki or Pts-ki/wt females and not from Pts-
ki/ki or Pts-ki/wt males suggested that the genotype of the parents plays an important role. 
Hence, we speculated whether the observed phenotypical diversity within the Pts-ki/ko mice 
was due to an allelic effect (homozygous versus heterozygous), a mother effect or a father 
effect.  
 
Although still under investigation, our preliminary observations point toward a tendency of 
mother effect (Pts-ki/ki females) in combination with allelic effect (homozygosity) to be 
responsible for the diverse compound heterozygous phenotypes (Figure 19). The tendency of 
a homozygous mother effect is made based on observations indicating that “affected” Pts-
ki/ko mice only arised from Pts-ki/ki females and not from Pts-ki/wt female, Pts-ki/ki males 
or Pts-ki/wt males (Figure 19).  
 
We hypothesize that a transfer of biopterin from mother to the offsprings via the milk might 
be of functional significance and perhaps provide an explanation for the two diverse 
compound heterozygous phenotypes.  
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This hypothesis is supported by the observations indicating that the condition of the 
“affected” Pts-ki/ko mice becomes progressively more severe after birth when they depend on 
biopterin provided via the milk from their mothers. Another, indication in agreement of this 
hypothesis is the lack of milk-white-belly in the “affected” Pts-ki/ko mice.  
 
Previous, biopterin measurements in different human body fluids and tissues have shown that 
the concentration of biopterin was highest in the milk (Matsubara and Gaull, 1985, Leeming 
et al., 1976, Dhondt et al., 1982). In fact, the biopterin concentration in milk was found to be 
89 times higher than in serum which suggests that a dietary supply of biopterin might has an 
important role in the development of human infants (Matsubara and Gaull, 1985). Moreover, 
neopterin was also measured to be present in milk yet in smaller concentrations than biopterin 
(Matsubara and Gaull, 1985). Seen in this perspective, we would like to measure biopterin 
and neopterin concentrations in mother milk from lactating Pts-ki/ki females, Pts-ki/wt 
females, Pts-ko/wt females and wt/wt females using published mouse milking procedures 
(DePeters and Hovey, 2009, Ragueneau, 1986).  
 
Altogether, the results presented in this study demonstrated that “affected” Pts-ki/ko mice is a 
suitable mouse model to study BH4 deficiency as it mimics the biochemical hallmarks of 
human BH4 deficiency thus can be used for further investigations of human BH4 deficiencies 
and future treatment studies. 
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2.6 Supplementary Information 
Primary screening at the GMC: 
Anatomical observations and X-ray analysis showed no phenotypical differences between 
Pts-ki/ki and wt/wt mice but the bone densitometry showed significant decreased body mass 
content as well as increased body weight and lean mass in Pts-ki/ki males compared to wt/wt 
males. This observation was not seen in Pts-ki/ki females but only in Pts-ki/ki males thus a 
secondary dysmorphology screen was not suggested.  
 
In terms of behaviour two tests were performed, an open field test and a pre-pulse inhibition 
test. The open field test revealed significant increased locomotor activity in the mutant mice 
compared to the control mice. However, no significant genotype effect was observed on the 
rearing activity (vertical locomotion) or centre time (anxiety-related behaviour). Moreover, no 
significant genotype effect was observed in the pre-pulse inhibition test.  
Assessment and evaluation of basic neurological and motor functions were examined by a 
modified-SHIRPA protocol (systematical behavioural and functional observations). The 
SHIRPA-results revealed no difference in grip strength or rotarod but there was a tendency 
towards more activity/alertness (more active in viewing jar and showed more defecation) in 
the Pts-ki/ki mice compared to the wt/wt mice.  
 
Nociception was investigated by exposing the mice to the hot plate test and the reaction-times 
indicated that no significant genotype or sex effect was found hence additional pain-related 
studies was not suggested. Examination of the eyes and vision by ophthalmoscope and slit 
lamp analysis showed no association of the Pts-R15C-ki allele and the occurrence of anterior 
segment abnormalities, retinal fundus abnormalities or axial eye length abnormalities thus no 
further tests were recommended.  
 
Body composition analysis by non-invasive NMR to determine the body fat and lean mass 
content in the mice as well as the indirect calorimetry to determine the energy metabolism 
from gas exchange was performed. The NMR revealed that Pts-ki/ki mice have a significantly 
reduced body mass but in males the body fat content was increased and the lean mass was 
decreased (Figure 11). No shift in body composition could be detected in Pts-ki/ki females. 
No other variables monitored during the indirect calorimetry trial were substantially affected.  
 
The spontaneous breathing (activity, rest and sleep) as a measure for the lung function 
showed a significant higher tidal volume in Pts-ki/ki females at activity resulting in higher 
values for body mass related parameters, yet no diversity in breathing pattern was found for 
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the Pts-ki/ki males. Besides this observation no genotype-related differences were observed in 
respiratory rates or timing (normal adaptation (respiratory rates) from rest to activity) between 
Pts-ki/ki and wt/wt mice.  
 
Blood was collected by retroorbital puncture and subdivided for further analysis within the 
following areas: clinical chemical, haematology, allergy, immunology and steroids. 
Intraperitoneal glucose tolerance test showed no genotype-related difference but a tendency 
towards an increased plasma glucose levels was observed in fasted mutant mice. Moreover, 
the female mutant lost more weight than female control mice due to overnight fasting, 
conversely this genotype effect was not observed in males.  
 
The clinical chemical parameters revealed a slightly increased (Pts-ki/ki females) and 
decreased (Pts-ki/ki males) sodium concentration, significant increased (Pts-ki/ki females) 
and decreased (Pts-ki/ki males) chloride concentration, increased cholesterol and triglyceride 
levels in both mutant males and females but mainly significant in Pts-ki/ki females. In 
addition, a higher alkaline phosphatase activity was observed in Pts-ki/ki mice compared to 
wt/wt mice.  
The animal blood count showed at slightly increased haemoglobin concentrations in mutant 
animals resulting in significantly higher mean corpuscular haemoglobin and mean corpuscular 
haemoglobin concentration values.  
 
The immunology and allergy screen showed no changes in the frequencies of most leukocyte 
subsets in peripheral blood but only subtle differences in the frequency of CD11b+ expressing 
NK cells (a maturation marker for NK cells) and slightly lower levels of immunoglobulins 
IgG1, IgG2b and IgE in Pts-ki/ki female mice (Figure 12A). The immunoglobulin IgE 
concentration were re-measured in plasma samples from female mice (wt/wt and Pts-ki/ki) 
and also the second time the same tendency was observed (Figure 12B). Due to the lower 
levels of IgG1, IgG2b and IgE in Pts-ki/ki females a secondary test with a new cohort of mice 
(n=10 to 12 per sex per group) to confirm the observed phenotype was suggested.  
 
Corticosterone showed a sex-specific difference within the wild-type mice conversely this 
was not observed in the Pts-ki/ki mice. In contrast, testosterone verified an expected sex-
specific difference in both the Pts-ki/ki and wt/wt mice nevertheless no steroid phenotype was 
found in the Pts-ki/ki mice.  
 
Finally, no pathological alternations were shown in the Pts-ki/ki mice compared to wt/wt 
mice upon dissection and macroscopic pathological examination as well as histological 
analysis.  
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3.1 Abstract 
In the liver, BH4 has been found to regulate its own biosynthesis through feedback inhibition 
of GTP cyclohydrolase I (GTPCH) mediated by GTP cyclohydrolase feedback regulatory 
protein (GFRP). Moreover, L-phenyalanine has been shown to reverse this BH4-mediated end-
product feedback inhibition and instead imply a feedforward stimulation of the BH4 
biosynthesis.  
In contrast to the liver, where
 
phenylalanine stimulates the BH4 biosynthesis by displacing 
BH4 from the GTPCH-GFRP protein-complex, the regulation of BH4 biosynthesis in the brain 
is not yet understood. However, GFRP seems to play an important role as studies in rat brain 
have shown that GFRP mRNA was abundant in serotonin neurons within the brainstem, but 
undetectable in dopamine neurons of the midbrain or norepinephrine neurons of the locus 
coeruleus. Moreover, analysis in primary neuronal cultures have indicated that GFRP 
regulates the BH4 biosynthesis in serotonin neurons but not in dopamine or norephinephrine 
neurons which suggest that GFRP has a specific function in brain serotonin homeostasis.  
To study the in vivo role of GFRP in liver and brain as well as its potential contribution to 
human diseases, we aimed of generating the first animal model for GFRP, a conditional 
knock-out by targeted mutagenesis of the murine Gchfr gene. Besides understanding the in 
vivo function of the Gchfr gene by studying the consequences of the Gchfr knock-out, we aim 
to find clinical relevant phenotype in the GFRP-deficient mice and thereby identify a human-
specific counterpart. 
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3.2 Introduction  
BH4 is synthesized de novo from guanosine triphosphate (GTP) by three enzymes: GTP 
cyclohydrolase I (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS) and sepiapterin 
reductase (SR) (Thöny et al., 2000) (Figure 1). The committing step of the BH4 biosynthesis 
is the conversion of GTP to NH2TP catalyzed by GTPCH (Thöny et al., 2000). The GTPCH 
activity, which directly affects the BH4 levels, is predominantly regulated at the 
transcriptional level by various proinflammatory cytokines such as interferon-γ, interleukin 1β 
and tumor necrosis factor-α as well as bacterial lipopolysaccharide but is also regulated at the 
post-transcriptional level by phosphorylation (Gesierich et al., 2003, Milstien et al., 1996, 
Werner-Felmayer et al., 2002, Imazumi et al., 1994, Lapize et al., 1998). Additionally, in vitro 
studies on rat liver extracts have demonstrated that BH4 regulates its own biosynthesis 
through feedback inhibition of GTPCH and that this end-product feedback inhibition is 
mediated through protein-complex formation with GTP cyclohydrolase feedback regulatory 
protein (GFRP) (Harada et al., 1993). Furthermore, L-phenylalanine has been shown to 
reverse this BH4-mediated feedback inhibition as it changes the inactive GTPCH-GFRP 
complex to its active form (Yoneyama et al., 1997).  
Whereas, the BH4 biosynthesis in the liver is well understood, the regulation of BH4 
biosynthesis in brain is not yet known. Even so, GFRP appears to play an important role as 
primary neuronal culture studies have demonstrated that GFRP regulates BH4 biosynthesis 
within serotonin neurons but not within dopamine or norephinephrine neurons suggesting that 
GFRP is specifically expressed in some brain tissue or cell types (Kapatos et al., 1999).  
Based on these indications, we hypothesize that GFRP has a specific function in brain 
serotonin homeostasis. To study the in vivo role of GFRP in liver and brain in further details 
as well as its potential contribution to human s, we aim to generate the first animal model for 
GFRP, a conditional knock-out for the murine Gchfr gene.  
When the conditional Gchfr knock-out mouse has been successfully generated, we attend to 
generate mice with a complete, a peripheral (liver-specific and kidney-specific) and a 
neuronal Gchfr-deletion (CNS-specific and brain-tissue-specific) and subsequently subject 
them to comprehensive phenotypical analysis including biochemical and metabolic 
investigations on BH4-and neurotransmitter-related pathways. In that way learn why GTPCH 
is regulated by BH4 and phenylalanine via GFRP in some cell types but not in others. In the 
study presented here, we describe the two Gchfr gene targeting strategies used in order to 
generate the first animal model for GFRP, a conditional knock-out for the murine Gchfr gene.  
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3.3 Method and materials 
Gene targeting strategy 
The murine Gchfr gene (Ensembl Transcript ID: ENSMUSG00000046814) encoding for 
GFRP is located at chromosome 2 and consists of 3 exons: 101 bp, 95 bp and 449 bp, 
respectively. In order to generate a conditional Gchfr knock-out mouse a targeting vector 
leading to deletion of exon 2 was cloned (PolyGene Transgenetics AG, Switzerland). Deletion 
of exon 2 was chosen as a conditional insertion 5’ of exon 1 would pose a risk of interfering 
with the poorly characterized promoter region. On the other hand, involvement of exon 3 
would likely interfere with expression of a mapped gene in close proximity in opposite 
direction and with unknown function. The crystal structure of GFRP (Maita et al., 2002) 
suggested that a deletion of exon 2 would cause inhibition of the two binding sites for 
GTPCH and phenylalanine, respectively, leading to a total loss of function hence at targeting 
vector with a “floxed” exon 2 was generated.  
 
Construction of D153 targeting vector 
Targeting vector D153 was constructed with a 1282 bp short arm of homology and a 5.3 kb 
long arm of homology including exon 2 and 3 of the Gchfr gene. In addition, a pseudo-vector 
D152 (not shown) was generated for setting up the screening conditions of the transfected 
ES cell clones. For positive (neomycin gene) and negative (thymidine kinase (TK) gene) 
selection a LoxP-neo-TK-LoxP cassette was introduced between the short and the long arm of 
homology. Moreover, a LoxP site was added 200 bp upstream of exon 2. The targeting vector, 
which is shown in Figure 20A, was after successful construction transfected into ES cells 
derived from the C57BL/6 strain. Positive ES cell clones, in which homologous 
recombination has occurred, were genetic characterized by PCR (not shown) as well as 
Southern blot analysis using external 5’ and 3’ probes (not shown). Both the PCR and 
Southern blot analysis were performed by Dr. Tanja Scherer and M.Sc. David Meili.  
 
Several studies have revealed that TK expressing mice are infertile (Braun et al., 1990) thus 
the LoxP-neo-TK-LoxP cassette was deleted by transfecting one correctly targeted ES cell 
clone with Cre recombinase. Cre recombinase transfection led to three different targeted 
Gchfr loci depending on the recombination between the three LoxP-sites (Figure 20B). 
Correct Cre recombination event was determined by Dr. Tanja Scherer using a PCR approach 
(not shown).  
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One ES cell clone with “floxed” exon 2 was chosen for morula aggregation which was carried 
out at the Institute of Laboratory Animal Science at the University of Zürich in collaboration 
with Dr. Thorsten Buch and Dr. Pawel Pelczar (Figure 20B). Morula aggregation led to 
generation of four chimeras which were subsequently back-crossed with mice derived from 
the C57BL/6-albino strain (B6-Tyr <cBrd> provided by Dr. Pawel Pelczar at the Institute of 
Laboratory Animal Science) in order to generate heterozygous Gchfr-floxed mice (Figure 21).   
 
Alternative strategy: Construction of D154 targeting vector 
A 2048 bp fragment including a LoxP-FRT-neomycin-FRT cassette from the BBV16rapidflirt 
vector (kindly provided by Dr. Thorsten Buch) was subcloned into the D151 targeting vector 
(previous used to generate targeting vector D153 and pseudo-vector D152) consisting of exon 
2 of the murine Gchfr gene and a LoxP-site 200 bp upstream of exon 2. The subcloning which 
was performed by TOPO Gene Tech led to the generation of a LoxP-FRT-neo-FRT-exon2-
loxP targeting vector called D154 (Figure 22). Recently, this targeting vector was recently 
linearized and electoporated into ES cells derived from the C57BL/6 strain.  
  
Conditional Gchfr knock-out mouse to study the role of GFRP in vivo 
 91  
3.4 Results 
Targeted disruption of the Gchfr gene 
In order to generate a conditional knock-out mouse of the Gchfr gene encoding for GFRP, we 
chose a classical strategy for homologous recombination in C57BL/6 derived embryonic stem 
(ES) cells using a targeting vector (D153) containing a LoxP-neo-TK-LoxP-exon2-LoxP 
motif to “flox” exon 2 of the murine Gchfr gene and thereby generate a conditional Gchfr 
knock-out mouse. The targeting strategy for deletion of the murine Gchfr gene is depicted in 
Figure 20.  
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Figure 20: Targeting vector D153 used to generate conditional Gchfr knock-out mice 
A: Schematic representation of Gchfr gene locus (top), targeting vector D153 including a LoxP-neo-TK-LoxP-
cassette (middle) and the Gchfr gene locus after the homologous recombination event (bottom). B: Transfection 
of the ES cells with Cre recombinase in order to delete the neo-TK-cassette cause three different targeted Gchfr 
loci depending on the Cre recombination event between the LoxP-sites. Deletion of the neo-TK-cassette is 
necessary as studies have shown that TK expressing mice are infertile. The “floxed” exon 2 locus (left) result in 
a conditional Gchfr knock-out mouse which requires breeding with a Cre-deleter mouse (complete, tissue-
specific or cell-specific) to generate a complete Gchfr knock-out mouse. Both the LoxP (middle) and LoxP-
neo-TK-LoxP (right) targeted Gchfr loci result in complete Gchfr knock-out mice (not conditional).  
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After successful construction of targeting vector D153 and correctly targeting into C57BL/6 
derived ES cells, followed by morula aggregation, four chimeras were born (Figure 21).  
 
The four chimeras (3 males and 1 female, one male was ~ 5% chimeric but the three others 
were 50-80 % chimeric) were at the sexual mature age back-crossed with mice derived from 
the C57BL/6-albino strain to generate heterozygous Gchfr-floxed mutant mice (Figure 21).  
 
 
  
Figure 21: Two chimeras born after morula aggreation together with three C57BL/6-albino littermates 
Morula aggregation at the Institute of Laboratory Animal Science at the University of Zürich in collaboration 
with Dr. Thorsten Buch and Dr. Pawel Pelczar led to generation of four chimeras (3 males and 1 female, one 
male was ~ 5% chimeric but the three others were 50-80 % chimeric). In this figure, two of the four chimeras 
born after morula aggregation (both in left corner with black (C57BL/6)/white (C57BL/6-albino) fur color) are 
depicted together with three of their C57BL/6-albino (all with white fur and red eyes) littermates. 
 
Regardless of the relative high chimerism, the four chimeras did not cause generation of 
heterozygous Gchfr-floxed mice indicating lack of germline transmission. Hence, the morula 
aggregation step was repeated to achieve new chimeric mice with perhaps an even higher 
chimerism. Despite, using several different and improved morula aggregation strategies, the 
correctly Gchfr targeted ES cell clones did not led to generate of new chimeras as 
consequence a second and new targeting vector, named D154, was generated (Figure 22). 
Altogether, this alternative Gchfr gene targeting strategy involving an improved targeting 
vector D154 and new ES cells was decided as the previous correctly D153 targeted ES cell 
clones were shown to be unworkable for the generation of chimeric mice.  
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The second and alternative gene targeting strategy for generation of conditional Gchfr knock-
out mice using a newly generated targeting vector D154 is depicted in Figure 22.  
In contrast to the previous targeting vector D153, the new and improved targeting vector 
D154 consisted of “only” two LoxP-sites surrounding the exon 2 (this was done in order to 
decrease the number of recombination possibilities between the LoxP-sites after Cre 
recombinase transfection). Moreover, targeting vector D153 contained a FRT flanked 
neomycin-cassette between the two LoxP-sites for positive selection of the ES cells (Figure 
22). Construction of the D154 targeting vector was successful thus it was recently linearized 
and electoporated into ES cells derived from the C57BL/6 strain. At this current state, we are 
ready to analyze positive Gchfr targeted ES cell clones by PCR and Southern blot analysis 
(same screening strategy as used for targeting vector D153) to confirm correctly insertion of 
targeting vector D154 after homologous recombination in the ES cells. 
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Figure 22: Alternative targeting strategy to generate conditional Gchfr knock-out mice 
A: Schematic representation of Gchfr gene locus (top), targeting vector D154 including the LoxP-FRT-neo-FRT-
cassette (middle) and the Gchfr gene locus after the homologous recombination where the genomic DNA has been 
introduced into the ES cells (bottom). B: Targeting vector D154 contains two LoxP-sites and a flanked neo-
cassette which means that breeding with a FLP recombinase and/or Cre recombinase expressing mice will lead to 
the generation of a Gchfr knock-out mouse.  
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3.5 Discussion 
This present study, describes two different gene targeting strategies used for the generation of 
the first animal model for GFRP, a conditional knock-out for the murine Gchfr gene.  
 
The initial gene targeting strategy which was based on a targeting vector (D153) consisting of 
a LoxP-neo-TK-LoxP-exon2-LoxP motif, led via morula aggregation to the generation of four 
chimeras (three males and one female, one male was ~ 5% chimeric but the three others were 
50-80 % chimeric) (Figure 21).  
 
Despite the relative high chimerism of the four chimeras no heterozygous Gchfr-floxed mice 
were generated after back-crossing with C57BL/6-albino mice indicating the lack of germline 
transmission. Furthermore, replication of the morula aggregation step in order to generate new 
chimeric mice using the same ES cell clone were unsuccessful suggesting that the ES cells no 
longer were useful for generation of chimeras. This last observation was presumably due to the 
additionally step involving transfection with cre recombinase in order to delete the TK-cassette 
which in previous studies have been shown to cause infertile mice (Braun et al., 1990). Due to 
lack of germline transmission and the overall condition of the ES cells, a second Gchfr gene 
targeting strategy was launced.  
Recently, the new and improved targeting vector (D154), which consists of a LoxP-FRT-
neomycin-FRT-exon2-loxP motif has been linearized and electoporated into ES cells derived 
from the C57BL/6 strain thus we are now ready to genetic characterize the correctly 
transfected ES cell clones by PCR and Southern blot analysis.   
 
Assuming that the Gchfr-knock-out mouse after successful generation is not exhibit lethal, we 
aim to generate and characterize different tissue-specific and neuron-specific GFRP knock-
out mice including a complete Gchfr knock-out mouse, a peripheral Gchfr knock-out mouse 
(liver-specific and kidney-specific) and a neuronal Gchfr knock-out mouse (both an entire 
Gchfr brain deletion (CNS-specific) and brain tissue-specific).  
 
At this state, we hypothesize that a complete deletion of the Gchfr gene is not essential but 
rather is associated with dystonia or potentially developmental abnormalities. Nevertheless, 
comprehensive phenotypical, behavioral and molecular analysis of the Gchfr mouse models 
will assess this hypothesis, but also facilitate the searching for a human counterpart. As GFRP 
is the only gene within the BH4 metabolism for which no human deficiency has yet been 
described (Thöny and Blau, 2006). 
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4.1 Supporting Information on SLC6A4 gene analysis 
Screening for polymorphism in the human SLC6A4 gene  
Intronic primers were designed with the online program ExonPrimer (http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html) to flank 15 exons in the human SLC6A4 gene (listed in 
Table S1). The PCR was performed in a final volume of 25 µl containing 1 µl of genomic 
DNA template (100 ng), 1 µl of forward and reverse primer (5 µM), 0.5 µl 10 mM 
deoxyribonucleoside triphosphates (dNTPs), 0.2 µl Hot FirePol Hotstart DNA polymerase 
(Solis Biodyne), 1.5 µl 25mM MgCl2, 2.5 µl 10x reaction buffer (Mg2+ free from Solis 
Biodyne) and 5 µl 5x Q-solution (Qiagen). The PCR reactions were performed in a GeneAmp 
PCR System 9700 from Applied Biosystems using standard thermal cycling: hot start 
activation at 95oC for 15 minutes, followed by 35 cycles of denaturation 95°C for 1 minute, 
annealing 55°C for 45 seconds and extension at 72°C for 1 minute, a final extension was 
performed at 72°C for 10 minutes and termination at 4oC. The same primers as mentioned 
above (listed in Table S1) were used to directly sequence the amplified PCR products with 
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing PCR was 
performed in a 10 µl reaction mixture consisting of 0.5 µl PCR product, 0.8 µl primer (5 µM), 
1.5 µl BigDye and 1.25 µl 5xsequencing buffer (both BigDye and 5xsequencing buffer from 
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems)) using standard thermal 
cycling: (activation at 95oC for 1 min, followed by 25 cycles of 96oC for 10 seconds, 50oC for 
5 seconds, 60oC for 3 minutes and termination at 4oC). After end run 15 µl H2O was added to 
the sequencing reactions before purified by gel filtration (using MultiScreen HV 96-well filter 
plates (Millipore) with Sephadex G-50 (GE Healthcare)) and analyzed on a 3130xl Genetic 
Analyzer (Applied Biosystems). Sequencing results were compared with the wild-type 
sequence of the SLC6A4 gene using the Mutation Surveyor (Demo) Software v3.20 from 
SoftGenetics (Transcript ID: ENST00000394821 or accession number NM_001045.4). 
 
Genotyping of SLC6A4 gene-linked polymorphic promoter region (5-HTTLPR) 
PCR was used to amplify the polymorphism in the SLC6A4 gene-linked polymorphic 
promoter region (5-HTTLPR) consisting of a 44 base pair (bp) insertion or deletion. Two 
oligonucleotide primers previously described in (Esterling et al., 1998) (forward 5’-
CCGCTCTGAATGCCAGCACCTAAC-3’ and reverse 5’-AGAGGGACTGAGCTGGAC 
AACCAC-3’) were used to generate two 5-HTTLPR allele-specific fragments: short (S) allele 
479 bp and long (L) allele 523 bp. The PCR was performed in a final volume of 25 µl 
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containing 1 µl of genomic DNA template (100 ng), 1 µl of forward and reverse primer (5 
µM), 0.5 µl 10 mM deoxyribonucleoside triphosphates (dNTPs), 0.2 µl Hot FirePol Hotstart 
DNA polymerase (Solis Biodyne), 1.5 µl 25mM MgCl2, 1.5 µl 10x reactionsbuffer (Mg2+ free 
from Solis Biodyne) and 5 µl 5x Q-solution (Qiagen). The PCR reactions were performed in a 
GeneAmp PCR System 9700 from Applied Biosystems using standard thermal cycling: hot 
start activation at 95oC for 15 minutes, 35 cycles of denaturation 95°C for 30 seconds, 
annealing 61°C for 30 seconds and extension at 72°C for 1 minute, a final extension at 72°C 
for 10 minutes and termination at 4oC. The PCR products were run on a 1.5% agarose gel and 
visualized under ultraviolet (UV) light in the presence of GelRed 10,000X in water (Biotium).  
 
Genotyping of STin2 VNTR  
PCR amplification of the VNTR region in intron 2 was performed by using two 
oligonucleotide primers previously described in (Cook et al., 1997), HTT2X 5’-
TGGATTTCCTTCTCTCAGTGATTGG-3’ and HTT2Y 5’-TCATGTTCCTAGTCTTACGC 
CAGTG-3’. The primers amplify fragments at different length according to the number of 
copies present in intron 2: 345 bp represent 9 copies, 360 bp 10 copies and 390 bp 12 copies. 
The PCR was performed in a final volume of 25 µl containing 1 µl of genomic DNA template 
(100 ng), 1 µl of forward and reverse primer (5 µM), 0.5 µl 10 mM deoxyribonucleoside 
triphosphates (dNTPs), 0.2 µl Hot FirePol Hotstart DNA polymerase (Solis Biodyne), 1.5 µl 
25mM MgCl2, 1.5 µl 10x reactionsbuffer (Mg2+ free from Solis Biodyne) and 5 µl 5x Q-
solution (Qiagen). The PCR reactions were performed in a GeneAmp PCR System 9700 from 
Applied Biosystems using standard thermal cycling: hot start activation at 95oC for 15 
minutes, 35 cycles of denaturation 95°C for 15 seconds, annealing 57°C for 30 seconds and 
extension at 72°C for 30 seconds, a final extension at 72°C for 5 minutes and termination at 
4oC. The PCR products were run on a 1.5% agarose gel and visualized under ultraviolet (UV) 
light in the presence of GelRed 10,000X in water (Biotium).  
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Table S1.  
Primers used for PCR-amplification and sequencing of 5-HTTLPR, STin2VNTR and 
the 15 exons of the human SLC6A4 gene  
 
Region Primer Sequence (forward and reverse) Product size (bp) 
______________________________________________________________________ 
5HTTLPR    5’-CCGCTCTGAATGCCAGCACCTAAC-3’          479 (S) or 523 (L) 
  5’-AGAGGGACTGAGCTGGACAACCAC-3’          
HTT2X     5’-TGGATTTCCTTCTCTCAGTGATTGG-3’        345 (9 copies), 360 (10 copies) or 390 (12 copies)            
HTT2Y            5’-TCATGTTCCTAGTCTTACGCCAGTG-3’ 
Exon 1               5’-GCCTCAAAGTGACGCAAAA-3’  258   
  5’-AGGCGGGGAAGAAGGTC-3’    
Exon 2  5’-CTCCCAGTGGAGGCACAG-3’  264   
  5’-CCGGCTGTGTCCAGTCTAT-3’ 
Exon 3  5’-CATGTAGCAAATAGGATGT -3’  732   
  5’-CAGGTCACAGCCCACC -3’ 
Exon 4  5’-AGTCACAGATTGGTTGGGC-3’  298   
  5’-GATTCCAGAAGAAGGTCC-3’    
Exon 5  5’-GTTTCAGCCTTTTGCCGTT-3’  359   
  5’-TTTTAAGAAGCCAAACCCC-3’ 
Exon 6  5’-CCTCAAAGGAGCAGCACAG-3’  329  
  5’-TGTGTTTGGTGTGGAAGGA-3’    
Exon 7  5’-CTCCCTTCTCCTTCTCCCC-3’  306 
  5’-AGCCACATTTCAGTTGTCC-3’ 
Exon 8  5’-TCTGCACTTAGCCACATGG-3’  283 
  5’-CCAATCACCTTCCTCCACA-3’ 
Exon 9  5’-CACGGACAGATGCTCCTTA-3’  317 
  5’-CCTTCTTTGGAAAATTTCA-3’  
Exon 10  5’-TGGCTGAGTTTTCCTCTGT-3’  261 
  5’-TGAGTCCAGCTGAGTCTTC-3’ 
Exon 11  5’-CTTACCCCTCCCTCCTGTT-3’  311 
  5’-GGCACTGTGTGAGATGGAA-3’ 
Exon 12  5’-CCCCTGCAGGTCTCTGTAG-3’  241 
  5’-CAGCCCTTTGCTACTGTGC-3’  
Exon 13  5’-CTCTCCCAGAGAATCAGGG-3’  265 
  5’-GCCCAGCCATTACAATTCA-3’ 
Exon 14  5’-TGGTGTTTGTGGTATCGGA-3’  358  
  5’-CATGCCTCCTGGTGAATCT-3’ 
Exon 15  5’-CCAACTCGCTCTTAGATGT-3’  491 
  5’-ATCCTAACTGATGATAGGG-3’ 
_______________________________________________________________________ 
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5.1 Abstract  
Using a genetic candidate gene approach and whole exome sequencing, we identified in two 
unrelated individuals with autism spectrum disorder (ASD) and isolated low serotonin in 
brain as reflected by the serotonin end-metabolite 5-hydroxindolacetic acid (5-HIAA) in CSF 
- a combination of heterozygous non-synonymous mutations in serotonin-related and/or 
autism-associated genes. Besides the previously reported codon-alterations from association 
studies, we newly identified in the plasma membrane monoamine transporter gene SLC29A4, 
encoding a putative serotonin re-uptake transporter protein PMAT, the alterations p.A138T or 
p.D326E with reduced transporter activity. DNA sequencing of SLC29A4/PMAT in 125 
individuals with ASD and approximately 300 unaffected control subjects revealed the non-
synonymous heterozygous alteration p.M24L or p.D29G in seven additional subjects with 
ASD (and not in 300 control subjects). According to a hypothetical “genetic accumulation-
model” where the affected subjects must differ from non-affected family members (parents 
and siblings) in the sum of all mutations, the two ASD patients showed additional alterations 
in mainly serotonin homeostasis, but also other candidate genes that have previously been 
linked to ASD and/or intellectual disability. Our findings link a combination of mutations in 
several serotonin-related genes to ASD and mental retardation concomitant to low serotonin 
in CNS.  
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5.2 Introduction  
Autism spectrum disorders (ASDs), which includes Kanner autism, Asperger’s syndrome and  
pervasive developmental disorder – not otherwise specified (PDD-NOS), are a group of 
complex, lifelong neurodevelopmental disorders characterized by severe deficits within three 
behavioural domains: 1) social interaction, 2) verbal and non-verbal communication as well 
as 3) repetitive, restrictive or stereotypic behavior (Muhle et al., 2004, Geschwind, 2009). 
Numerous, family and twin studies have reported that ASDs are highly heritable disorders 
suggesting that approximately 90 % of variance is attributable to genetic factors (Levy et al., 
2009). Despite, the strong genetic evidence, the identity and number of genes involved or 
responsible for ASDs are not yet known (Muhle et al., 2004).  
Nevertheless, it is generally assumed that the genes involved in the pathogenesis of autism are 
implicated in the overall processes of neuronal signal transmission, including molecules such 
as synaptic scaffolding proteins, cell adhesion molecules, protein involved in second-
messenger systems, secreted proteins, receptors and transporters (Castermans et al., 2010) and 
that this involvement takes place in multiple brain regions including the frontal lobes, anterior 
temporal lobes, caudate and cerebellum (Abrahams and Geschwind, 2010).  
 
One aspect of ASDs which has been consistent and well-studied over the years is the elevated 
blood serotonin (hyperserotoninemia) found in one-third of the individuals with autism (Lam 
et al., 2006). Serotonin plays an important role in the early neural development thus the high 
levels of serotonin has been suggested to cause loss of serotonin terminals in cerebral cortex 
via a negative feedback system medicated by serotonin receptors and subsequent influencing 
the neuronal development (Lam et al., 2006, Whitaker-Azmitia, 2001, Boylan et al., 2007).  
 
Furthermore, studies have shown that patients diagnosed with ASDs demonstrated clinical 
improvements upon administration of selective serotonin re-uptake inhibitors (SSRIs) 
(Veenstra-Vanderweele et al., 2009, Buitelaar and Willemsen-Swinkels, 2000).  
Altogether, suggestion that an unbalance in peripheral and central serotonin homeostasis is of 
special interst for ASDs thus supporting the common perception that the serotonergic 
neurotransmission represents a logical candidate for autism pathology (Bartlett et al., 2005, 
Anderson et al., 2009). Due to the serotonin hypothesis of autism, the genes which encodes 
for brain serotonin metabolism and neurotransmission have received particular more attention 
than other categories of genes (Scott and Deneris, 2005). 
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In a recent published paper, we demonstrated that isolated low  brain serotonin as reflected by 
the serotonin end-metabolite 5-hydroxindolacetic acid (5-HIAA) in CSF is associated with 
atypical autism (PDD-NOS) and the functional heterozygous p.G56A mutation in the 
serotonin re-uptake transporter (SERT) gene SCL6A4 in combination with a homozygous 
long (L/L) 5-HTT gene-linked polymorphic promoter (5-HTTLPR) region (Adamsen et al., 
2010). Interestingly, daily treatment with serotonin precursor 5-hydroxytryptophan and 
aromatic amino acid decarboxylase (AADC) inhibitor carbidopa led to clinical improvements 
and normalization of the 5-HIAA levels in the CSF and urine indicating that the brain 
serotonin turnover normalized (Ramaekers et al., 2001).  
5.3 Results and Discussion 
 
To follow up, this newly discovered association with promising treatment possibilities, we 
screened genomic DNA from a Caucasian cohort of 125 unrelated patients diagnosed with 
ASDs and unknown, normal or isolated low 5-HIAA in the CSF by first using a genetic 
candidate gene approach including genes encoding for SERT, plasma membrane monoamine 
transporter (PMAT) and GTP cyclohydrolase feedback regulatory protein (GFRP), as they 
have all been found to be directly involved in serotonin homeostasis. The GFRP/GCHFR and 
PMAT/SLC29A4 genes were included even though thus far no mutations have been identified 
within these two genes. Mutations in the genes encoding for aromatic amino acid 
decarboxylase (AADC) and monoamine oxidase A (MAO-A) were ruled out due to normal 
catecholamines and homovanillic acid (HVA) levels in the CSF. All exons and exon-
boundaries were sequenced from the following genes: SERT (SLC6A4, OMIN: 182138, 
ENST00000394821), PMAT (SLC29A4, OMIM: 609149, ENST00000297195) and GFRP 
(GCHFR, OMIM: 602437, ENST00000260447) (Supplementary Information).  
In 7.2 % of the 125 ASDs affected patients with unknown, normal or isolated low 5-HIAA in 
the CSF, we identified four non-synonomous mutations within the SLC29A4 gene encoding 
for PMAT: p.M24L, p.D29G, p.A138T and p.D326E, respectively (Figure 23). The 
individual exon-sequening turned out to be negative for mutations within the GCHFR gene 
encoding GFRP. However, 4 % of the 125 ASDs affected patients with unknown, normal or 
isolated low 5-HIAA in the CSF were carrying the heterozygous p.G56A alteration in the 
SLC6A4 gene encoding for SERT, which previously has been associated with autism and 
rigid-compulsive behaviours (Sutcliffe et al., 2005). In one patient, we found both a mutation 
within the SERT/SLC6A4 gene (p.G56A) and the PMAT/SLC29A4 gene (p.D326E). 
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G GGC GT AG T G N T G AG C TT C AC TGATGAGCTTCACCTTCGNCAGTCAC
TGATGAGCTTCACCTTCGNCAGTCACG GGC GT AG T G N T G AG C TT C AC
b
C A C C T G C G G T G A T C C T G G T G C G C T T T G A T G T G C C G C
C A C C T G N G G T G A T C C T G G T G C G C T T T G A N G T G C C G C
Figure 23: Four newly identified PMAT mutations in the SLC29A4 gene 
Out of 125 patients diagnosed with ASDs and normal or isolated low 5-HIAA in the CSF, 9 patients were 
carrying a heterozygous mutation in the SLC29A4 gene encoding for PMAT: p.M24L, p.D29G, p.A138T and 
p.D326E, respectively. p.M24L was found in few patients with autism (two with normal 5-HIAA), p.D29G was 
found in two patients with ASDs (one with normal 5-HIAA), p.A138T was found in patient MT with ASD and 
isolated low 5-HIAA and finally, p.D326E was found in patient PL with ASD and isolated low 5-HIAA. 
Moreover, PL was found to carry the heterozygous p.G56A mutation in the SLC6A4 gene encoding for SERT.   
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Whereas, the SERT-G56A alteration is a known mutation with gain of function regarding 
serotonin transport (Sutcliffe et al., 2005), mutations within the PMAT/SLC29A4 gene have 
not prior been described thus making the four newly identified PMAT-mutations first of their 
kind. Several studies have suggested strong evidence for linkage between autism and a region 
on chromosome 7q22-7q32 (Abrahams and Geschwind, 2008) which is interesting in terms of 
our findings as the SLC29A4 gene is located on chromosome 7p22.1 (Engel et al., 2004).   
 
Using genomic DNA from an independent group of approximately 300 unaffected control 
subjects, we immediately ruled out the possibility that these four newly identified PMAT-
mutations were single nucleotide polymoprhisms (SNPs) (Supplementary Information).  
 
Apart from PMAT-A138T and PMAT-D326E, the serotonin re-uptake transporter mutations 
within the PMAT/SLC29A4 gene were all found in more than one ASD affected patient 
(Table 1). PMAT-M24L and PMAT-D29G, which are both located in the N-terminal tail 
(Figure 24), were found in five and two ASDs affected patients, respectively with normal or 
unknown 5-HIAA levels in the CSF (Table 1). 
 
Table 1: Serotonin re-uptake transporter mutations found in 125 ASDs patients diagnosed with normal, 
unknown or isolated low 5-HIAA in the CSF 
___________________________________________________________________________ 
Gene            Protein         Heterozygous mutation           Patient (ASDs)                  5-HIAA in CSF (nmol/L) 
__________________________________________________________________________________________ 
SLC6A4 SERT p.G56A    CM (PDD-NOS) Low (Adamsen et al., 2010) 
SLC6A4 SERT p.G56A    PL (PDD-NOS) a Low (Table 2)  
SLC6A4 SERT p.G56A    VE (Asperger’s) Normal but in low range 
SLC6A4 SERT p.G56A    ARN (PDD-NOS) Unknown 
SLC6A4 SERT p.G56A    CAT (Autism) Unknown 
 
SLC29A4 PMAT p.M24L    CF (Autism)  Normal 
SLC29A4 PMAT p.M24L    PM (Autism)  Normal 
SLC29A4 PMAT p.M24L    KAP (Autism) Unknown 
SLC29A4 PMAT p.M24L    FER (Autism) Unknown 
SLC29A4 PMAT p.M24L    7542 (Autism) Unknown 
SLC29A4 PMAT p.D29G    AH (PDD-NOS) Normal 
SLC29A4 PMAT p.D29G    ACI (Autism) Normal 
SLC29A4 PMAT p.A138T   MT (Asperger’s)  Low (Table 2) 
SLC29A4 PMAT p.D326E   PL (PDD-NOS) a Low (Table 2) 
__________________________________________________________________________ 
a
 Patient PL was found both to carry a heterozygous mutation within the SERT/SLC6A4 gene (SERT-G56A) and the 
PMAT/SLC29A4 gene (PMAT-D326E), respectively. 
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In contrast, PMAT-A138T which is located in the third membrane-spanning domain (Figure 
24), was found in patient MT diagnosed with Asperger’s syndrome and isolated low 5-HIAA 
in the CSF (Table 2). Likewise, PMAT-D326E which is located in the third cytoplasmic loop 
(Figure 24), was found in patient PL diagnosed with PDD-NOS and isolated low 5-HIAA in 
the CSF (Table 2). In addition, patient PL was found to carry the functional heterozygous 
SERT-G56A alteration (not shown).  
 
aExtracellular
Intracellular
COO-
NH3+
 
Figure 24: Position of four newly identified alternations in the secondary structure of PMAT  
The SLC29A4 gene encoding the serotonin re-uptake transporter PMAT, is translated into a plasma membrane 
transporter protein composed of 530 amino acids. Hydropathy analysis has predicted the presence of 11 
membrane-spanning domains, a cytoplasmic N-terminus (NH3+) and an extracellular C-terminus (COO-). The 
four newly identified mutations in the PMAT gene SLC29A4 (PMAT-M24L, PMAT-D29G, PMAT-A138T and 
PMAT-D326E) are marked by filled red circles. Two of the PMAT mutations (PMAT-M24L and PMAT-
D29G) are located in the N-terminal tail, whereas one is located in the third membrane-spanning domain 
(PMAT-A138T) and one in the third cytoplasmic loop (PMAT-D326E), respectively. The four PMAT 
mutations which were all tested to be negative in approximately 300 independent and unaffected control 
subjects were found in a total of 9 patients diagnosed with ASDs and normal (PMAT-M24L and PMAT-D29G) 
5-HIAA in CSF or isolated low 5-HIAA in CSF (PMAT-A138T and PMAT-D326E).  
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To investigate in further details, the two PMAT-mutations: A138T and D326E, respectively 
which were associated with ASDs and isolated low 5-HIAA in the CSF, we analyzed the 
PMAT protein quantification, subcellular localization in MDCK (Madin-Darby canine 
kidney) cells and radiolabeled substrate transport activities of the two mutated PMAT proteins 
and compared them with wild-type PMAT (Supplementary Information) (Figure 25).  
 
The subsequently, cell surface biotinylation and Western blot analysis demonstrated 
comparable plasma membrane expression of PMAT-wild-type (wt), PMAT-A138T and 
PMAT-D326E protein (Figure 25A).  
 
When expressed in MDCK cells and observed by confocal microscopy, the two mutated 
PMAT proteins were located in the plasma membrane similar to wild-type PMAT (wt) 
(Figure 25B). Demonstrating that these two PMAT mutations do not influences the 
localization of the serotonin re-uptake transporter protein in the plasma membrane.  
 
To ascertain the functional properties of the two PMAT mutations, A138T and D326E, 
respectively, we screened a variety of radiolabeled substrates including serotonin, dopamine 
and MPP+ (1-methyl-4-phenylpyridinium1) for uptake activity (% of wild-type) (Figure 25C). 
The functional studies showed that both PMAT-A138T and PMAT-D326E exhibit reduced 
transport activity towards serotonin, dopamine and MPP+ compared to wild-type PMAT (wt) 
(Figure 25C).  
 
Despite, the reduced transport activity compared to wild-type PMAT, the two PMAT mutant 
proteins exhibit similar transport efficiencies for serotonin, dopamine and MPP+ thus 
demonstrating similar substrate specificity and thereby not functionally distinct from each 
other (Figure 25C). Consequently, in terms of the substrate uptake activity, the localization of 
the two PMAT mutations in the third membrane-spanning domain and cytoplasmic loop, 
respectively appeared to be irrelevant.  
 
Whereas SERT-G56A is known to cause an up-regulation regarding serotonin transport (gain 
of function), our functional data suggested that the two PMAT mutations (PMAT-A138T and 
PMAT-D326E) are not “loss of function” but rather showed a reduced transport activity 
towards serotonin (Figure 25C).  
                                                 
 
 
1
 MPP+ (1-methyl-4-phenylpyridinium) is a neurotoxin that causes Parkinson’s disease by selectively damaging 
dopaminergic nerve terminals (Engel et al., 2004). 
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a
PMAT WT      A138T        D326E      EYFP-C1
b
PMAT WT EYFP-C1A138T D326E
***
** **
***
*****
c
 
Figure 25:  PMAT protein expression, membrane localization and substrate transport activity 
A: Cell surface biotinylation and Western blot analysis demonstrated comparable plasma membrane expression 
of PMAT-wild-type (wt), PMAT-A138T and PMAT-D326E protein. Empty pEYFP-C1 vector was transfected 
into MDCK cells to obtain the control cell line. Double or multiple protein bands around the expected 
molecular size (~75 kDa) were observed for the YFP tagged PMAT proteins, which could be due to differential 
glycosylation of PMAT. B: Confocal microscopy imaging of MDCK cells expressing PMAT-wild-type, 
PMAT-A138T, PMAT-D326E and empty pEYFP-C1 vector. The two mutated PMAT proteins (A138T and 
D326E) were shown to be located in the plasma membrane similar to wild-type PMAT (wt). C: The serotonin 
(5-HT), dopamine and MPP+ transport activity were significantly reduced in the PMAT-A138T and PMAT-
D326E transfected MDCK cells, respectively compared to the MDCK cells transfected with PMAT-wild-type. 
PMAT-wild-type (white bar), PMAT-A138T (black bar) and PMAT-D326E (gray bar). For all the transport 
activity experiments, the values are indicated in mean ± S.D. from three independent experiments (n=3) with 
different cell passages. For each experiment, uptake was carried out in triplicates in three different wells on the 
same plate. Significant difference from the corresponding value for PMAT-wild-type (100 % transport activity) 
is indicated by asterisks: **, p < 0.01 and ***, p < 0.001 (Student’s t test). 
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Both the SERT and PMAT gene variants, we have identified thus far have all been present in 
their heterozygous state (Figure 23). From genomic DNA sequencing analysis of the parents 
of the affected ASDs patients (PMAT-A138T and PMAT-D326E/SERT-G56A), we know 
that the SERT and PMAT mutations are inherited from unaffected patents and that “simple” 
haplotype association/analysis can not explain heritability of these disorders (not shown).  
 
Hence, to understand the underlying genetic linking ASDs with isolated low 5-HIAA in the 
CSF with serotonin re-uptake transporter mutations, we performed whole exome sequencing 
on the two ASDs affected patients carrying PMAT-A138T and PMAT-D326E (and SERT-
G56A), respectively plus their unaffected parents and sibling (Supplementary Information).  
 
By including the unaffected parents and sibling (in both cases a sister) we particular aimed to 
address the question why the parents from whom the affected patient has inherited the 
heterozygous serotonin re-uptake transporter mutation (or mutations) is unaffected.  
 
To analyse the whole exome sequencing data we focused on candidate genes which have been 
published to be involved in serotonin and/or autism (for more information about the search 
strategy and selection criteria see Supplementary Information).  
The candidate gene search led to two lists: one containing the candidate genes published to be 
involved in serotonin (Supplementary Table S2) and one with the candidate genes published 
to be involved in autism, ASDs and ASD-related syndromes (Supplementary Table S3).  
 
We filtered the whole exome sequencing data for non-synonymous amino acid substitutions 
within serotonin-related and/or autism-associated candidate genes (Supplementary Table S2 
and Supplementary Table S3). Furthermore, we excluded using NCBI population diversity, 
the non-synonymous mutations with an allele frequency higher than 1.  
 
The result of the whole exome sequence analysis and thereby the sum of all the non-
synonymous amino acid substitutions in family MT and PL with an allele frequency <1 are 
shown in Table 3.  
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In parallel, we measured the serotonin levels both in blood (ng/ml) and platelets (ng/109) in 
the two ASDs affected patients MT and PL (Table 2) plus detected common non-coding 
VNTR (5-HTTLPR and STin2 VNTR) polymorphisms within the SLC6A4 gene (Table 3).  
 
 
Table 2: Summary of metabolic findings in patient MT (Asperger’s) and PL (PDD-NOS)   
_________________________________________________________________________ 
Patient    Age (yrs)     5-HIAA (nmol/l)     HVA (nmol/l)      HVA/5-HIAA (ratio)           Serotonin  
                  Blood (ng/ml) Platelets (ng/109)  
 
MT   9.6 64.7  389.6 6.0 287  1041 
PL  6.2 73.6  399.8 5.4  221  675 
Ref *  5-10 133 (88-178) 523 (144-801) 1.5-3.5  50-220**  125-500** 
_________________________________________________________________________ 
* Reference values and ranges see also N. Blau, L. Bonafe, M.E. Blaskovics, Disorders of phenylalanine and 
tetrahydrobiopterin metabolism Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases Springer 
2nd Edition, Blau, N., Duran, M., Blaskovics, M.E., Gibson, K.M. (eds) (2003) 89-106.   
** Reference values see Burtis, C.A., Ashwood, E.R., Tietz Fundamentals of Clinical Chemistry, 5th edition, 
2001.  
 
As shown in Table 2 both patient MT and PL exhibit low isolated 5-HIAA levels in the CSF 
and elevated serotonin levels in the blood as well as in the platelets compared to the reference 
values. The elevated serotonin levels in the blood and platelets support the previous studies 
showing that one-third of all ASDs affected individuals have hyperserotoninemia (Cross et 
al., 2008, Leboyer et al., 1999). Moreover, the PCR-analysis of the non-coding VNTR 
polymorphisms within the SLC6A4 gene shown in Table 3 demonstrated that patient MT and 
PL are both carrying the L/S variant of the SLC6A4 promoter region in combination with 
12/12 STin2 VNTR and 10/12 STin2 VNTR, respectively.  
 
Using a hypothetical “genetic accumulation-model” (Figure 26), where all the non-
synonymous findings from the serotonin-related and/or autism-associated candidate gene lists 
(Supplementary Table S2 and Supplementary Table S3) with an allele frequency <1 were 
amalgamated (“total gene hits”) in the affected patients (MT and PL) plus their unaffected 
family members (parents and sisters), then the cumulative genetic burden of the two ASD 
affected patients showed more “serotonin gene hits” indicating alterations in mainly serotonin 
homeostasis compared to the other family members (Table 3 and Figure 26).  
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Patient MT
L/S
12/12
Father
L/S
12/10
Mother
L/L
12/12
Codon-
Exchange
p.A138T
p.G56A
-
-
p.L59P
p.N407S
p.G329S
p.G389S
p.S704C
p.M1820L
p.P1821V
p.Y129S
p.V470M
Sibling
(Sister)
n.d.
n.d.
Gene
SLC29A4 (PMAT)
SLC6A4 (SERT)
5-HTTLPR
STin2VNTR
ITGB3
CNTNAP2
HTR3D
CYFIP1
DISC1
CACNA1C
CACNA1C
HTR3B
CFTR
11
3
8
1
10
2
9
2
Cumulative genetic burden:
“Total gene hits”
“Serotonin gene hits”
Patient PL
L/S
12/10
Father
L/L
10/10
Mother
S/S
12/12
Codon-
Exchange
p.D326E
p.G56A
-
-
p.M408V
p.L160F
p.R177H
p.G389S
p.R264Q
p.S704C
p.G36A
p.P1820L
p.M1821V
p.V470M
Sibling
(sister)
n.d.
n.d.
16
9
16
7
9
5
11
6
Gene
SLC29A4 (PMAT)
SLC6A4 (SERT)
5-HTTLPR
STin2VNTR
SLC22A1
SLC22A1
HTR3D
CYFIP1
DISC1
DISC1
HTR3D
CACNA1C
CACNA1C
CFTR
Cumulative genetic burden:
“Total gene hits”
“Serotonin gene hits”
 
Figure 26: Cumulative genetic burden using a “genetic accumulation-model” 
When all the non-synonymous findings from the serotonin-related (in red) and autism-associated (in gray) 
candidate gene lists with an allele frequency <1 are weighed, the cumulative genetic burden shown more 
“serotonin gene hits” in the two index patients compared to their healthy family members. The two VNTR 
polymorphisms (5-HTTLPR and STin2VNTR) in the SLC6A4 gene are not included in the cumulative genetic 
burden as their functions have been found to be complex and controversial. In bold are the genes, which are, 
mutated in both patient MT and PL. Full-triangle: homozygous, half-triangle: heterozygous and empty-triangle: 
wild-type. n.d. not determined. 
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Most interestingly, the whole exome sequence analysis revealed that patient MT among 
others was carrying heterozygous mutations in the autism-associated CNTNAP2 gene 
encoding for contactin-associated protein-like 2 and ITGB3 gene encoding for integrin β-3, 
respectively (Table 3). Whereas, the heterozygous variant in the CNTNAP2 gene (p.N407S) 
was not detected in the NCBI dsSNP database and negative in the 300 unaffected control 
subjects (Supplementary Information), the heterozygous variant in the ITGB3 gene 
(p.L59P) was a known variant which previously has been published to be associated with 
austism in co-occurrence with the SLC6A4 gene primarily in males (Weiss et al., 2006a, 
Weiss et al., 2006b, Ma et al., 2010, Napolioni et al., 2011, Coutinho et al., 2007).  
 
Despite, a tendency towards a genetic accumulation of mutations within serotonin re-uptake 
transporter genes in co-occurrence with mutations in autism-associated genes, our whole 
exome sequencing results, does not explain why the parents from whom the affected patients 
have inherited the heterozygous serotonin re-uptake transporter mutation (or mutations) is 
unaffected thus further investigations are necessary in order to elucidate this issue.  
 
Currently, we are increasing the ASDs affected cohort by including more autistic patients and 
by in silico analysis e.g. 1000 Genomes Project. Moreover, we are searching the whole exome 
sequencing data for de novo mutations within patient MT and PL.  
 
Together, our data support the common perception that ASDs are caused by the concurrent 
effect of several different genes (polygenic mechanism) rather than caused by only one single 
gene (monogenic cause) (Castermans et al., 2004). Although, environmental factors have not 
been shown to be a cause of ASDs, they may well act as second “hits” in genetically 
susceptible individuals (Castermans et al., 2004).   
 
Treatment of one PDD-NOS affected patient with serotonin re-uptake transporter mutation 
(SERT-G56A) and isolated low 5-HIAA in the CSF has prior been shown to cause an 
improvement of the clinical features and normalization of the brain serotonin turnover 
(Ramaekers et al., 2001). In this perspective, it could be interesting to investigate whether all 
ASDs affected patients with serotonin re-uptake transporter mutations in combination with 
low brain serotonin would benefit from 5-hydroxytryptophan and carbidopa treatment. 
 
If serotonin abnormalities due to hyperserotoninemia, isolated low 5-HIAA in the CSF or 
functional mutations in serotonin related genes, could be demonstrated to be essential in the 
etiology of ASDs, the possibility for new and improved therapies could easier be identified. 
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5.4 Supplementary Information  
Screening for mutations in the human SLC29A4 gene  
Intronic primers were designed with the online program ExonPrimer (http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html) to flank the exons in the human SLC29A4 gene (see 
Table S1). PCR reactions were performed in a final volume of 25 µl containing 1 µl of 
genomic DNA template (100 ng), 1 µl of each primer (forward and reverse) (5 µM), 0.5 µl 10 
mM deoxyribonucleoside triphosphates (dNTPs), 0.2 µl Hot FirePol Hotstart DNA 
polymerase (Solis Biodyne), 1.5 µl 25mM MgCl2, 2.5 µl 10x reaction buffer (Mg2+ free from 
Solis Biodyne) and 5 µl 5x Q-solution (Qiagen). 
 
Table S1:  
Primers used for PCR-amplification and sequencing of the human SLC29A4 gene 
___________________________________________________________________________ 
 
Region Primer Sequence (forward and reverse)   Product size (bp) 
Exon 2            5’-ATGGATCCCTCAGCCTTCT-3’     285  
  5’-ACAGCCCAGCCTGCTTT-3’    
Exon 3  5’-GGTGACTGTAGCCATGCGT-3’    242 
  5’-CAGGCCATGATGGAGGAT-3’ 
Exon 4  5’-CAGGAGTCAGTGCAGGGG-3’    253 
  5’-GGAAACTGGGTGAGTGGGT-3’    
Exon 5  5’-GACTCTGCAGGAGGGGC-3’     263  
  5’-GATGGGGTCGGAAGTGG-3’ 
Exon 6  5’-TCTCCCAAGTTGACAGGTG-3’    198  
  5’-AAGAAGCTTCCAGAGCCCA-3’    
Exon 7  5’-GTCTGTGTGTGGACGGGG-3’     403 
  5’-GGGGACAGAGAAGGGGAC-3’ 
Exon 8-9 5’-CCCGTGTCTCCTGTCCTC-3’     563 
  5’-CAGGGCCTCCCTTGTCAC-3’ 
Exon 10 5’-GGATGTGGCTAGAGGCTGT-3’    403 
  5’-GTCTAGCCTGGGTTTCCTC-3’ 
Exon 11 5’-GTCACCGCACCTCACACC-3’     312 
  5’-CACTGAGGTGGGGACAGG-3’ 
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The PCR reactions were performed in a GeneAmp PCR System 9700 from Applied 
Biosystems using standard thermal cycling: hot start activation at 95oC for 15 minutes, 
followed by 35 cycles of denaturation 95°C for 1 minute, annealing 55°C for 45 seconds and 
extension at 72°C for 1 minute, a final extension was performed at 72°C for 10 minutes and 
termination at 4oC. The same forward and reverse primers as mentioned above were used to 
sequence the amplified PCR products with BigDye Terminator v1.1 Cycle Sequencing Kit 
(Applied Biosystems).  
Sequencing PCR was performed in a 10 µl reaction mixture consisting of 0.5 µl PCR product, 
0.8 µl primer (5 µM), 1.5 µl BigDye and 1.25 µl 5x sequencing buffer (BigDye and 
5xsequencing buffer were both from BigDye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems)) using standard thermal cycling: (activation at 95oC for 1 min, followed by 25 
cycles of 96oC for 10 seconds, 50oC for 5 seconds, 60oC for 3 minutes and termination at 
4oC). After end run 15 µl H2O was added to the sequencing reactions before purified by gel 
filtration (using MultiScreen HV 96-well filter plates (Millipore) with Sephadex G-50 (GE 
Healthcare)) and analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). Sequencing 
results were compared with wild-type sequence of the SLC29A4 gene by using Mutation 
Surveyor (Demo) Software v3.20 from SoftGenetics (Transcript ID: ENST00000297195 or 
accession number NM_001040661). 
 
Screening for mutations in the human SLC6A4 gene 
Screening of genomic DNA for mutations in the human SLC6A4 gene as well as detection of 
non-coding VNTR polymorphisms (5-HTTLPR and STin2 VNTR) in the human SLC6A4 
gene were performed as previously described in (Adamsen et al., 2010).  
 
Screening of 300 control subjects for PMAT-M24L, D29G, A138T and D326E 
300 control subjects (genomic DNA kindly provided by PD Dr. Martin Hersberger and 
Jacqueline Marti-Jaun) were screened for the four newly discovered variants M24L, D29G, 
A138T and D326E within the SLC29A4 gene encoding for PMAT to test whether these 
variants were “simple” single nucleotide polymorphisms (SNPs) or mutations (same primers 
and PCR conditions as descrived under “Screening for mutations in the human SLC29A4 
gene”). The 300 control subjects (600 chromosomes in total giving a polymorphism 
frequency >0.01 and a <5 % possibility of missing a polymorphism (Collins and Schwartz, 
2002)) represented all ages, both sex and with a Caucasian background.  
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Construction of PMAT Mutations by Site-Directed Mutagenesis 
To facilitate the determination of membrane localization, PMAT mutants were constructed 
using yellow fluorescence protein (YFP)aaA-tagged wild-type human PMAT as template. 
YFP was tagged at the N-termini of the wild-type and mutant PMAT transporters, as previous 
studies have shown that the YFP tagging had no effect on substrate selectivity and kinetic 
behaviors of the transporter (Zhou et al., 2007). The wild-type human PMAT was previously 
sub-cloned into the YFP vector pEYFP-C1 (Clontech, Palo Alto, CA) (Engel et al., 2004). 
PMAT-A138T and D326E mutations were introduced into wild-type PMAT/pEYFP-C1 
vector by site-directed mutagenesis (PMAT/pEYEP-C1 vector was kindly provided by Dr. 
Joanne Wang from University of Washington, Seattle).  
 
Primers were designed to introduce threonine at position 138 and glutamic acid at position 
326, respectively. A138T_F: 5’-GCACACCAGGATCACCACAGGCTACCTCTTAGC-3’ 
(forward) and A138R_R: 5’-GCTAAGAGGTAGCCTGTGGTGATCCTGGTGTGC-3’ 
(reverse) as well as D326E_F: 5’-CCTACATGCGCTTTGAGGTGCCGCGGCCAAGGG-3’ 
(forward) and D326E_R: 5’-CCCTTGGCCGCGGCACCTCAAAGCGCATGTAG G-3’ 
(reverse). 10 ng of the DNA template (PMAT/pEYFP-C1 vector) was mixed with 1 µl 20 mM 
deoxyribonucleoside triphosphates (dNTPs), 5 µl 10xreaction buffer G (Solis BioDyne), 1 µl 
of each primer (forward and reverse) (10 uM) and 1 µl HotGyroPol (Solis BioDyne) in a final 
volume of 50 ul. The PCR conditions included an initial denaturation cycle (95oC for 15 
minute); 15 cycles of denaturation (95oC for 30 seconds), annealing (55oC for 1 minute), and 
extension (72oC for 6 minutes); a termination at 4oC. PCR products were digested with 10U 
of DpnI at 37oC for 1 hour to remove the parental DNA followed by transformation into 
DH5α supercompetent Escherichia coli cells by heat shock (30 minutes on ice, 42oC for 90 
seconds, 5 minutes on ice) followed by incubation for 1 hour at 37oC in 500 µl LB-medium. 
300 µl of the incubation-mixture was plate on kanamycin/neomycin/agar-plates overnight at 
37oC. Positive colonies were confirmed by DNA sequencing using one of the following 
primers (For A138T with forward: A138T_1F: 5’-CAGGAGTCAGTGCAGGG G-3’ and/or 
reverse: A138T_1R: 5’-GGAAACTGGGTGAGTGGGT-3’ and for D326E with forward 
D326E_1F: 5’-ACAGCCACCGGGACAGGCCA-3’ and/or reverse D326E_1R: 5’-ACTCGA 
GGCCGGGGAACAGG-3’) and BigDye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems). Sequencing reactions (0.5 µl DNA, 1.5 µl BigDye and 1.25 µl 5x sequencing 
buffer both from Terminator v1.1 Cycle Sequencing Kit) were purified by gel filtration (using 
MultiScreen HV 96-well filter plates (Millipore) with Sephadex G-50 (GE Healthcare)) and 
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analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). Sequencing results were 
compared with wild-type sequence of the SLC29A4 gene by using Mutation Surveyor (Demo) 
Software v3.20 from SoftGenetics (Transcript ID: ENST00000297195 or accession number 
NM_001040661). 
 
Stable Expression in MDCK (Madin-Darby canine kidney) Cells 
YFP-tagged mutant constructs were transfected into MDCK cells using Lipofectamine 2000 
transfection reagent (Invitrogen, Carlsbad, CA). Stably transfected cell lines were obtained by 
culturing cells in minimal essential medium containing 10% fetal bovine serum and G418 
(1000 µg/ml). Empty pEYFP-C1 vector was transfected into MDCK cells to obtain the 
control cell line. After 2-3 weeks of drug selection, fluorescence-positive cells were purified 
by a FACS Vantage SE sorter (BD Biosciences, San Jose, CA) at the Cell Analysis Center at 
the University of Washington, Health Sciences Center. The sorted cells were cultured and 
maintained in minimal essential medium containing G418 (200 µg/ml). 
 
Confocal Fluorescence Microscopy   
To determine the cellular localization of YFP-tagged mutant transporters, ~2x105 cells were 
grown on top of microscope cover glass in 6-well plates (Falcon) for 2-3 days until confluent. 
Cells were mounted onto microscope glass slides with Fluoromount-G (Electron Microscopy 
Sciences, Hatfield, PA) and visualized with a Leica SP1 confocal microscope equipped with 
an argon laser as the light source at the Keck Microscopy Facility at the University of 
Washington. Images were captured by excitation at 488 nm and emission at 515 nm.   
 
Functional Characterization in MDCK cells 
Stably transfected MDCK cells were plated in 24-well plates and allowed to grow for 2-3 
days until confluent. Growth medium was aspirated and each well was rinsed once with 
Krebs-Ringer-Henseleit buffer (5.6 mM glucose, 125 mM NaCl, 4.8 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM CaCl2, 1.2 mM MgSO4, 25 mM HEPES, pH 7.4) and preincubated in the 
same buffer for 15 min at 37oC. Transport assays were performed at 37oC by incubating cells 
in KRH buffer containing a 3H-labeled ligand. [3H]MPP+ (85 Ci/mmol) was obtained from 
American Radiolabeled Chemicals, Inc. (St. Louis, MO). [3H]5-HT (5-hydroxy-[1,2-
3H]tryptamine creatinine sulfate, 28.1 Ci/mmol) and [3H] dopamine (3,4-dihydroxy-[2,5,6-
3H]phenylethylamine, 51.3 Ci/mmol) were from PerkinElmer Life Sciences, Inc.  All other 
chemicals were obtained from Sigma (St. Louis, MO).  
SLC29A4 mutations associated with ASDs and low or normal 5-HIAA in CSF  
 128  
Uptake was terminated by washing the cells three times with ice-cold KRH buffer. Cells were 
then solubilized with 0.5 ml of 1N NaOH and neutralized with 0.5 ml of 1N HCl. 
Radioactivity in the cell lysate was quantified by liquid scintillation counting. Protein 
concentration in each well was measured using BCA protein assay kit (Pierce) and the uptake 
in each well was normalized to its protein content. In all studies, cells transfected with an 
empty vector were served as a background control. Transporter-specific uptake was calculated 
by subtracting the background uptake in vector-transfected cells. 
 
Isolation of Plasma Membrane Proteins by Cell Surface Biotinylation   
Stably transfected MDCK cells were plated onto 60 mm plates and cultured until confluent. 
Cells were washed twice with 3 ml of ice-cold PBS/CM (138 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4, 1.5 mM KH2PO4, 0.1 mM CaCl2, 1 mM MgCl2, pH 8.0). Biotinylation was carried 
out on ice by incubation with 1 ml of ice-cold PBS/CM containing a membrane-impermeable 
biotinylation reagent Sulfo-NHS-SS-biotin (0.5 mg/ml) (Pierce, Rockford, IL). After two 
successive 20 min incubations at 4oC with freshly prepared NHS-SS-biotin and gentle 
shaking, cells were briefly rinsed with 3 ml of PBS/CM containing 100 mM glycine. Cells 
were further incubated at 4oC with the same solution for 20 min to ensure complete quenching 
of the unreacted NHS-SS-biotin.  Cells were then solubilized on ice by incubating in 1 ml of 
lysis buffer containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM 
phenylmethyl-sulfonyl fluoride and Protease Inhibitors Cocktail (Roche) for 1 h with 
occasional vortexing. Protein concentrations were measured from the supernatant lysate and 
fifty microliters of UltraLink Immobilized NeutrAvidin protein (Pierce) was then added to the 
supernatant for the isolation of membrane proteins.  
Membrane proteins were subjected to Western blot using a mouse monoclonal anti-yellow 
fluorescent protein antibody (JL-8) (BD Biosciences) at 1:1000 dilution, followed by 
horseradish peroxidase-conjugated goat anti-mouse IgG (1:20,000 dilution). The 
chemiluminescent signals in the Western blots were detected by using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) followed by exposure of the blots to x-ray films. Band 
intensity was quantified by densitometry using the ImageQuant software (Molecular 
Dynamics). As reported previously (Zhou et al., 2007), double or multiple protein bands 
around the expected molecular size (~75 kDa) were observed for the YFP tagged PMAT 
proteins, which could be due to differential glycosylation of PMAT.   
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Data Analysis  
For all uptake experiments, data were expressed as the mean ± S.D. from three independent 
experiments (n=3) with different cell passages. For each experiment, uptake was carried out 
in triplicates in three different wells on the same plate. Where applicable, p values were 
obtained through Student’s t-test.   
 
Whole exome sequencing and sequence analysis 
Whole exome sequencing was carried out by Andrea Patrignani and Dr. Remy Bruggmann in 
collaboration with the Functional Genomics Center Zürich (FGCZ). The color space sequence 
reads (paired end 50x35) were mapped to the human genome assembly hg19 
(ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromFa.tar.gz) using the software 
Bioscope 1.2.1 from Applied Biosystems (Life Technologies, Carlsbad, CA, USA). After 
mapping, the single nucleotide polymorphisms (SNPs) were called by using the DiBayes 
algorithm (Life Technologies, Carlsbad, CA, USA) with high and medium stringency 
settings. The obtained SNPs were classified into intronic, intergenic, coding (synonymous and 
non-synonymous amino acid substitutions) and splice-site variants with a custom software 
pipeline. Furthermore, all SNPs were compared to dbSNP build 132, OMIM and clinically 
relevant mutation. 
 
Search strategy and selection criteria 
To analyse the whole exome sequencing data from the Functional Genomic Centre Zürich 
(FGCZ), we focused on candidate genes published to be involved in serotonin as well as 
candidate genes involved in autism spectrum disorders (ASDs). In order to find these 
candidate genes we first made a litterateur searched in Pubmed with the term: “serotonin” in 
combination with “synthesis”, “metabolism”, “transporter”, “receptor”, “transcription factor”, 
“regulation”. This was followed by a literature searched with the term: “autism” in 
combination with “candidate genes”, “genes” and “genetics”. These Pubmed search strategies 
led to the generation of two lists: one containing the candidate genes of interest published to 
be involved in serotonin (see table S2) and one with the candidate genes of interest involved 
in autism, ASDs and ASD-related syndromes (see table S3).  
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Screening of mutations in human GFRP gene 
The following intronic primers were used to screen exon 1-3 in the human GFRP gene: For 
exon 1: GFRP5, 5’-TCCTCCCCGCACTCCACCTT-3’ (forward) and GFRP6: 5’-CTCC 
TGTCCTACCTGTCGGC-3’ (reverse), for exon 2: GFRP7, 5’-TCAAACTCCTCCCACCTC 
AA-3 (forward) and GFRP8: 5’-TAGAAGCAGGGAGCAGGGAG-3’ (reverse), for exon 3: 
GFRP9, 5’-CTGGGACGCTGGGGAACCTG-3 (forward) and GFRP10: 5’-GTCAAGCAGT 
GGGAGAGGGC-3’ (reverse). PCR reactions were performed in a final volume of 25 µl 
containing 1 µl of genomic DNA template (100 ng), 1 µl of each primer (5 µM), 0.5 µl 10 
mM deoxyribonucleoside triphosphates (dNTPs), 0.5 µl Hot FirePol Hotstart DNA 
polymerase (Solis Biodyne), 1.5 µl 25mM MgCl2, 2.5 µl 10x reaction buffer (Mg2+ free from 
Solis Biodyne) and 5 µl 5x Q-solution (Qiagen). The PCR reactions were performed in a 
GeneAmp PCR System 9700 from Applied Biosystems using standard thermal cycling: hot 
start activation at 95oC for 15 minutes, followed by 35 cycles of denaturation 95°C for 60 
seconds, annealing 54°C for 45 seconds and extension at 72°C for 30 seconds, a final 
extension was performed at 72°C for 10 minutes and termination at 4oC. The same forward 
and reverse primers as mentioned above were used to sequence the amplified PCR products 
with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing PCR 
was performed in a 10 µl reaction mixture consisting of 0.5 µl PCR product, 0.8 µl primer (5 
µM), 1.5 µl BigDye and 1.25 µl 5x sequencing buffer (Both BigDye and 5x sequencing buffer 
were from the BigDye Terminator v1.1 Cycle Sequencing Kit) using standard thermal 
cycling: (activation at 96oC for 1 min, followed by 25 cycles of 96oC for 10 seconds, 54oC for 
5 seconds, 60oC for 1.5 minutes and termination at 4oC). After end run 15 µl H2O was added 
to the sequencing reactions before purified by gel filtration (using MultiScreen HV 96-well 
filter plates (Millipore) with Sephadex G-50 (GE Healthcare)) and analyzed on a 3130xl 
Genetic Analyzer (Applied Biosystems). Sequencing results were compared with the 
reference sequence (Transcript ID: ENST00000260447 or accession number NM_005258.2) 
of the GCHFR gene.   
 
Screening of 301 control subjects for CNTNAP2-N407S mutation 
Intronic primers were designed to flank exon 8 in the human CNTNAP2 gene: Forward: 
CNTNAP2_F: 5’-TTCATTTTATTCTGTGTTTTCCTCA-3’ and reverse CNTNAP2_R: 5’-
TGGAAATTGCAATAAGTTTCAGG-3’. PCR reactions were performed in a final volume 
of 25 µl containing 2 µl of genomic DNA template (100 ng), 0.5 µl of each primer (10 µM), 
0.25 µl 10 mM deoxyribonucleoside triphosphates (dNTPs), 0.2 µl Hot FirePol Hotstart DNA 
SLC29A4 mutations associated with ASDs and low or normal 5-HIAA in CSF  
 131  
polymerase (Solis Biodyne), 1.5 µl 25mM MgCl2 and 2.5 µl 10x Puffer B2 (Mg2+ free from 
Solis Biodyne). The PCR reactions were performed in a GeneAmp PCR System 9700 from 
Applied Biosystems using standard thermal cycling: hot start activation at 95oC for 15 
minutes, followed by 35 cycles of denaturation 95°C for 60 seconds, annealing 54°C for 45 
seconds and extension at 72°C for 30 seconds, a final extension was performed at 72°C for 10 
minutes and termination at 4oC. The same forward and reverse primers as mentioned above 
were used to sequence the amplified PCR products with BigDye Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems). Sequencing PCR was performed in a 10.5 µl reaction 
mixture consisting of 0.8 µl PCR product, 0.8 µl primer (5 µM), 1.5 µl BigDye and 1.5 µl 5x 
sequencing buffer (BigDye and 5xsequencing buffer were both from BigDye Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems)) using standard thermal cycling: (activation at 
96oC for 1 min, followed by 25 cycles of 96oC for 10 seconds, 54oC for 5 seconds, 60oC for 
1.5 minutes and termination at 4oC). After end run 15 µl H2O was added to the sequencing 
reactions before purified by gel filtration (using MultiScreen HV 96-well filter plates 
(Millipore) with Sephadex G-50 (GE Healthcare)) and analyzed on a 3130xl Genetic Analyzer 
(Applied Biosystems). Sequencing results were compared with the reference sequence 
(Transcript ID: ENST00000297195 or accession number NM_001040661) of the CNTNAP2 
gene.   
 
5.5 Case report 
Case report (MT)    
A now 11 year old boy was born after an uncomplicated pregnancy, delivery and neonatal 
period. Both parents are known to suffer from anxiety disorder since childhood but do not 
have further health problems. His father works as a bank director and his mother used to work 
as a nurse in an infirmary. For his anxiety disorder paroxetine, a SSRI drug was prescribed to 
the father. The mother takes sertraline (an antidepressant of the selective serotonin reuptake 
inhibitor (SSRI) class). A 5 year old younger sister is healthy. The psychomotor and speech 
development were normal in the patient. However, the parents noticed that he did not show a 
normal imitative play and from early infancy, he suffered from sleeping problems due to 
anxiety. When he started kindergarten at the age of 2 ½ years he was described as a nervous 
child who did not seeking contact with other children, was found to be “egocentric”, did not 
play with fantasy, did not like changes and responded with anxiety, but showed restrictive 
interests in busses and trains.  
SLC29A4 mutations associated with ASDs and low or normal 5-HIAA in CSF  
 132  
He had few stereotypic movements like putting his hands in front of his mouth with an 
anxious expression. He had an extreme phobia for insects. From the age of 5 years he was 
seen by a child psychiatrist who suspected Asperger’s syndrome with attention deficit 
disorder and prescribed methylphenidate in combination with risperidone at night. Formal 
testing and observation at home and in school at the age of nearly 9 years was performed by 
the centre for autism, using DSM-IV criteria, neuropsychological tests, evaluation of socio-
emotional comprehension, Childhood Autism Rating Scale (CARS), and the Childhood 
Apperception Test (CAP). His physical and neurologic examinations were completely normal. 
In conclusion, he was found to fulfil all criteria for Asperger’s syndrome with a CARS score 
of 39.5, indicating moderate to severe autism.  
After informed consent, laboratory investigations at the age of 9 ½ years revealed normal 
routine tests including amino-acid levels. The only abnormality observed was a moderately 
diminished serum gamma-tocopherol. In addition spinal fluid analysis showed a low 
serotonine metabolite 5-HIAA at 65 nmol/L (normal range: 88-178 (Blau et al., 2003)), a 
normal HVA concentration at 389 nmol/L (reference: 144-801) with an elevated HVA/5-
HIAA ratio at 6 (normal value 1.5-3.5). Spinal fluid concentrations for L-dopa, 5-
hydroxytryptophane, pterins and L-N5-methyltetrahydrofolate were normal. The whole blood 
serotonin level was slightly elevated at 287 ng/ml (normal range 50-200 (Burtis and 
Ashwood, 2001)) and platelet serotonin content was elevated at 1041 ng/109 platelets ( normal 
range: 125-500 (Burtis and Ashwood, 2001).  
 
Case report (PL) 
A now 8 year old boy was born by caesarean delivery after a pregnancy of 37 weeks, 
complicated by maternal hypertension and gestational diabetes. His birth weight was 3.7 kg. 
His parents were healthy and non-consanguineous. He had an 11 month older sister in good 
health. After a normal neonatal period he was described as an inactive baby never crying that 
could be put anywhere. Developmental motor milestones were attained normally but as he 
started toe-walking from the age of 2 years, he would frequently fall. From the age of 2 years, 
he started to have severe eating problems and would only eat biscuits, chicken and French 
fries. During his first two years, he did not respond to his name, never pointed or attracted 
joint attention; he never waved good-bye and showed restrictive interests with absent 
imitative play. From the age of 3 years, he developed stereotypic patterns like running in 
circles, turning light switches on and off, balancing movements and head banging against the 
floor.  
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Because of serous middle ear effusions and suspected hearing loss at the age of two years, 
bilateral tympanic drains were placed but postoperatively there was no improvement of his 
response to external stimuli and speech did not develop.  
He could utter single word fragments using syllables from the age of 3 years and 
developmental dysphasia was suspected. From the age of 4 ½ years he was transferred from 
kindergarten to a special school for mentally handicapped children.  
The Autism Diagnostic Interview for parents (ADI-R) revealed that he fulfilled all criteria of 
infantile autism between the age of 4 and 5 years. Physical examination did not show any 
dysmorphic features and neurological status was completely normal. Twenty-four EEG 
monitoring and brain MRI were found normal.  
Laboratory investigations at the age of 6 years revealed normal CSF cell counts, protein and 
glucose levels. Spinal fluid analysis showed diminished concentrations for the serotonin end-
metabolite 5-HIAA but normal levels for the dopamine end-metabolite HVA, intermediate 
metabolites L-dopa, 5-hydroxytryptophane, pterines and L-N5-methyl- tetrahydrofolate. 
Serum amino-acids were normal including L-tryptophane. The whole blood serotonin level 
was slightly elevated at 221 ng/ml (normal range 50-200 (Burtis and Ashwood, 2001)) and 
platelet serotonin content was elevated at 675 ng/109 platelets (normal range: 125-500 (Burtis 
and Ashwood, 2001)). Biochemical blood examination revealed slight deficiencies for serum 
and red blood cell folate content, as well as vitamin C, D, gamma-tocopherol, beta-carotene, 
zinc and selenium. He received vitamin and trace element supplements to correct these 
alimentary deficiencies. 
From the age of 6 years he visited a special institute for autistic children and received re-
education by the TEACCH method (Treatment and Education of Autistic and 
Communication related handicapped CHildren) and using pictogrammes. Follow-up 
assessment at the age of 7 4/12 years using the ADI-R, Autism Diagnostic Observation Scale 
(ADOS) as well as observation at home and school, revealed moderate improvement with 
respect to non-verbal communication and behaviour, so that he now  fulfilled the criteria for 
atypical autism (PDD-NOS).  
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